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General Introduction
Prostate carcinoma is the most frequently diagnosed malignancy in men over 45 
years old, with an incidence of over 9500 in the Netherlands [1], and a worldwide 
incidence of almost 900,000 [2]. External beam radiotherapy (RT) is a curative 
treatment option for patients with localized prostate cancer, both as definitive 
treatment [3], and in patients relapsing after radical prostatectomy [4]. Due to setup 
uncertainties, such as interfraction variation and intrafraction motion of the prostate 
[5], margins are applied around the clinical target volume (CTV), thus creating the 
planning target volume (PTV). Application of these margins, however, inevitably leads 
to irradiation of surrounding normal tissues, potentially leading to radiation induced 
toxicity. After prostate RT, anorectal toxicity has the largest impact on quality of life 
[6]. It should be noted, however, that late anorectal toxicity comprises different 
symptoms [7], and patients seem to be bothered most by complaints like urgency, 
soiling and fecal loss, rather than by symptoms like blood loss or mucus loss [8].
Given the dose-response relationship for prostate carcinoma in RT [9;10], there is a 
tendency towards dose escalation. However, while increasing the tumor dose 
improves control rates, care must be taken not to pay a high price in treatment 
morbidity [11], inasmuch as several dose-effect relationships for anorectal toxicity 
have been identified [12-14]. It has been shown that, when offered the choice, patients 
prefer a lower radiation dose over a higher dose, in order to reduce the risk of side 
effects [15], indicating that, from the patients’ point of view, toxicity reduction is more 
important than improving tumor control rates.
In the previous years, the development of three-dimensional conformal RT (3D-CRT) 
[16] and intensity-modulated RT (IMRT) [17] has allowed more conformal dose 
distributions to the target volume, while selectively sparing surrounding tissues. In 
reports on prostate IMRT, anorectal toxicity rates vary from 26% to 73% for acute 
toxicity, and from 5% to 65% for late toxicity [18-21]. These numbers indicate on the 
one hand that anorectal toxicity is a serious problem, even after highly conformal 
IMRT, and on the other hand that toxicity rates vary largely between studies, 
dependent on the used scoring instrument [22].  Besides conformal RT techniques, 
image-guided RT, like fiducial marker based portal imaging and cone beam CT 
imaging [23], is used for prostate position verification and correction, enabling smaller 
CTV-to-PTV margins. In addition to improved treatment delivery and image guidance, 
daily inserted endorectal balloons (ERBs) have been applied in prostate RT because of 
its rectal wall sparing effect [24-26], and its assumed prostate immobilizing effect 
[27;28], thereby reducing CTV-to-PTV margins.
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Outline of the thesis
The aim of this thesis is to identify anatomic structures that may be involved in the 
development of fecal incontinence-related complaints after RT and to investigate 
potential dose-effect relationships for these structures. Furthermore, it is investigated 
whether an ERB has a beneficial effect on the doses to these structures and 
subsequently on the development of anorectal toxicity. 
In Chapter 2, an overview of the use of ERBs in prostate RT is given, based on the 
international literature. The effects of different types of ERBs on prostate motion, 
target localization, dosimetric consequences and anorectal toxicity are discussed. 
Furthermore, patients’ tolerance, clinical practice and potential pitfalls are described. 
Finally, recommendations about ERB application and future research are made.
Although the effect of ERBs on rectal wall doses has been described previously 
[24-26], its effect on anal wall doses is not known. Given the dose-effect relationships 
for fecal incontinence regarding the anal wall [14], Chapter 3 describes a planning 
study, in which the effect of an ERB on anal wall dose parameters is investigated in 
3-field and 4-field 3D-CRT, and IMRT. Furthermore, a method for delineation of the 
anal wall is suggested, both with and without an ERB. 
In contrast to the application of ERBs in definitive RT, its use in post-prostatectomy RT 
has only been mentioned sporadically, and no comparative studies on its dosimetric 
effect have been performed. Therefore, in Chapter 4, a comparative study is 
described, investigating the effect of an ERB on both anal wall and rectal wall doses 
in post-prostatectomy IMRT, using international guidelines for CTV delineation.
Chapter 5 presents the results of a study using anorectal function testing in patients 
with and without fecal incontinence-related complaints after prostate RT. The 
differences in anorectal functions are compared between these groups, and more 
specifically between patients with and without incontinence, urgency and frequency. 
Furthermore, dosimetric parameters to the anal wall and rectal wall are compared 
between these groups, and the associations between both functional and dosimetric 
parameters and the different complaints are analyzed. Based on these associations, 
hypotheses regarding anatomic substrates for these complaints are described. Also, 
the effect of an ERB on the investigated parameters is explored.
Subsequently, in Chapter 6 an attempt is made to separately delineate four individual 
pelvic floor muscles considered to be involved in normal fecal continence, on 
planning CT scans of patients irradiated for prostate cancer. Dosimetric parameters to 
The aim of the abovementioned techniques is to enable dose escalation to the tumor, 
while reducing the risk of radiation induced toxicity. To effectively prevent anorectal 
complaints, however, knowledge of its pathophysiology is needed, in order to be able 
to selectively spare the structures involved in the development of these symptoms. 
Identification of objective changes in patients with anorectal complaints after RT 
might help to unravel its underlying pathogenesis. In patients with rectal bleeding, 
for example, mucosal changes have been observed on endoscopy [25]. In addition, 
several dose-volume and dose-surface parameters for the rectal wall have been 
identified as predictor for rectal bleeding [13]. Regarding the bothering fecal inconti-
nence-related complaints, however, less is known about its origin and development. 
Yeoh et al. observed progressive anorectal dysfunction after prostate RT, using 
anorectal manometry testing, with an inverse relationship between fecal incontinence 
scores and rectal compliance and anal squeeze pressure [29], suggesting that both 
rectal and anal factors are involved in its development. Others have confirmed this 
hypothesis [30], although the exact pathophysiology, especially the relation between 
anatomic substrates and radiation doses, is still unknown.
To enable dose evaluation to normal tissues, such as the anorectum, structures of 
interest are delineated on patients’ planning CT scans and the dose parameters to 
these organs (e.g. mean dose), as calculated by a treatment planning system, are 
retrieved. It has been suggested that when evaluating dosimetric parameters as 
predictors for anorectal toxicity, not only the anorectum as a whole should be 
considered, but also doses to the anal wall separately [14], suggesting that the anal 
wall and rectal wall are different anatomic substrates. Furthermore, normal fecal 
continence is a complex process, and rather than just the anal wall, four specific pelvic 
floor muscles are thought to be involved in maintaining fecal continence: the internal 
anal sphincter, external anal sphincter, puborectalis muscle, and levator ani muscles 
[31;32]. The role of these muscles in radiation-induced fecal incontinence has yet to be 
elucidated. 
As mentioned above, ERBs are used in prostate RT, as it has been shown that rectal 
wall doses are reduced when an ERB is applied, which may lead to reduced late rectal 
toxicity [24-26]. Clinical data on this effect, however, are scarce. Furthermore, its effect 
on anal wall doses and fecal incontinence-related complaints is not known. Another 
unsolved issue of ERB application is whether or not it has a prostate immobilizing 
effect, which has been observed in some studies [27;28] and which may lead to 
smaller CTV-to-PTV margins and potentially lower anorectal toxicity rates. There is, 
however, no consensus on this issue, as other investigators have not observed this 
effect [33;34]. 
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these structures are obtained from the treatment planning system and are compared 
between patients with and without urgency, incontinence and frequency, and 
differences in muscle involvement are described. In addition, dose-effect curves are 
presented for these muscles and for the anal wall and rectal wall, and dose constraints 
are formulated that can be used in RT planning. Finally, differences in the prevalence 
of complaints and in dosimetric parameters between patients treated with ERB and 
without ERB are described.
As there is no consensus on the effect of ERBs on interfraction variation and 
intrafraction prostate motion, in Chapter 7 the results of a comparative study are 
presented, which was conducted at the M.D. Anderson Cancer Center Orlando, FL, 
USA. Fifteen patients were treated without ERB and fifteen patients were irradiated 
with a daily inserted ERB. In all patients, intrafraction prostate motion was continuously 
monitored with an electromagnetic tracking system. The effect of the ERB on both 
interfraction variation and on intrafraction motion is presented in this chapter. 
A general discussion, based on the abovementioned chapters is given in Chapter 8; 
Chapter 9 provides a summary of the thesis.
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CHAPTER 2 ENDORECTAL BALLOONS IN PROSTATE RADIOTHERAPY: A SYSTEMATIC REVIEW
Introduction
There is a dose-response relationship of prostate cancer in external beam radiotherapy 
(RT) [1,2]. However, dose-escalation is limited by toxicity of surrounding normal 
tissues, and improved tumor control might be at the cost of higher toxicity rates [3]. In 
particular anorectal toxicity has a great impact on patients’ quality of life [4].
Three-dimensional conformal radiotherapy (3D-CRT) [5] and intensity-modulated 
radiotherapy (IMRT) [2] have allowed more conformal dose distributions to the 
prostate, while selectively sparing surrounding normal tissues. Anorectal toxicity rates 
in IMRT range from 26% to 73% (acute) and from 5% to 65% (chronic) [6-9]. 
Despite highly conformal RT, uncertainties due to patient set-up errors and prostate 
motion [10] require a margin around the clinical target volume (CTV), thus creating 
the planning target volume (PTV). Minimizing these uncertainties allows smaller 
margins, thereby reducing the dose to the anorectal complex. However, as 74% of 
prostate cancer foci are located in the peripheral zone and in the close proximity of 
the rectum [11], care must be taken not to underdose the tumor.
In addition to improved treatment delivery and developments in image-guided RT 
[12,13], daily inserted endorectal balloons (ERBs) are being used to immobilize the 
prostate, thereby reducing CTV-to-PTV margins [14-20]. A second reason for ERB 
application is its rectal wall (Rwall) sparing effect by pushing parts of the rectum away 
from the high-dose regions [15,19-28]. 
In this paper, experience with the application of ERBs in prostate 3D-CRT, IMRT, and 
proton therapy, published in the international literature, is reviewed.
Materials and methods
We performed a systematic literature review based on database searches in PubMed/
MEDLINE and included articles up to June 2009. Terms used for the search were 
‘balloon’, ‘endorectal balloon’, ‘rectal balloon’, ‘rectal catheter’ and synonyms 
combined with one or more of the following: ‘prostate’, ‘prostate cancer’, ‘radiotherapy’, 
‘radiation’, ‘IMRT’, ‘rectal toxicity’ and synonyms. Furthermore, these terms were 
combined with the respective key words for each paragraph. Publications mentioned 
in the reference list of articles found in the automatic search and considered suitable 
were manually searched for. Only papers published in English were included. 
Abstract
Background and purpose: Endorectal balloons (ERBs) are being used in prostate 
radiotherapy for prostate immobilization and rectal wall (Rwall) sparing. Some of their 
aspects, however, have been questioned, like patient’s tolerance and their value in 
modern high-precision radiotherapy. This paper gives an overview of published data 
concerning ERB application in prostate radiotherapy.
Materials and methods: Systematic literature review based on PubMed/MEDLINE 
database searches. 
Results: Overall, ERBs are tolerated well, although patients with pre-existing anorectal 
disease have an increased risk of developing ERB-related toxicity. Planning studies 
show reduced Rwall and anal wall (Awall) doses with ERB application. Clinical data, 
however, are scarce, as only one study shows reduced late rectal damage. There is no 
consensus about the immobilizing properties of ERBs and it is recommended to use 
additional set-up and correction protocols, especially because there are potential 
pitfalls.
Conclusion: ERBs seem well-tolerated and in planning studies reduce anorectal wall 
doses. This may lead to reduced anorectal toxicity, although clinical studies are 
warranted to confirm this hypothesis and to further investigate the immobilizing 
properties of ERBs, preferably in combination with advanced techniques for position 
verification.
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silkolatex coating, used for barium enema procedures (Nordmann, Rüsch AG, Kernen, 
Germany). Balloon diameters with 40 cc and 60 cc of air are 3.7 and 4.3 cm, respectively 
[26]. The third balloon (ERB3) consists of a 15-cm-long rigid shaft with a non-latex 
retention cuff (4.5-cm-long) fixed on it (EZ-EM, Westbury, NY). Air volumes of 60 and 
100 cc [22,32] create balloon diameters of 5.5-6.0 cm.
In a direct comparison of these three balloons [24] patients preferred ERB2; inflation of 
ERB3 was painful in 25%, because of the largest ERB diameter. Technologists preferred 
the ERB1, as it was easiest to handle and to insert. Insertion of ERB3 was more difficult, 
because of the rigid, short shaft. Recently, a RT-specific ERB was reported on (ERB4), 
consisting of a 20-cm-long flexible shaft of polyvinylchloride with a 3-cm-long silicon 
balloon (QLrad B.V., Dalfsen, The Netherlands) [33]. It is not open-ended and equipped 
with a stopper and depth markers; inflated with 80 cc of air its diameter is 6.0 cm. 
In addition to different ERB types, both prone [18] and supine [24] treatment positions 
have been reported. 
Prostate motion and target localization
The role of ERBs as prostate immobilizers, to reduce interfraction and intrafraction 
variations in prostate position and thus CTV-to-PTV margins, has been investigated. 
D’Amico et al. evaluated intrafraction prostate motion by obtaining CT-images at 1-min 
time intervals, both with and without an air-filled (60 cc) ERB1 in place [14]. They 
concluded that gland immobilization is possible with ERBs, as the balloon reduced 
the maximum prostate displacement in any direction from 4 mm to ≤1 mm. A reduction 
in interfraction motion was observed with an air-filled (40 cc) ERB2 in repeated CT-
examinations: maximum displacement in the AP direction of >5 mm occurred in 2/10 
patients, compared to 8/10 patients without ERB [15]. With a 100 cc air-filled ERB3, only 
small interfraction displacements were observed. The largest mean (1 SD) displacement 
was in the SI direction: 0.92 mm (1.78) [17,20]. Additionally, no organ displacement was 
seen during normal breathing with an ERB inserted. Given this limited prostate 
motion, smaller CTV-to-PTV margins were advised when using an ERB.
However, not all reports were able to confirm these immobilizing features. No 
differences in systematic and random prostate deviations were found between 
patients with and without an 80 cc air-filled ERB1 using fiducial marker-based daily 
portal imaging [12]. The largest interfraction variation was in the AP direction (4.7 mm, 
1 SD), which was attributed to the presence of stool and gas between the ERB and 
Rwall. In addition, off-line corrections reduced the systematic prostate displacements 
equally in both groups. Based on these findings, it was concluded that ERB application 
does not effectively reduce interfraction prostate motion and the use of positioning 
Results
Types of endorectal balloons
In 1979, for the first time, ERB application in prostate RT was reported [29]. To our 
knowledge, four different ERBs have been described since then, three originating 
from diagnostic radiology, and one especially developed for RT purposes (Fig. 1).
The first ERB (referred to as ERB1) consists of a 9-cm-long latex balloon fixed on a 
33-cm flexible shaft of polyvinylchloride (Medrad, Pittsburgh, PA). It was originally 
designed as an endorectal coil in magnetic resonance imaging (MRI) and the balloon 
has a concave shape for optimal conformation to the prostatic-rectal interface. In 
prostate RT 60, 80, and 100 cc of inflated air have been reported [24,30,31], resulting in 
balloon diameters of 4.0-4.5 cm. The second ERB (ERB2) is a 5-cm-long silkolatex 
balloon, fixed on a 30-cm-long two-way rectal tube, made of soft rubber with a 
Fig. 1   The endorectal balloons, mentioned in the literature: ERB1 (a), ERB2 (b), ERB3 
(c), and ERB4 (d). See text for specifications.
22 23
2
CHAPTER 2 ENDORECTAL BALLOONS IN PROSTATE RADIOTHERAPY: A SYSTEMATIC REVIEW
Van Lin et al. directly compared ERB1 (80 cc), ERB2 (40 cc), ERB3 (100 cc) and no ERB in 
four-field 3D-CRT plans [24]. Significant reductions in normal tissue complication 
probability (NTCP), Rwall mean dose and Rwall volumes exposed to ≥50 Gy and ≥70 
Gy (V
50
 and V
70
, respectively) were seen with all ERBs, both with and without SV 
inclusion in the CTV. Large volume ERBs (ERB1 and ERB3) were the most advantageous. 
Additional analysis of spatial dose distribution over the inner Rwall mucosa using 
dose-surface maps (DSMs) showed an ERB-induced reduction of relative surface 
exposed to intermediate and high doses.
Although scarce, some reports have described the dosimetric effect of ERBs in IMRT. 
In the previously mentioned study by Patel et al. ERB3 reduced absolute Rwall V
60
, V
65
, 
and V
70
 in IMRT as well [22]. Interestingly, Rwall doses in 3D-CRT with ERB were the 
same as in IMRT without ERB. IMRT combined with ERB increased Rwall sparing even 
more. Despite some differences in V
50
 and V
70
 , Van Lin et al. observed no significant 
reductions in NTCP or Rwall mean dose  by any of the ERBs in IMRT [24]. However, 
relative Rwall surfaces exposed to intermediate and high doses were significantly 
reduced. In another study, IMRT with ERB3 (100 cc) was superior in normal tissue 
sparing, especially the rectum and femoral heads, as compared to six-field 3D-CRT 
with ERB3 [28].   
In conclusion, in photon therapy ERBs have a Rwall sparing effect for the intermediate- 
and high-dose regions. As both dose-levels are predictive factors for late rectal 
bleeding [36,37], ERBs may consequently reduce late toxicity. Even in highly conformal 
IMRT, ERBs appear to add extra sparing. With SV inclusion in the CTV, larger volume 
ERBs seem most beneficial. Similar to Rwall sparing, a recent study demonstrated that 
an 80 cc air-filled ERB4 also significantly reduces anal wall (Awall) doses in both 
3D-CRT and IMRT, with a reduction in Awall mean dose of 12 Gy in 3D-CRT and 7.5 Gy 
in IMRT [33]. Comparable to the Rwall, this effect was attributed to Awall displacement. 
Fig. 2 shows an IMRT planning with and without a modified air-filled ERB4 (100 cc).
Introduction of an air cavity, influencing the dose distribution, may also contribute to 
Rwall dose reduction. Due to electronic disequilibrium in air cavities, perturbation of 
the dose near the air-tissue interface occurs, which leads to lower doses in the tissues 
adjacent to the air cavity. Monte Carlo calculations of parallel-opposed photon beams 
have shown dose reductions up to 21% at the air-rectum interface [38]. Reductions at 
1 and 2 mm depth were 15% [39] and 11%, respectively [38].
In similar simulations using multiple-beam IMRT, a 15% dose reduction at the air-tissue 
interface was observed [19,32]. At distance from the cavity the dose built up rapidly, 
with 8% and 5% lower doses at 1 mm and 2 mm, respectively. The posterior part of 
correction protocols was advocated. A similar recommendation was made for dose-
escalation with a 60 cc air-filled ERB2 [34].
Drawing definite conclusions on the immobilizing properties of ERBs is difficult, 
because of (a) different imaging techniques for positioning verification, (b) differences 
in imaging frequency, (c) non-uniformity in scoring of variations (e.g. maximum 
displacements, SDs), (d) variation in patient position, and (e) different ERBs and inflated 
volumes. Therefore, in accordance with the abovementioned suggestions, we 
recommend that, when using ERBs, position verification and correction protocols 
continue to be used to prevent large day-to-day variations. 
As the ERB is situated directly adjacent to the anterior Rwall and can be well visualized 
by portal imaging [14,15], it can assist in localizing the prostate and thus reduce 
CTV-to-PTV margins. A posterior field margin of 1 mm behind the anterior ERB surface 
has been suggested when online portal imaging is used, as the anterior Rwall could 
be defined with an accuracy of 1-2 mm, which was equal to the maximum AP prostate 
displacement. [14]. Others confirmed this improved set-up due to ERBs, although they 
advised more conservative posterior PTV margins: 10 mm in 3D-CRT and 4 mm in 
IMRT [21,35].
Dosimetric consequences
As numerous reports have described dose-volume and dose-surface relationships of 
anorectal toxicity [36], several groups have investigated the dosimetric effect of ERBs 
in an attempt to reduce toxicity. 
3D-CRT and IMRT
A 40 cc air-filled ERB2 significantly reduced Rwall doses in 4-field 3D-CRT [15,21], 
especially high-dose exposure to the posterior Rwall. This phenomenon was 
attributed to an increased distance between the prostate and the posterior Rwall. 
However, with seminal vesicles (SVs) included in the target volume, only inflation with 
60 cc led to significant reductions of intermediate and high Rwall doses [26], without 
significantly altering the bladder dose [27]. Based on these findings, inflation with 60 
cc of air was recommended. A 60 cc air-filled ERB3 reduced Rwall volumes exposed to 
>60 Gy in six-field 3D-CRT, irrespective of SV inclusion in the CTV [22]. Rwall sparing 
with ERB1 (60 cc) in four-field 3D-CRT proved to be best when the ERB was applied 
during all 40 treatment sessions, compared to 0 and 15 fractions [23]. However, it 
should be noted that in this study fairly wide PTV margins of 15 mm were used for 
treatment without ERB, compared to 5 mm with ERB.
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Anorectal toxicity
Although many planning studies have shown a beneficial effect of ERBs and several 
reports have mentioned toxicity rates after treatment with ERBs, only one comparative 
clinical study has been published so far. Van Lin et al. compared 24 patients with and 
24 patients without ERB1, treated with four-field 3D-CRT to a total dose of 67.5 Gy, by 
repeated rectosigmoidoscopies [25]. Patients treated with ERB showed significantly 
less late rectal toxicity, with no grade 2 or grade 3 toxicity. Grade 3 rectal bleeding was 
experienced by 1 patient in the no-ERB group. Grades 1-3 late rectal bleeding was 
experienced by 33% and 13% in the group without and with ERB, respectively. 
However, given the small group sizes, this difference did not reach statistical 
significance. During follow-up, high-grade Rwall telangiectases, indicating severe late 
mucosal damage, were significantly less frequently observed in the group with ERB. 
DSM analysis showed that in the ERB group a significantly higher proportion of the 
mucosa was exposed to doses <40 Gy, while less mucosa received higher doses, 
compared to the group without ERB. Interestingly, in mucosal areas exposed to >40 
Gy at the anterior Rwall less high-grade telangiectases were observed in the ERB 
group, which was attributed to either a physical property of the ERB (i.e. dose 
build-up), or a radiobiological phenomenon (i.e. stretching of the Rwall, leading to 
hypoxia and therefore radioresistance).
Endoscopy was also performed by Goldner et al. in 166 of 486 patients, treated with 
3D-CRT and ERB in a prospective multicenter dose-escalation study, showing an 
overall 2-year rate of telangiectases of 57%, 40% congested mucosa and 2 patients 
having grade 1 ulceration [40]. At 40 months, the actuarial EORTC/RTOG late rectal 
grade ≥2 toxicity rate was 36%. Recently, 5-year results of the trial have been published, 
showing an actuarial late rectal grade ≥2 toxicity rate of 29% for all patients with no 
difference between the two dose-levels [41].
Woel et al. described acute toxicity in patients treated with four-field 3D-CRT (total 
dose 75.6 Gy), using ERB1 during the first 15 fractions [42]. At the end of the treatment 
course a significant increase in hemorrhoidal irritation and anal skin reaction was 
observed. At 3 months after treatment, all investigated symptoms had returned to 
baseline values with standard interventions. One year later, the primary endpoint of 
this study was presented, being late rectal bleeding grade 3, which was estimated to 
be 10% after 2 years. All patients with rectal bleeding used anti-coagulants, whereas 
none of the non-bleeders did [43]. 
The Baylor College of Medicine/Methodist Hospital group has been using ERBs in 
prostate IMRT since 1998. Acute side effects in 100 patients, treated to a prescribed 
dose of 76 Gy were low with 11% and 6% grades 1 and 2 gastrointestinal (GI) toxicity, 
the prostate, located 6 mm from the air-tissue interface, received the same dose, 
compared to the phantom without air cavity. These results suggest that ERBs have an 
anterior Rwall sparing effect without underdosing the prostate. Although not showing 
Rwall sparing, another study confirmed that an air-filled ERB did not underdose the 
prostate, compared to a water-filled ERB [35].
Proton therapy
In proton therapy water-filled ERBs are used, in order to optimize the proton dose 
distribution. Vargas et al. compared plans with a 100 cc saline-filled ERB1 and 100 cc 
saline placed directly in the rectum, prescribing a total dose of 78-82 Gray equivalents 
[31]. For the whole rectal volume the ERB significantly reduced V
10
 -V
65
, whereas for the 
Rwall improved V
10
 -V
50
 were observed. For the Rwall volume at the PTV level, V
10
 -V
30 
were significantly reduced. With SV inclusion in the CTV, the ERB led to no significant 
improvement. The authors concluded that Rwall doses were low for both ERB and 
water alone and that the latter is an alternative for most patients. However, in selected 
cases application of an ERB led to significant, though small improvements in rectal 
dose.
Fig. 2   Transverse (top) and sagittal (bottom) dose distribution of IMRT plans  
without (left) and with ERB (right) in place (prescribed dose 78 Gy). Contours: 
rectal wall (green), anal wall (purple) and PTV (blue). Color figure at p 161.
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These studies indicate that application of ERBs is safe and well-tolerated, although 
care must be taken in patients with pre-existing anorectal disease.
Caveats 
Some reports specifically address potential disadvantages or caveats in ERB application. 
The reproducibility of daily ERB insertion has been questioned. Court et al. observed 
a mean intrafraction shift of the anterior ERB wall of 1.8 mm (maximum 7.2 mm), 
mainly in the posterior direction [30], which was attributed to patient relaxation after 
insertion. It was suggested that this could be reduced by a waiting period between 
insertion and irradiation. In addition, an interfraction change in the angle of the 
balloon of 2.5-5.7° was observed. Wang et al. reported random errors in balloon 
positioning of up to 4.5 mm and maximum variations in balloon diameter of 2.8 mm, 
which were not correlated [49]. The variation in isocenter position was considered 
acceptable with ERB. Both groups advised frequent use of image-guidance to reduce 
set-up errors. In contrast, others called balloon placement “highly reproducible”, with 
the largest variability in the SI direction (mean SD 3.1 mm) [22]. As mentioned 
previously, not all studies are conclusive about ERBs reducing prostate motion. Added 
to these data, it can be concluded that position verification strategies are necessary 
when using ERBs. 
Another caveat is the finding that application of a 50 ml fluid-filled Medrad endorectal 
coil, identical to the one used in prostate RT, significantly changed prostate shape and 
volume in prostate MRI, with reductions in prostate diameter and volume up to 15.7% 
and 18%, respectively [50]. Apart from its influence on RT planning, in combination 
with balloon displacement and deformation this may lead to an extra set-up 
uncertainty. Three-dimensional image-guidance (e.g. cone-beam CT), may be useful 
to investigate this phenomenon. 
Although phantom studies did not show a disadvantageous effect of ERBs on the 
dose distribution in the target volume, two reports have mentioned possible 
underdosage due to set-up variations. Ahmad et al. compared IMRT plans with ERB3 in 
place with two plans with a set-up error of ±5 mm [51]. Despite minimal impact on the 
mean doses to the prostate and SV, coverage of the latter significantly changed, 
increasing the volume exposed to <70 Gy from 0.53% to 6.26%, while for the prostate 
this increase was minimal. They concluded that set-up deviations of 5 mm had 
minimal impact on doses to the tumor and normal tissues, and that clinical research 
must determine the clinical impact of SV dose inhomogeneity. The same group 
investigated plans with ERBs in both the most superior and inferior positions, and 
without ERB, simulating ERB repositioning inaccuracies and failure to inflate, 
respectively [52]. Again, SV doses significantly decreased by ERB repositioning, 
respectively, and grades 1 and 2 GU toxicity occurring in 38% and 35%, respectively 
[18]. After a median follow-up of 31.3 months rectal toxicity grades 1, 2, and 3 were 
seen in 10.3%, 6.9%, and 1.7%, respectively [32]. 
Toxicity rates in 1255 patients treated with conformal proton therapy (with or without 
photon therapy) and a 120 cc water-filled ERB were low: acute grade ≥3 GI toxicity was 
seen in <1%, whereas late grades 3 and 4 GI toxicity occurred in 1% and 0.2%, 
respectively, presenting within 2.5 years after treatment. Late GU toxicity, mainly 
urethral strictures, was reported in 14 patients [44]. 
Reports on ERBs in post-prostatectomy radiotherapy are scarce. However, minimization of 
CTV motion, target volume consistency and reproducibility have been arguments to 
use ERBs in post-operative RT as well. Irradiated to a median dose of 64 Gy, the acute 
toxicity profile was acceptable: 82.5% grades 0-1 and 17.5% grade 2 GU toxicity [45]. 
In conclusion, although potentially leading to increased acute anal irritation, ERB 
application may reduce late Rwall damage, and subsequently lower late toxicity rates. 
However, clinical data are scarce, making it hard to draw definite conclusions on this 
topic. More comparative, clinical studies are needed on the use of ERBs, especially 
combined with modern treatment techniques, such as IMRT.
Patient’s tolerance
In a direct comparison 5/20 patients experienced a painful inflation of ERB3 [24]. This 
was reported to disappear after approximately 1 min, although no formal scoring was 
performed. Many investigators report a good ERB tolerability [12,15,20,22,42], although 
three studies specifically addressed this issue.
A prospective multicenter trial showed that a 40 cc air-filled ERB2 did not cause major 
complaints in 79% of patients receiving 3D-CRT. Twenty-one percent experienced signs of 
blood and/or pain and in 4% treatment with ERB had to be stopped [46]. Balloon 
discomfort was significantly correlated to acute RT-related rectal side effects. Patients with 
pre-existing hemorrhoids did not have an increased risk of complaints, whereas in another 
study this was considered a contra-indication for the use of ERBs, as ERB1 application led 
to grade 3 anal irritation in a patient with hemorrhoids [12]. Tolerance in a study employing 
IMRT was even better, with none of 396 investigated patients stopping the treatment with 
a 100 cc air-filled ERB3 [47]. Only 0.8% required volume reduction to 50 cc and 4.3% 
required local anesthetic gel facilitating the insertion. Patients with pre-existing anorectal 
disease had a higher risk of developing acute anorectal toxicity. Equally good results were 
found in a group of 3561 patients, treated with conformal proton therapy with 120 cc 
water-filled ERBs [48]. An overall tolerance rate of 97.6% was seen with only 2.4% of the 
patients receiving 1 or more fractions without ERB. 
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Modern techniques for position verification could be useful in further clinical research 
on ERB application. For example, cone-beam CT can visualize interfraction variation of 
both ERB position and shape, and its influence on the CTV and surrounding pelvic 
anatomy, as well as changes in SV position. Electromagnetic tracking can be used to 
get real-time information on intrafraction prostate variability when using ERBs [54]. It 
could be very interesting to use these techniques for direct comparison of situations 
with and without ERB. Additional factors to investigate could be strategies to reduce 
gas and stool (e.g. medication, gas release before ERB insertion) and to cope with 
relaxation after ERB insertion, for example, to wait some minutes before starting the 
treatment [16,30].
Finally, ERBs themselves could be further modified. Customized balloons could lead 
to optimal conformation to individual anatomic variations. In the future, ERBs could 
be applied in the treatment of other pelvic tumors, e.g. gynecological malignancies 
[55]. These are topics for future research.
without affecting the normal tissue doses. ERB failure led to a significant dose 
reduction to both the prostate and SV and decreased the mean dose to the upper 
rectum, which was attributed to posterior displacement of these organs. Portal 
imaging was suggested to visualize these failures. Given the underdosage after failure 
of placement or inflation, it can be concluded that when ERB application cannot be 
continued, e.g. because of complaints, new treatment planning is necessary.
Air-filled ERBs introduce a significant density heterogeneity into the treatment 
volume. Song et al. evaluated how a conventional treatment planning system handles 
this heterogeneity by comparing its dose calculations with those of a Monte Carlo 
simulation, using a four-field box technique [53]. They observed consistent and 
predictable differences between the calculation methods, with a reduction in the 
high-dose regions and a widening of the low-dose regions in the Monte Carlo 
calculations. In addition, a potential underdosage of 3.4% mean dose near the 
peripheral zone of the prostate was found for the posterior beam. One might argue, 
however, that even without an ERB variable amounts of gas can be present in the 
rectum over a treatment course. By applying an ERB this amount can be held constant 
and accounted for in treatment planning. 
Workload and clinical practice
Published data on the workload of ERB application show an additional 2-3 min set-up 
time needed per treatment session [12,22]. In our institution (Radboud University 
Nijmegen Medical Centre), a physician inserts the first ERB at the CT-scanner to ensure 
a proper position and checks patient’s acceptance. To maintain this position, the ERB 
is gently pulled towards the anal canal and the stopper is adjusted to minimize ERB 
movement. The technologists insert the ERB before every treatment fraction. For 
hygienic reasons, disposable ERBs are used. 
Conclusions and future perspectives
Several planning studies have shown dosimetric advantages with ERB application, 
although comparative clinical studies, preferably using IMRT, are essential before 
drawing definite conclusions. Other potential benefits of ERBs may be improved 
target localization and reduced prostate motion. However, as there is no consensus 
about these topics, further investigation is warranted. Until then, additional set-up 
and correction protocols, and image-guidance are recommended, especially because 
there are potential pitfalls. Overall, ERBs are well-tolerated, although they should be 
omitted in patients with pre-existing anorectal disease.
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CHAPTER 3 ANAL WALL SPARING EFFECT OF ENDORECTAL BALLOON IN PROSTATE RADIOTHERAPY
Introduction 
Dose escalation leads to improved treatment outcomes in prostate radiotherapy, 
especially for intermediate- and high-risk patients [1-3]. However, the major 
dose-limiting factor is anorectal toxicity, resulting in both acute and late adverse 
effects. Bowel symptoms have a greater impact on quality of life than urinary and 
sexual symptoms [4]. In addition, patients appeared to be most bothered by 
complaints such as soiling, fecal loss and urgency rather than by symptoms of 
proctitis, such as mucus discharge and bleeding [5]. In a large prospective trial the 
fecal incontinence rate was 17% at 4 years after a dose of 78 Gy [6]. 
Several reports have described the relationship between dose-volume parameters to 
the anal canal and fecal incontinence [6-10]. A statistically significant correlation was 
shown between radiation doses to the anal-sphincter region and the risk of fecal 
leakage in the dose range of 45-55 Gy [9]. Recently Peeters et al. have found a 
dose-volume effect for anal incontinence by separately delineating the contour of the 
anal wall (Awall) from the rectal wall (Rwall) [6]. These results suggest that reducing 
the dose to the Awall may result in reduction of the incidence of radiation-induced 
anal toxicity.
Nowadays, 3D conformal radiotherapy (3D-CRT) and especially intensity-modulated 
radiotherapy (IMRT) offer the possibility to selectively spare surrounding normal 
tissues. Daily inserted endorectal balloons (ERBs) have been used to reduce rectal 
toxicity [11-14] and have been shown to have a significant Rwall sparing effect in both 
3D-CRT and IMRT [14]. 
The purpose of this planning study was to investigate the Awall sparing effect of an 
ERB for both 3-field 3D-CRT and 4-field 3D-CRT and IMRT, by comparing treatment 
plans with and without ERB, in localized prostate cancer patients. 
Materials and methods
Twenty-four patients with localized adenocarcinoma of the prostate were included in 
this study after informed consent was given. Besides apparent preexisting anal irritation 
or hemorrhoids, no exclusion criteria were applied. Before CT-scanning, patients used 
a laxative suppository (bisacodyl 5 mg) and were advised to use a light breakfast. 
Additionally they were instructed to drink 500 mL of water for bladder filling.
Abstract 
Background and purpose: To investigate the anal wall (Awall) sparing effect of an 
endorectal balloon (ERB) in 3D conformal radiotherapy (3D-CRT) and intensity-modu-
lated radiotherapy (IMRT) for prostate cancer.
Materials and methods: In 24 patients with localized prostate carcinoma, two planning 
CT-scans were performed: with and without ERB. A prostate planning target volume 
(PTV) was defined, and the Awall was delineated, using two different methods. 
Three-field and 4-field 3D-CRT plans, and IMRT plans were generated with a 
prescription dose of 78 Gy. In 144 treatment plans, the minimum dose (D
min
), maximum 
dose (D
max
), and mean dose (D
mean
) to
 
the Awall were calculated, as well as the Awall 
volumes exposed to doses ranging from ≥20 Gy to ≥70 Gy (V
20
 -V
70
, respectively). 
Results: In the 3D-CRT plans, an ERB significantly reduced D
mean
, D
max
, and V
30
 -V
70
. For 
IMRT all investigated dose parameters were significantly reduced by the ERB. The 
absolute reduction of D
mean
 was 12 Gy in 3D-CRT and was 7.5 Gy in IMRT for both 
methods of Awall delineation.
Conclusions: Application of an ERB showed a significant Awall sparing effect in both 
3D-CRT and IMRT. This may lead to reduced late anal toxicity in prostate radiotherapy.
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slice with a visible ERB lumen and was defined as the difference between the outer 
contour and inner contour of the anal canal, the latter being delineated around the 
ERB shaft. On the CT images without ERB the outer contour was delineated starting at 
the anal verge, using the same length as was obtained from the images with ERB. As 
the anal canal is actively closed by the internal and external anal sphincters and no 
anal lumen was seen on the CT slices without ERB, no inner anal canal contour was 
delineated separately. Therefore, the Awall on these images was defined as the total 
volume within the outer anal canal contour. The delineation of the Awall derived by 
this method is referred to as Awall
methA
 (Fig. 2). The second method used to contour 
the Awall, was performed by considering the anal canal as the distal 3 cm of the 
anorectum [6, 9, 16]. Based on this definition, for each patient a second Awall contour 
was defined, consisting of the caudal 3 cm of the anorectum starting at the anal 
verge, referred to as Awall
methB
. 
The ERB (Fig. 1) consists of a 20-cm-long flexible shaft of polyvinylchloride with a 
silicon balloon (Hospimed International B.V., Dalfsen, The Netherlands). Deflated, the 
ERB has a diameter of 13 mm. After inflation with 80 cc of air, the diameter is 60 mm 
and the length is 30 mm. Within 20 min, two planning CT-scans (one without and one 
with an 80-cc inflated ERB) per patient were obtained in a supine position at 3-mm 
slice thickness (AcQsim spiral CT, Philips Medical Systems, Bothell, WA). All balloons 
were inserted by the same person (R.J.S.) and were gently pulled towards the anal 
sphincter to ensure a proper position in relation to the prostate. To maintain this 
position, the ERB was fixed, using a clamp, preventing it from sliding more cranially 
(Fig. 1).
All CT images were imported into the Pinnacle3 treatment planning system (Philips 
Medical Systems, Fitchburg, WI). The clinical target volume (CTV) was defined as the 
prostate and was outlined on each CT slice. Furthermore, the following structures 
were delineated: femoral heads, bladder and anorectal wall, the latter being 
subdivided into Rwall and Awall.
In the literature, different methods for Awall delineation have been described. In this 
study, two delineation methods were used.  The first method was derived from 
Vordermark et al. [7], using the rectal lumen as the cranial boundary for the anal canal. 
First, a distinction between Rwall and Awall was made on the CT images with ERB. 
The Awall was outlined extending from the anal verge to the slice below the lowest 
Fig. 1   The inflated endorectal balloon (Hospimed International B.V.).
Fig. 2   Transversal (top), sagittal (middle) and frontal (bottom) view of delineated 
Rwall (green) and Awall (purple) for CT-scans without ERB (left column) and 
with ERB in place (right column). Color figure at p 162.
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In all treatment plans doses to the PTV, urinary bladder, femoral heads and rectum 
were calculated, as well as several dose parameters to the Awall: minimum, maximum 
and mean dose (D
min
, D
max
, and D
mean
, respectively) and Awall volumes (%) exposed to 
≥20 Gy (V
20
), ≥30 Gy (V
30
), ≥40 Gy (V
40
), ≥50Gy (V
50
), ≥60 Gy (V
60
), and ≥70 Gy (V
70
). 
The mean Awall V
20
 -V
70
 of the total population were plotted for each planning technique 
to create a mean dose-volume histogram (DVH).
The SPSS 14.0 software for Windows (© SPSS Inc., 1989-2005) was used for statistical 
calculations. The Wilcoxon signed rank test was used for paired comparison of the 
measured parameters in the same subjects with and without ERB. Differences with a 
two-tailed p-value < 0.05 were considered significant.  
Results 
The mean prostate volumes (±1 SD) with and without ERB were 41.70 (±19.42) cc and 
42.68 (±21.22) cc, respectively, and did not differ significantly (p = 0.475). The length of 
the Awall
methA
 ranged from 2.1 to 3.6 cm with a median length of 3.0 (±0.44) cm. The 
mean Awall
methA
 volumes were 14.60 (±3.21) cc with ERB and 13.96 (±3.12) cc without 
ERB (p = 0.407); the Awall
methB
 volumes were 15.07 (±3.09) cc and 14.03 (±2.91) cc, 
respectively, and were also not significantly different (p = 0.265). 
In five randomly chosen patients the Awall was delineated thrice by two independent 
observers (R.J.S. and E.v.L.). No large variations were found: the interobserver and 
intraobserver co-efficients of variation (± 1 SD) were 2.8 ± 0.9% and 1.9 ± 1.2% in the 
plans without ERB and were 4.1 ± 1.1% and 4.0 ± 2.0% in the plans with ERB, respectively. 
The dose to the PTV was equal in all plans without ERB and with ERB, with mean doses 
(±1 SD) of 77.1 (±0.4) and 76.8 (±0.3) Gy in the 3-field technique, 76.9 (±0.3) and 76.2 
(±0.4) Gy in the 4-field technique, and 78.4 (±0.2) and 78.2 (±0.2) Gy in IMRT, 
respectively. The ERB did not significantly alter the doses to other organs at risk: Rwall 
D
mean 
(±1 SD) without and with ERB were 31.8 (±6.2) and 31.6 (±6.6) Gy in 3-field 3D-CRT, 
33.7 (±6.3) and 32.9 (±7.1) Gy in 4-field 3D-CRT, and 26.6 (±4.7) and 26.9 (±5.0) Gy in 
IMRT, respectively. Bladder D
mean
 were 25.4 (±14.1) and 21.9 (±13.0) Gy, 25.1 (±13.7) and 
22.7 (±13.9) Gy, and 20.8 (±11.3) and 18.1 (±11.4) Gy, respectively. D
max
 to the femoral 
heads were equal in plans with and without ERB, and ranged from 47.3 (±2.8) Gy in 
IMRT to 51.9 (±0.6) Gy in 3-field 3D-CRT.
To obtain the planning target volume (PTV) a 3D CTV-to-PTV margin of 7 mm was 
used [14]. A total dose of 78 Gy in 2 Gy-fractions was prescribed to the ICRU reference 
point in 3D-CRT and to the PTV in IMRT. Three-field 3D-CRT, 4-field 3D-CRT [15] and 
IMRT treatment plans were generated in all patients and for both CT-scans with and 
without ERB, resulting in a total of 144 plans. 
In the 3-field technique three coplanar photon beams of 18 MV were used (anterior, 
left-lateral and right-lateral). The 4-field technique was planned with four coplanar 18 
MV photon beams (anterior, posterior, left-lateral and right-lateral). In both 3D-CRT 
plans a higher weight was given to the lateral beams than to the anterior and posterior 
beams with a restriction of 50 Gy to the femoral heads [15]. A multileaf collimator was 
used to individually spare the bladder and rectum. 
Inverse planned step-and-shoot IMRT plans were generated, consisting of five 
coplanar, non-opposing 10 MV photon beams (0°, 50°, 95°, 265°, and 310°) with a 
maximum of 60 segments. Table 1 shows the objectives for the inverse planning. A 
maximum dose of 30 Gy was tolerated outside the delineated structures. 
Table 1   IMRT treatment planning objectives and weight factors. 
ROI Type Target dose (Gy) Volume (%) Weight
Bladder Max DVH 50 15 2
Bladder Max DVH 68 2 3
Left femur Max Dose 40 1
Right femur Max Dose 40 1
Rwall Max DVH 32 8 10
Rwall Max DVH 40 5 10
Rwall Max DVH 55 4 1
Rwall Max Dose 70 10
Awall Max DVH 20 20 1
Awall Max DVH 30 13 1
Awall Max DVH 40 8 1
Awall Max DVH 50 4 1
Awall Max Dose 60 10
PTV Max Dose 79.5 80
PTV Uniform Dose 78 80
PTV Min Dose 77
Abbreviations: ROI: region of interest; Rwall: rectal wall; Awall: anal wall; PTV: planning target volume; Max/Min 
Dose: maximum/minimum allowable dose; DVH: dose volume histogram.
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As displayed in Table 2, in 3-field 3D-CRT both Awall D
mean
 and D
max
 were significantly 
reduced by the ERB, lowering D
mean
 to the Awall
methA
 by 12.0 Gy (p < 0.001) and D
max
 by 
8.0 Gy (p = 0.001). These differences were also statistically significant for Awall
methB
: 
D
mean
 and D
max
 were reduced by 11.9 Gy (p < 0.001) and 4.6 Gy (p = 0.001), respectively. 
D
min
 was not significantly different between the plans with and without ERB.  With ERB 
mean parameters V
30
 -V
70
 to the Awall
methA 
were significantly reduced with absolute 
reductions of 15-25% (p < 0.001; Fig. 4). For Awall
methB
 a significant reduction in all 
volumes receiving 20-70 Gy was seen with ERB in place (data not shown).
The ERB significantly reduced D
mean
 and D
max
 to the Awall
methA 
in the 4-field technique 
by 11.9 Gy (p < 0.001) and 10.1 Gy (p < 0.001), respectively (Table 2). D
mean 
and D
max
 to 
Awall
methB
 were also significantly reduced by 11.7 Gy (p < 0.001) and 6.7 Gy (p < 0.001), 
respectively. The ERB did not alter Awall D
min
 significantly. Insertion of an ERB resulted 
in a significant reduction of V
20
 -V
70
 for both delineation methods of the Awall, with 
absolute reductions of 10-27% (p-value ranging from 0.03 to <0.001; Fig. 4).
In IMRT, all Awall dose parameters were significantly decreased in the plans with ERB 
(Table 3). Awall
methA
 D
mean
 was reduced by 7.5 Gy (p < 0.001). D
min
 without ERB was 3.1 
Gy, compared to 2.4 Gy with ERB (p = 0.001), whereas the balloon lowered D
max
 by 10.4 
Gy (p = 0.002). All these differences remained statistically significant for the Awall
methB 
delineation method. The ERB resulted in significant mean absolute reductions of V
20
 
-V
70
 in both Awall
methA
 and Awall
methB
 (Table 3).
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Table 3   Mean doses and dose-volume parameters (± 1 SD) to the anal wall in  
IMRT technique.  
IMRT AwallmethA AwallmethB
No ERB ERB p-value No ERB ERB p-value
Dmean (Gy) 27.5 (± 8.5) 20.0 (± 10.1) < 0.001 27.2 (± 8.6) 19.7 (± 9.0) < 0.001
Dmin (Gy) 3.1  (± 1.5) 2.4 (± 1.4) 0.001 3.4 (± 1.6) 2.4 (± 1.4) < 0.001
Dmax (Gy) 79.4 (± 7.2) 69.0 (± 20.0) 0.002 78.9 (± 12.1) 71.2 (± 15.5) 0.001
V20 (%) 48 (± 16) 36 (± 21) 0.001 48 (± 16) 34 (± 19) < 0.001
V30 (%) 36 (± 14) 22 (± 16) < 0.001 35 (± 14) 21 (± 14) < 0.001
V40 (%) 28 (± 12) 15 (± 13) < 0.001 27 (± 13) 14 (± 11) < 0.001
V50 (%) 22 (± 11) 11 (± 11) < 0.001 21 (± 11) 10 (± 9) < 0.001
V60 (%) 16 (± 9) 8 (± 8) < 0.001 16 (± 9) 8 (± 7) < 0.001
V70 (%) 10 (± 7) 5 (± 6) < 0.001 10 (± 6) 4 (± 5) 0.001
Abbreviations: V
20
-V
70
: volumes (%) of the anal wall receiving 20-70 Gy; other as in Table 2.
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IMRT with ERB resulted in the lowest dose parameters to the Awall with absolute D
mean
 
reductions of 20 Gy compared to 3D-CRT without ERB, 9 Gy compared to 3D-CRT with 
ERB, and 7.5 Gy compared to IMRT without ERB, respectively.
The ERB was tolerated well by all patients. During inflation, all patients experienced a 
raise in local pressure on the rectum, which was described as a tendency to defecate 
and had disappeared within 15 s after inflation. 
Discussion 
This planning study has shown that application of an ERB in prostate radiotherapy 
significantly reduces doses to the Awall in both 3D-CRT and IMRT with an average 
reduction in D
mean
 of 7.5-12.0 Gy. This dose reduction can be explained by two 
properties of the ERB, as demonstrated in Fig. 3. First, the inflatable part of the balloon 
causes an anterior shift of the prostate, thereby increasing the distance between the 
PTV and the anal wall. Second, the shaft of the ERB pushes the posterior and lateral 
parts of the anal wall away from the high-dose regions.
In Fig. 3 the differences in dose distribution on the Awall between the six different 
treatment techniques, represented by iso-dose lines, for one patient, are displayed. 
Fig. 4 shows a graph of the mean Awall
methA
 V
20
 -V
70
 of all patients in the six different 
plans. In the plans without ERB, IMRT reduced all investigated parameters compared 
to 3D-CRT. Interestingly, when an ERB was applied in combination with 3D-CRT, no 
differences were seen in the high-dose regions compared to the IMRT plans without 
ERB. However, V
20
 and V
30
 were significantly higher in the 3D-CRT with ERB plans (p < 
0.003), except for V
30
 in the 3-field technique with ERB (p = 0.09). When Awall D
mean
 
were compared, no significant differences were seen between 3D-CRT with ERB (29.4 
Gy and 29.0 Gy in the 3-field and 4-field techniques, respectively) and IMRT without 
ERB (27.5 Gy) (Tables 2 and 3). 
Fig. 3   Differences in dose distribution on the anal wall (purple contour) between  
6 different plans within 1 patient (3-field technique without ERB (a), 3-field 
technique with ERB (b), 4-field technique without ERB (c), 4-field technique 
with ERB (d), IMRT without ERB (e), and IMRT with ERB (f), respectively. Blue area: 
planning target volume; green contour: rectal wall). Color figure at p 163.
Fig. 4   Mean V20-V70 of the 6 different techniques.
Abbreviations: 3field: 3-field technique; 4field: 4-field technique; - ERB: without ERB; + ERB: with ERB.
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According to the literature, there is no uniform way for Awall delineation. In the 
present study two different methods were used. The first method is based on a study 
by Vordermark et al. [7], although in their study no ERBs were applied. They found a 
median sphincter length of 4 cm, whereas in the present study this was 3 cm (range 
2.1-3.6 cm). An explanation for this variation might be the fact that Vordermark et al. 
used a CT slice thickness of 1 cm at the anal canal, whereas in our study 3-mm slices 
were obtained. Furthermore, by application of an ERB the cranial Awall boundary 
might be easier to assess. As a result, the Awall length might be estimated more 
accurately. A median Awall length of 3 cm is in concordance with several previous 
studies, where the anal wall was defined as the lowest 3 cm of the anorectum [6, 9, 
16]. However, these authors used this definition in all patients, irrespective of individual 
variations, whereas anal endosonography measurements have shown individual 
differences in length of the anal canal in a group of healthy volunteers [17].
The mean Awall
methA
 volumes on the CT-scans with and without ERB were 13.7 and 
14.6 cc, respectively. For Awall
methB
 these volumes were 14.0 and 15.1 cc, respectively. 
Compared to those reported by Peeters et al. [6] these volumes are slightly larger, as 
they found a mean anal volume of 10 cm3 by constructing an inner wall contour of the 
anorectum, using the model of Meijer et al. [18], which automatically constructs an 
inner wall from a delineated outer wall. However, as mentioned in their discussion 
they assumed that on every slice the wall volume is the same in the whole anorectum, 
which is debatable.  al-Abany et al. on the other hand described a mean (±SD) 
anal-sphincter region volume of 22 (±4) cm3, calculated as the total volume within the 
outer contour of the anal-sphincter region [9]. In the present study, the Awall was also 
considered to be a solid organ. When the scans with and without ERB were compared, 
no significant differences between the Awall volumes were found. This suggests a 
justification to delineate the anal wall as a solid organ. For both Awall delineation 
methods, application of an ERB led to significant dose reductions to the Awall.
Fecal incontinence is a serious problem after prostate radiotherapy, bothering a 
significant subpopulation of irradiated prostate cancer patients [5]. Its impact might 
be underestimated, especially when not actively asked for. Peeters et al. [6] analyzed 
641 patients, who were divided into four groups, based on Awall D
mean
 (range) 
quartiles: 52 Gy (46-67), 41 Gy (38-46), 33 Gy (28-38) and 19 Gy (2-28). They observed a 
significant association between RTOG/EORTC gastrointestinal (GI) toxicity grade ≥2 
and anal parameters in the low- and intermediate-dose regions as well as D
mean
. Also, 
a significant correlation between the endpoint “incontinence requiring pads” and all 
investigated dosimetric parameters was found, except for D
max
. When comparing the 
lowest and highest Awall D
mean
 groups, this resulted in an increased incidence of 
incontinence from 5% to 17%, while the 4-year cumulative incidence of GI toxicity 
grade ≥2 almost doubled (16% vs. 31%). Compared to these data, results from the 
present study suggest that application of an ERB may decrease the incidence of both 
GI toxicity grade ≥2 and incontinence requiring pads. The highest Awall D
mean
 was 
found in the 3D-CRT plans without ERB (41 Gy), whereas in the IMRT plans with ERB 
this was reduced to 20 Gy. According to the data provided by Peeters et al. [6], this 
would imply a reduction in 4-year cumulative incidence of GI toxicity grade ≥2 from 
29% to 16% and a reduction in incontinence requiring pads from 9% to 5%. As the 
present results are obtained from a planning study, the beneficial effect of an ERB 
needs to be confirmed in the clinical situation to evaluate and quantify the reduction 
in anal toxicity rates. The reduction of rectal toxicity by insertion of an endorectal 
balloon has been described previously [19]. 
Although the abovementioned studies show a dose-volume effect for fecal 
incontinence, the exact pathophysiology of radiation-induced anal toxicity is not 
clear. Petersen et al. [20] hypothesized that there are two categories of factors 
influencing incontinence: core factors and associated factors. The first category 
contains aspects of the anorectal organ itself, including changes in anal resting tone, 
squeezing pressure, and rectal volume or compliance, while the second category 
includes other disturbances of the lower digestive tract, such as diarrhea and proctitis. 
With respect to the first category, Yeoh et al. prospectively evaluated the effect of 
prostate radiotherapy on anorectal motor and sensory function, using anorectal 
manometry [21]. They concluded that at 2 years after radiotherapy there was a 
reduction of basal anal pressures and anal pressures in response to squeezing and 
increased intra-abdominal pressure. Also, there was a decrease in rectal compliance 
and rectal volumes associated with sensory perception and the desire to defecate. 
The fact that fecal incontinence is caused by a combination of anal and rectal factors 
is in concordance with a study done by Kushwaha et al. [22]. As a result, the Rwall and 
the Awall should be considered as separate critical normal tissues and both should be 
delineated and evaluated in treatment planning. 
As insertion of an endorectal balloon increases the distance between the main part 
of the anorectal wall and the PTV, both the Awall and Rwall are spared. Recently, 
excellent long-term biochemical control rates have been reported in localized 
prostate cancer patients treated with hypofractionated IMRT utilizing a rectal balloon, 
indicating no disadvantageous effect of the ERB on tumour control [Teh BS, et al., 
personal communication, 2008].
The fact that the DVH parameters for the high-dose regions and Awall D
mean
 in the 
3D-CRT plans with ERB in place were comparable to those in the IMRT plans without 
ERB indicates that an ERB in 3D-CRT might lead to a comparable Awall dose exposure 
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as can be achieved with IMRT without ERB. Given the previously described low toxicity 
rates in prostate IMRT [23,24], this suggests that application of an endorectal balloon 
in 3D-CRT might lead to a comparable low incidence of anal toxicity. In our department, 
IMRT combined with ERB is now daily practice in prostate radiotherapy. 
In conclusion, according to this planning study, application of an endorectal balloon 
is a patient friendly way to significantly reduce doses to the Awall in both prostate 
3D-CRT and IMRT with the most beneficial effect for IMRT combined with an ERB. This 
dose reduction may lead to a decrease in fecal incontinence. However, clinical 
research is warranted to confirm the expected beneficial effect on anal toxicity. The 
anal canal should be considered as a separate and important critical normal organ, to 
be spared in prostate radiotherapy.
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Introduction
Salvage radiotherapy (RT) is a curative treatment option for prostate cancer patients 
relapsing after radical prostatectomy. Recently, as in definitive prostate RT, a dose- 
response relationship has been established for this salvage treatment [1;2]. Increasing 
the dose from 60 Gy to 70 Gy led to an improved 5-year biochemical relapse-free 
survival from 25% to 58% [2]. However, an increase in dose inevitably leads to higher 
doses to surrounding normal tissues, especially to the rectum and anal canal. 
In a cohort of more than 950 patients acceptable late anorectal toxicity rates have 
been reported after post-prostatectomy RT with a median dose of 64 Gy [3]. However, 
given the abovementioned advantage of dose-escalation up to a dose of 70 Gy, 
toxicity rates mentioned in previous reports may increase, as several authors have 
mentioned dose-effect relationships for anal and rectal toxicity [4-6].
One way of sparing surrounding normal tissues is the use of highly conformal intensity- 
modulated radiotherapy (IMRT). In addition, in definitive prostate RT endorectal balloons 
(ERBs) are applied to decrease doses to the rectal wall (Rwall) and anal wall (Awall) 
[7-10]. To our knowledge, the effect of an ERB on anorectal doses or toxicity in post-
prostatectomy RT has not been investigated, although a single report has mentioned 
favourable genitourinary toxicity rates after postoperative IMRT with ERB [11]. 
We performed a planning study to investigate whether application of an ERB has a 
beneficial effect on anorectal doses in post-prostatectomy IMRT, i.e. if its use can 
counteract the potential increase in toxicity, caused by a dose-escalation up to 70 Gy. 
Therefore, treatment plans with and without ERB were compared, applying international 
guidelines for delineation of the clinical target volume (CTV). 
Materials and methods
Twenty consecutive patients, referred for salvage RT after prostatectomy, were 
included in this study, after informed consent was given. Two planning CT-scans per 
patient with 3 mm slice thickness were obtained in a supine position (Brilliance Big 
Bore CT, Philips Medical Systems, Bothell, WA, USA): one with ERB and one without 
ERB. No exclusion criteria were applied, except preexisting anorectal disease [12]. 
Before scanning, patients used a laxative suppository (bisacodyl 5 mg) and were 
advised to eat a light breakfast. Furthermore, they were instructed to drink 500 ml of 
water for bladder filling.  
Abstract
Background and purpose: To investigate the effect of an endorectal balloon (ERB) on 
anal wall (Awall) and rectal wall (Rwall) doses in high-dose post-prostatectomy inten-
sity-modulated radiotherapy (IMRT). 
Materials and Methods: For 20 patients, referred for salvage IMRT after prostatectomy 
for prostate cancer, two planning CT-scans were performed: one with and one without 
an air-filled ERB. A planning target volume (PTV) was defined, using international 
guidelines. Furthermore, the Awall and Rwall were delineated. On both scans, IMRT 
plans were generated with a prescribed dose of 70 Gy. The mean dose (D
mean
), 
maximum dose, minimum dose and volumes exposed to doses ranging from ≥20 Gy 
to ≥70 Gy (V
20
-V
70
) to the Awall and Rwall were calculated. Finally, inner Rwall surface 
areas exposed to doses ranging from ≥20 Gy to ≥70 (A
20
-A
70
) were calculated. Dose-
parameters were compared between plans with and without ERB.
Results: All Awall parameters, except V
70
, were significantly reduced by the ERB with an 
overall D
mean
 reduction of 6 Gy. Absolute reductions in dose-volume parameters 
varied from 5% to 11%. Significantly reduced Rwall V
30
, V
40
, and A
40
 were observed with 
ERB, irrespective of the target volume size.
Conclusions: ERB application significantly reduces Awall and to a lesser degree Rwall 
doses in high-dose post-prostatectomy IMRT. 
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Delineation of the Awall and Rwall has been described previously [7;15]. The Awall was 
considered a continuation of the Rwall and included the muscular structures forming 
the anal canal. On the scans with ERB, on each slice an outer anal wall contour was 
delineated from the anal verge up to the lowest slice with an ERB lumen. The inner 
anal wall contour was delineated around the ERB shaft. The difference between the 
outer and inner anal wall contour was defined as the Awall volume. On the scans 
without ERB, the same Awall length was applied as was obtained from the scans with 
ERB, starting at the anal verge. Furthermore, the same method was used, although 
the Awall volume was defined as the volume within the outer anal wall contour, as no 
inner anal wall contour could be identified, due to active closure of the anal canal. 
Recently, these delineation methods were shown to be reproducible and to lead to 
similar Awall volumes [7]. Next, outer rectal wall contours were delineated, followed 
by construction of inner rectal wall contours, using 5 mm wall thickness on slices 
without ERB and 3 mm on slices with ERB [15]. The inner rectal wall contours were 
subtracted from the outer rectal wall contours, thus creating the Rwall volume. The 
Rwall was delineated from the top of the Awall up to the rectosigmoid flexure. Finally, 
the urinary bladder and femoral heads were delineated, and the bladder volume was 
calculated.
On both the scans with and without ERB, step-and-shoot IMRT plans were generated 
with the inverse planning module Direct Machine Parameter Optimization, consisting 
of 5 coplanar, non-opposing 10 MV photon beams (0°, 50°, 95°, 265° and 310°) with a 
maximum of 60 segments. The prescribed dose to the PTV was 70 Gy in 2 Gy fractions 
[2], requiring >99% of the PTV to receive 95% of the prescribed dose. 
In all treatment plans, doses to the PTV, urinary bladder and femoral heads were 
calculated, as well as the mean dose (D
mean
), maximum dose (D
max
) and minimum dose 
(D
min
) to the Rwall and Awall. Also Rwall and Awall volumes (%) exposed to ≥20 Gy 
(V
20
), ≥30 Gy (V
30
), ≥40 Gy (V
40
), ≥50 Gy (V
50
), ≥60 Gy (V
60
), and ≥70 Gy (V
70
) were 
deducted from the treatment plans. Rectal wall dose-surface maps were generated 
for calculation and visualization of the spatial dose distribution to the rectal mucosa 
[16]. These maps were constructed by virtually “unfolding” the rectum and displaying 
the spatial dose distributions to the inner rectal wall (Fig. 3). To be able to compare 
these dose distributions between plans with and without ERB, the surface areas (%) 
exposed to ≥20 Gy (A
20
), ≥30 Gy (A
30
), ≥40 Gy (A
40
), ≥50Gy (A
50
), ≥60 Gy (A
60
), and ≥70 
Gy (A
70
), were calculated in bins of 1 cm2. All dose parameters were compared between 
the plans with and without ERB. 
The ERB consists of a 20-cm-long flexible shaft of polyvinylchloride with a silicon 
balloon fixed on it (QLRAD B.V., Dalfsen, The Netherlands). The shaft diameter is 13 
mm. Inflated with 100 cc of air, the diameter of the balloon is 6.0 cm and its length is 
6.5 cm. After insertion and inflation, the ERB was gently pulled towards the anal canal. 
To maintain this position and to prevent a longitudinal shift, the ERB was fixed with an 
individually adjustable stopper (Fig. 1). 
All CT-images were imported into the Pinnacle3 treatment planning system, version 8.0h 
(Philips Medical Systems, Andover, MA, USA). The post-prostatectomy CTV was delineated 
according to international consensus guidelines [13;14]. First, the vesicourethral anastomosis 
was identified on both CT-scans. After that, the retropubic space was delineated from the 
superior edge of the symphysis pubis to 9-12 mm below the vesicourethral anastomosis, 
using the levator ani and obturator internus muscles (lateral) and anterior rectal wall 
(posterior) as anatomic boundaries. Above the superior edge of the symphysis pubis, the 
CTV was extended 3-4 cm cranially, including seminal vesicle remnants and up to the 
transected remnants of the vas deferens. Altogether, the cranial border did not extend 
more than 4 cm above the superior edge of the symphysis pubis. Anteriorly, 1-2 cm of the 
posterior bladder was included, posterior the CTV was bound by the mesorectal fascia. 
The sacrorectogenitopubic fascia or obturator internus muscle acted as lateral boundary 
at this level. The same boundaries were used on both scans. Fig. 2 shows an example of a 
CTV in a patient without and with ERB. According to our local protocol, a 9 mm isotropic 
margin from CTV to planning target volume (PTV) was applied. 
Fig. 1  The endorectal balloon. See text for specifications.
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For statistical calculations, the SPSS 16.0.2 software for Windows was used (SPSS Inc. 
1989-2007). The Wilcoxon signed rank test was used for comparison of the measured 
parameters between the plans with and without ERB. Spearman’s rho was calculated 
to investigate possible correlations between CTV volume and normal tissue doses, 
and to investigate whether the difference in dose, induced by an ERB, was correlated 
with the CTV volume. Differences with a p-value < 0.05 were considered statistically 
significant.
Fig. 2   Continued. Color figure at p 165.
Fig. 3   Example of a relative rectal wall dose-surface map in a patient without endorectal 
balloon (left) and with endorectal balloon (right). Color figure at p 165.
Fig. 2   Sagittal (a), transverse (b-d) and coronal (e-g) views of delineated CTV on 
CT-scans without endorectal balloon (left column) and with endorectal 
balloon (right column). Red contour: CTV; blue contour: PTV; green contour: 
rectal wall; purple contour: anal wall. Color figure at p 164.
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Results
The mean CTV volumes (± SD) without and with ERB were slightly different: 117 (± 27, 
range 83-203) cc and 110 (± 20, range 77-157) cc, respectively (p = 0.02).
Awall volumes with and without ERB were not significantly different (mean 13.8 cc 
and 14.2 cc, p = 0.10). However, significant differences in Rwall and bladder volumes 
were observed: mean Rwall volume without ERB was 36.5 (± 9.0) cc vs. 41.8 (± 6.2) cc 
with ERB (p = 0.003); bladder volumes were 343.5 (± 179.7) cc and 384.3 (± 179.8) cc, 
respectively (p < 0.001). PTV coverage was good in all plans, with >99% of the PTV 
receiving 95% of the prescribed dose. The median PTV dose was 70.6 Gy and 70.3 Gy 
for the plans with and without ERB, respectively. D
2%
 was 72.7 Gy and 73.0 Gy, 
respectively, and D
98%
 was 68.0 Gy and 67.8 Gy, respectively.
Table 1 shows the differences in dosimetric parameters on the Rwall and Awall 
between the treatment plans without and with ERB. A significant reduction of all 
Awall parameters, except V
70
, was observed with an ERB inserted, with an overall D
mean
 
reduction of 6 Gy. Absolute reductions in dose-volume parameters varied from 5% 
(V
70
) to 11% (V
30
 and V
40
). Rwall V
30
 and V
40
 were significantly reduced by 8% and 5%, 
respectively. Dose-surface map analysis showed a significant reduction in Rwall A
40
, 
with an absolute reduction of 6%. In addition, the mean dose to the urinary bladder 
was significantly lower in the plans with ERB (45.9 Gy vs. 38.8 Gy, p < 0.001). D
max
 to the 
femoral heads did not differ between both plans (55.7 vs. 56.6 Gy, p = 0.30). Fig. 4 
shows an example of the dose distributions with and without ERB.
The CTV volume without ERB significantly correlated with Rwall V
30
 (Spearman’s rho 
0.513, p = 0.02), but not with Awall doses. This indicates that increasing CTV volumes 
lead to higher Rwall V
30
. With ERB inserted, only Rwall D
min
 correlated with the CTV 
volume (Spearman’s rho 0.541, p = 0.01). In addition, the dosimetric advantage of ERB 
(i.e. the difference in Rwall doses between plans without and with ERB) correlated 
with neither of the CTV volumes, suggesting that the gain from ERB insertion is not 
dependent on the CTV volume.
All patients tolerated the ERB well and reported no complaints, other than the slight 
urge to defecate during inflation due to an increase in local pressure to the Rwall. This 
sensation disappeared after 10-20 s. 
Table 1   Mean (± SD) dosimetric parameters on rectal wall (Rwall) and anal wall 
(Awall) in situations without and with endorectal balloon (ERB). Bold entries 
indicate significant differences. 
No ERB ERB p-value
Rwall Dmean (Gy) 42.3 (± 4.2) 40.1 (± 5.5) 0.15
Dmin (Gy) 6.5 (± 5.7) 5.5 (±4.1) 0.48
Dmax (Gy) 74.4 (± 0.9) 73.7 (± 0.9) 0.01
V20 (%) 84 (± 10) 80 (± 12) 0.26
V30 (%) 61 (± 8) 53 (± 9) 0.004
V40 (%) 48 (± 7) 43 (± 7) 0.03
V50 (%) 41 (± 6) 39 (± 6) 0.27
V60 (%) 35 (± 5) 35 (± 6) 0.72
V70 (%) 19 (± 4) 16 (± 6) 0.08
A20 (%) 82 (± 11) 84 (± 11) 0.36
A30 (%) 71 (± 11) 66 (± 12) 0.22
A40 (%) 58 (± 10) 52 (± 8) 0.03
A50 (%) 49 (± 9) 46 (± 7) 0.64
A60 (%) 40 (± 7) 40 (± 7) 0.56
A70 (%) 21 (± 6) 17 (± 7) 0.07
Awall Dmean (Gy) 42.0 (± 9.0) 36.1 (± 8.9) 0.005
Dmin (Gy) 7.8 (± 3.4) 6.0 (± 3.4) 0.03
Dmax (Gy) 75.1 (± 1.5) 73.3 (± 3.3) 0.002
V20 (%) 74 (± 13) 66 (± 16) 0.006
V30 (%) 60 (± 16) 49 (± 15) 0.001
V40 (%) 51 (± 17) 40 (± 14) 0.003
V50 (%) 43 (± 16) 34 (± 14) 0.01
V60 (%) 35 (± 15) 27 (± 13) 0.03
V70 (%) 19 (± 12) 14 (± 9) 0.08
Abbreviations: D
mean
 = mean dose; D
min
 = minimum dose; D
max 
= maximum dose; V
x
 = relative volume exposed 
to x Gy; A
x
 = relative surface area exposed to x Gy. 
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with ERB. Regarding Awall dose parameters, all parameters, except V
70
, were 
significantly reduced by the ERB, with a D
mean
 reduction of 6 Gy. A recent study has 
shown the same effect of ERBs in primary prostate RT planned to a total dose of 78 Gy, 
with an Awall D
mean
 reduction of 7.5 Gy in IMRT [7]. Also, the absolute reductions in 
V
20
-V
70
 were in the same range as they are in the present study (5-14%). 
In several reports, dose-effect relationships for anorectal toxicity after definitive RT 
have been mentioned, implying that increasing doses lead to higher toxicity rates 
[4-6]. Regarding Awall doses, several dose-volume parameters, as well as D
mean
 have 
been found to be associated with fecal incontinence; for an increase of Awall D
mean
 by 
1 Gy, a hazard ratio for incontinence of 1.039 has been observed [4]. This means that 
in the present study, patients treated without ERB, which showed an increased Awall 
D
mean
 of 6 Gy, would have an increased incidence of incontinence by a factor (1.0396 =) 
of 1.26 compared to patients treated with ERB. In the same study, patients having an 
Awall D
mean
 of 41 Gy, which is almost equivalent to the No-ERB group from the present 
study, had a 4-year risk of developing fecal incontinence requiring pads of almost 
10%. The incidence of incontinence not requiring pads may have been even higher. 
Given the bothering nature of these complaints [18], every effort should be made to 
reduce the risk of these complaints. This may be accomplished by using ERBs. With 
regard to Rwall parameters, not only volumes exposed to high doses [4], but also 
volumes and surfaces exposed to intermediate doses (30-40 Gy) are predictive for the 
development of late rectal bleeding [5;6]. This suggests that, although the absolute 
reductions in the present study were small, with application of an ERB in post-prosta-
tectomy RT, late rectal bleeding may be reduced. These dose-effect relationships, 
however, have been derived from patients undergoing definitive RT. In the post-pros-
tatectomy setting, Cozzarini et al. have found correlations between late rectal 
bleeding and rectal V
50
-V
60
. However, volumes exposed to lower doses were not 
investigated [19]. Furthermore, as in many previous studies, they delineated the 
rectum from the anal verge up to the rectosigmoid flexure, thus including the anal 
canal, while it is clear from this and other studies [4] that dose- and volume-effect 
relationships are different for rectum and anal canal. 
Teh et al. have used ERBs in post-prostatectomy RT for consistency of the target 
volume by reducing prostate bed movement [11]. To our knowledge, however, no 
comparative study on this subject between the situation with ERB and without ERB 
has been performed so far. Without ERB, gold marker based portal imaging showed 
interfraction prostate bed motion to be minimal, [20], while Fiorino et al. showed a 
mean anterior shift of 2.5 mm for the anterior Rwall, changing the posterior border of 
the CTV, using weekly repeated CT-imaging [21]. This shift of the posterior CTV border, 
however, was observed only in the cranial half of the rectum. No shift was observed 
Discussion
This planning study shows that application of an ERB leads to reduced anorectal 
doses in high-dose post-prostatectomy IMRT, which can be explained by an increased 
distance between the PTV and posterior and lateral Rwall and Awall. This observation 
is in concordance with studies on ERB application in definitive prostate RT [7;15-17] 
and suggests that an ERB can be helpful in dose-escalated post-prostatectomy RT, as 
it may reduce anorectal toxicity. Furthermore, we observed that this ERB-induced 
reduction in anorectal dose was not influenced by the size of the CTV volume.
Several planning studies with ERB have shown reduced Rwall doses in both 3D 
conformal RT and IMRT, mainly in the intermediate- and high-dose range [16;17]. In 
the present study, significant reductions of V
30
, V
40
, and A
40
 were observed in the plans 
Fig. 4   Sagittal (a) and transverse (b-c) views of dose distributions in one patient 
without endorectal balloon (left) and with endorectal balloon (right).  
Contours as in Fig. 2. Color figure at p 166.
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in the caudal half of the rectum, which included the anal canal, as defined in the 
present study. In addition, Showalter et al. found a mean posterior shift of the anterior 
Rwall of 1.6-2.7 mm using cone beam CT, which they attributed to a reduced rectal 
volume over time during RT [22]. All these studies were performed without ERB. With 
application of an ERB, the rectal volume might be held more constant during all 
treatment sessions, thereby possibly reducing prostate bed, and thus CTV, variation. 
However, this has yet to be confirmed in a clinical study, e.g. by using daily cone beam CT. 
In addition to shifts of the rectum, large variations in bladder volumes have been 
observed in post-prostatectomy RT [21]. These variations, however, were only in the 
cranial and anterior direction, suggesting no influence of bladder filling on the CTV or 
present observations regarding Awall and Rwall doses. In the present study, bladder 
volumes were increased on the scans with ERB, which can be attributed to the 
sequence of scanning: in all patients the scans with ERB were obtained approximately 
15 minutes after the scans without ERB, leading to increased bladder filling. This might 
also explain the significantly reduced bladder dose on the plans with ERB. 
Due to the abovementioned variations and other setup uncertainties, CTV-PTV 
margins are applied. In our institution, an isotropic 9 mm margin is used. Electronic 
portal imaging of fiducial markers, implanted in the prostate bed has shown a 
relatively large number of fractions in which the total setup error exceeded 5 mm [20]. 
In addition, cone beam CT imaging of the pelvic anatomy led to the recommendation 
to use non-uniform margins, with nonetheless a posterior margin of 8.6 to 10.2 mm 
[22]. These data indicate that care must be taken not to use too small margins, as this 
might lead to underdosage of the CTV. Although ERBs potentially have a stabilizing 
effect, clinical data are warranted before margins can be reduced. In the meantime, 
adaptive RT, based on the image-guidance modalities mentioned above, might be 
helpful in reducing uncertainties, and thus CTV-PTV margins.
Different groups have suggested guidelines for CTV delineation [13;14;23-25], based 
on patterns of local failure. As most of the failures are located around the vesicourethral 
anastomosis, it is advocated to extend the caudal border of the CTV low enough to 
include this structure. Inevitably, this will lead to higher doses to the Awall. To 
counteract this effect, ERB application can reduce these doses, as shown in the 
present study. Although different guidelines for CTV delineation exist, the variation in 
delineation of the caudal part (i.e. near the Awall) is small between these guidelines. 
Therefore, the observed advantages regarding Awall doses are probably within the 
same range when another guideline is used. 
Compared to the Awall, less pronounced differences in Rwall doses were observed, 
possibly because of deformation of the prostatic fossa. By inflating the ERB, the 
anterior Rwall protrudes, which causes the cranial CTV to move backwards and shape 
around the ERB (Fig. 2b), so the PTV inevitably includes a larger portion of Rwall. This 
effect is potentially larger than it is in primary prostate RT, as in the latter situation the 
prostate prevents the rectum to protrude any further. However, in definitive RT, 
seminal vesicles can also be pushed around the Rwall, when an ERB is applied, and 
still a beneficial effect has been observed in this situation [16;17]. The present study 
showed that a small increase in Rwall volumes was observed on the scans with ERB. 
Further analysis revealed that on the scans without ERB the mean length of rectum 
was 8.7 cm, compared to 9.1 cm on the scans with ERB, which may explain this 
difference. Furthermore, as IMRT plans were generated based on our class solution for 
prostate IMRT, we acknowledge that in individual patients Rwall doses may be 
somewhat lower.
It should be noted that the abovementioned guidelines for CTV delineation were 
provided for salvage RT without ERB, whereas in this study they were used in both 
situations without and with ERB. However, the anatomic landmarks suggested as CTV 
boundaries in the used consensus guidelines could be identified on the scans with 
ERB as well. In addition, the CTV volumes in the plans without and with ERB were only 
slightly different (mean 117 and 110 cc). 
Finally, as the present observations were derived from a planning study, a clinical trial 
is needed to investigate whether the application of ERBs will lead to a decrease in 
anorectal toxicity.
In conclusion, in this planning study application of an ERB in high-dose post-prosta-
tectomy IMRT up to 70 Gy leads to reduced anorectal doses, especially regarding the 
Awall, with a mean reduction in D
mean
 of 6 Gy. Intermediate-dose parameters to the 
Rwall were also reduced. These observations suggest that ERB application can be 
helpful in post-prostatectomy dose-escalation, as it may reduce anorectal toxicity.
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CHAPTER 5 ANORECTAL DYSFUNCTION AFTER PROSTATE RADIOTHERAPY
Introduction
Late anorectal toxicity is a concern after dose-escalated external beam radiotherapy 
for prostate cancer. A recent update of a Dutch dose-escalation trial showed a 35% 
cumulative incidence of late anorectal toxicity grade ≥2 after 78 Gy [1]; the incidence 
of late grade ≥1 anorectal toxicity after intensity-modulated radiotherapy (IMRT) is up 
to 65% [2]. Anorectal toxicity comprises different symptoms [3], of which fecal 
incontinence and urgency seem to bother patients most [4]. Identification of specific 
anatomical and functional changes in patients with anorectal symptoms after 
radiotherapy might help to unravel its underlying pathophysiologic mechanisms, 
which are still unclear. Furthermore, if there is a relationship with radiation dose, this 
could help to define specific constraints in radiotherapy-planning.
Several reports have described objective changes in patients with rectal toxicity after 
external beam prostate radiotherapy, like mucosal changes on endoscopy in patients 
suffering from late rectal bleeding [5;6]. Dosimetric predictors for late rectal bleeding 
have been identified, in particular rectal volumes receiving intermediate or high 
doses [7;8]. Yeoh et al. have reported progressive anorectal dysfunction, evaluated 
with anorectal manometry, demonstrating a deterioration of anorectal motility and 
sensory function over time [9]. However, a dose-effect relationship for the anal canal 
and rectum was not investigated.
The goal of the present study is to explore the associations between dosimetric 
parameters, functional changes and specific anorectal complaints after external beam 
prostate radiotherapy by evaluating anorectal functions in patients with and without 
late anorectal toxicity. The results are compared to an untreated control group. 
Dose-effect relationships are investigated for the anal wall and the rectal wall separately.
Methods and materials
Sixty patients with localized prostate cancer, treated at our department between 
January 2000 and December 2007 were included in this study during regular 
follow-up. All patients were treated with external beam radiotherapy, either 3-field or 
4-field 3D-conformal radiotherapy, or 5-field IMRT, at least 90 days before inclusion in 
this study. The prescribed dose was 67.5 Gy or 70.0 Gy in fractions of 2.25 Gy or 2.50 
Gy, respectively. In 30 of the 60 patients a daily inserted endorectal balloon filled with 
80 cc of air was applied for rectal wall sparing (QLRAD B.V., Dalfsen, The Netherlands). 
In addition, 30 patients with a localized prostate carcinoma were analyzed prior to 
radiotherapy and served as a control group. All men had given informed consent.
Abstract
Purpose: To explore the influence of functional changes and dosimetric parameters on 
specific incontinence-related anorectal complaints after prostate external beam radio- 
therapy and to estimate dose-effect relationships for the anal wall and rectal wall.
Methods and materials: Sixty patients, irradiated for localized prostate cancer, 
underwent anorectal manometry and barostat measurements to evaluate anal 
pressures, rectal capacity and rectal sensory functions. In addition, thirty untreated 
men were analyzed as a control group. In thirty-six irradiated patients, the anal wall 
and rectal wall were retrospectively delineated on planning CT-scans and dosimetric 
parameters were retrieved from the treatment plans. Functional and dosimetric 
parameters were compared between patients with and without complaints, focussing 
on urgency, incontinence and frequency.
Results: After external beam radiotherapy, reduced anal pressures and tolerated rectal 
volumes were observed, irrespective of complaints. Patients with urgency and/or 
incontinence showed significantly lower anal resting pressures (mean 38 and 39 vs. 49 
and 50 mm Hg) and lower tolerated rectal pressures (mean 28 and 28 vs. 33 and 34 
mm Hg), compared to patients without these complaints. In patients with frequency 
almost all rectal parameters were reduced. Several dosimetric parameters to the anal 
wall and rectal wall were predictive for urgency (e.g. Anal D
mean
 >38 Gy), whereas some 
anal wall parameters correlated to incontinence and no dose-effect relationship for 
frequency was found.
Conclusions: Anorectal function deteriorates after external beam radiotherapy. 
Different incontinence-related complaints show specific anorectal dysfunctions, 
suggesting different anatomical and pathophysiologic substrates: urgency and 
incontinence seem to originate from both anal wall and rectal wall, whereas frequency 
seems associated with rectal wall dysfunction. Also dose-effect relationships differed 
between these complaints. This implies that anal wall and rectal wall should be 
considered separate organs in radiotherapy-planning.
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volumes (V) at which patients reported the moment when they first became aware of 
something present in the rectum (P-sense and V-sense, respectively), the first desire 
to defecate (P-urge and V-urge, respectively) and the moment they experienced an 
uncontrollable urge to defecate or discomfort (P-discomfort and V-discomfort, 
respectively) were recorded. 
Dose evaluation
Of thirty-six irradiated patients planning CT-scans were available for retrospective 2D 
delineation of the anal wall and rectal wall, using the Pinnacle3 treatment planning 
system (Philips Medical Systems, Fitchburg, WI). Of these patients, 17 were treated 
with an endorectal balloon and 19 were treated without a balloon. In the remaining 
24 patients, CT-planning had been performed as well. Due to the use of an older 
treatment planning system, however, retrospectively contouring the abovementioned 
structures was not possible. Therefore, these were excluded from analyses regarding 
dosimetry.  
As described previously [13], the anal wall was considered a continuation of the rectal 
wall and was outlined from the anal verge to the slice below the lowest slice with a 
rectal or endorectal balloon lumen. The outer anal wall contour encompassed the 
muscular structures forming the anal canal. In case of a balloon, an inner anal wall 
contour was delineated around the balloon shaft, and the anal wall volume was 
defined as the difference between the outer and inner anal wall contour. In patients 
without balloon the anal wall was defined as the volume within the outer anal wall 
contour, inasmuch as the anal canal is actively closed. Recently, it has been shown 
that these delineation methods are well reproducible and lead to identical anal wall 
volumes [13]. 
After the outer rectal wall contours were delineated on each CT-slice, an inner rectal 
wall was constructed using a 5 mm wall thickness on slices without endorectal 
balloon, and 3 mm on slices with balloon [14]. The volume of the inner rectal wall 
contour was subtracted from that of the outer rectal wall contour and this was defined 
as the rectal wall volume. The rectal wall was delineated from the top of the anal wall 
up to the rectosigmoid flexure.
From all treatment plans the anal wall and rectal wall minimum, maximum and mean 
dose (D
min
, D
max
, and D
mean
, respectively) and volumes (%) exposed to ≥20 Gy (V
20
), ≥30 
Gy (V
30
), ≥40 Gy (V
40
), ≥50Gy (V
50
), ≥60 Gy (V
60
), and ≥70 Gy (V
70
), were derived. In 
addition, to visualize the spatial dose distribution to the rectal mucosa, the dose to 
the inner rectal wall contours was displayed by means of virtual rectum “unfolding”, 
thus generating dose-surface maps [15]. In order to be able to compare these dose 
Late toxicity and functional assessment
During follow-up, all patients were seen every three months during the first two years 
after treatment and every year afterwards. Late anorectal toxicity was scored, based 
on items of the late ‘Radiotherapy-Induced Lower Intestinal Toxicity’ scoring system 
[3]. This system includes eight symptoms: anal blood loss, mucus loss, abdominal 
cramps, diarrhea, frequency, urgency, incontinence, and anal pain, scored 0 to 4 (0 = 
complaint is absent; 1 = complaint is present, although no therapy is required; 2 = first 
line treatment is required (e.g. peroral therapy); 3 = second line treatment is required 
(e.g. IV therapy); 4 = serious treatment is required (i.e. surgery or transfusions; not all 
complaints have a grade 4 score)). It has been shown that incontinence-related 
complaints (urgency, incontinence and frequency) bother patients most [4] and 
therefore we have focused on these three symptoms, as did previous investigators 
[10]. Because the majority of complaints were classified as grade 1 toxicity, the items 
were scored binary (i.e. absent or present). Complaints were considered present when 
they were reported at the most recent follow-up. Patients with and without complaints 
after radiotherapy are referred to as Complaints-group and No-complaints-group, 
respectively. Next, based on the presence or absence of urgency, incontinence and 
frequency these patients were divided into Urgency- and No-urgency-, Incontinence- 
and No-incontinence- and Frequency- and No-frequency-groups, respectively.
 
All ninety patients underwent anorectal manometry and barostat testing to evaluate 
anal pressures, rectal capacity and rectal sensory functions. During anorectal function 
testing patients were in left lateral position. In manometry, a customized anorectal 
motility catheter (Arndorfer Medical Specialties, Greendale, WI) with four radially 
oriented recording points 90 degrees apart and a 15-cm-long polyethylene bag 
attached to the distal end was inserted via the anal canal. A standard station 
pull-through technique was used [11] with a water-perfused catheter to assess resting 
and squeeze pressures at consecutive 1-cm levels of the anal canal in four separate 
quadrants. The resting anal canal pressure (P-resting) was defined as the highest 
resting pressure and the anal squeeze pressure (P-squeeze) as the highest increase 
over resting pressure during maximal active squeezing. Both values were calculated 
as the average pressure in the four recording points.
Rectal sensory thresholds were assessed during inflation of the bag, positioned at 5 
cm of the anal verge, using an electronic barostat (Distender II®, G&J Electronics Inc., 
Ontario, Canada). Barostat procedures were performed in accordance with previously 
described and validated techniques [11;12]. After an initial staircase distension (4 mm 
Hg steps, 30 s per step) to reduce variability, a rectal staircase distension was 
performed starting at an intrabag pressure of 0 mm Hg. At 1 min intervals, the intrabag 
pressure was increased 2 mm Hg and kept constant. Both the pressures (P) and 
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frequency, urgency and incontinence) eight patients reported all three complaints, 
fifteen reported to have a combination of two complaints, and ten patients had only 
one of these symptoms. Both urgency and incontinence, and urgency and frequency 
were significantly correlated (p = 0.001), whereas incontinence and frequency were 
not. Of the 36 patients, whose treatment plans were evaluated, 23 (64%) reported 
complaints, with frequency, incontinence and urgency reported in 14 (39%), 11 (31%) 
and 11 (31%) cases, respectively. In the control group no complaints were reported.
When the results of the anorectal function tests between the Complaints- and No-
complaints-group were compared, the Complaints-group tolerated a significantly 
lower V-discomfort than the latter (181 vs. 231 mL, p = 0.03). The other parameters did 
not significantly differ between these groups, although a borderline significant 
reduced P-resting was observed in the Complaints-group (43 vs. 51 mm Hg, p = 0.06). 
When patients were categorized according to specific symptoms, however, more 
distributions between patients, the surface areas (%) exposed to ≥10 Gy (A
10
), ≥20 Gy 
(A
20
), ≥30 Gy (A
30
), ≥40 Gy (A
40
), ≥50Gy (A
50
), ≥60 Gy (A
60
), ≥65 Gy (A
65
), and ≥70 Gy (A
70
), 
were calculated in bins of 1 cm2.
To correct for differences in biological effect of the different fractionation schedules, 
all mean, maximum and minimum doses were recalculated to an equivalent dose in 
2-Gy fractions (EQD
2
) using the following formula, based on the linear-quadratic (LQ) 
model [16]: 
EQD
2
 = D (d + [α/β]) / (2 + [α/β])
where D is the total physical dose (Gy) given in fractions of d Gy and α/β is a measure 
of fractionation sensitivity, which was set to 3 Gy for late anorectal toxicity [17].
Statistical analysis
The SPSS 14.0 software for Windows (© SPSS Inc., 1989-2005) was used for statistical 
calculations. The Kolmogorov-Smirnov test showed a normal distribution of the 
measured values for all parameters. One-way analysis of variance was performed to 
compare means between the Complaints- and No-complaints-group, and the control 
group. The independent t-test was used for comparison of both functional and dose 
parameters between the Complaints- and No-complaints-group. For comparison of 
categorical data (i.e. complaints and risk factors) between groups the chi-square test 
was used. Contingency tables were constructed and Pearson’s chi-square was 
calculated to determine the correlation between complaints. Regression analysis was 
performed to investigate possible associations between duration of follow-up and 
manometry outcomes (linear regression) and the presence of symptoms (logistic 
regression). P-values ≤ 0.05 were considered indicative for significant differences, 
although differences with p-values < 0.01 should be considered clearly significant, 
given the number of statistical tests (e.g. see Fig. 1)
Results
There were no statistically significant differences in baseline and treatment character-
istics between patients with complaints (n=38) and patients without complaints 
(n=22), nor when comparing with controls (n=30) (Table 1).
Thirty-eight (63%) of the irradiated patients reported one or more complaints, with 
the following distribution: frequency: 26 (43%), urgency: 22 (37%), incontinence: 19 
(32%), anal blood loss: 12 (20%), mucus loss: 11 (18%), diarrhea: 7 (12%), abdominal 
cramps: 1 (2%), and anal pain: none. Of the complaints related to incontinence (i.e. 
Fig. 1   Associations between complaints and the investigated parameters (solid lines 
represent p-values < 0.01; dashed lines represent p-values 0.01-0.05).  
This figure summarizes the associations listed in Tables 2 and 3 with p < 0.05. 
In addition, Anal D
mean
, V
20
 and V
30
 were associated with V-sense and V-urge 
(p-values ranging from 0.02 to 0.05).
Incontinence Urgency Frequency
Dmin Dmean V70V60V50V40V30V20Dmin Dmin Dmean V70V60V50V40V30V20Dmin A20 A30 A70A60A50A40
Anal wall dose parameters Rectal wall dose parameters
P-resting P-squeeze V-urgeV-senseP-discomfortP-urgeP-sense V-discomfort
Anorectal manometry 
parameters
Barostat measurement 
parameters
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measurements demonstrated significant differences between the groups (Table 2). 
The Urgency-group, irrespective of the presence of other complaints, showed a 
significantly lower P-resting and lower P-discomfort than the No-urgency-group. The 
same differences applied to the Incontinence- and No-incontinence-group. Compared 
to the No-frequency-group, the Frequency-group had reductions in almost all sensory 
thresholds.
In Table 3, anorectal dosimetric parameters are displayed, only including data with 
statistically significant differences between patients with and without complaints. No 
overall differences were observed between the Complaints- and No-complaints-
group. When specific complaints were compared, however, several differences were 
observed. The No-urgency-group received significantly lower doses to the anal wall 
Table 1  Patient characteristics.
  
Complaints No-complaints Control
n 38 22 30
Age (± 1 SD) 74 (5.2) 72 (6.0) 68 (8.0)
T-stage: T1 8 1 4
T2 11 13 8
T3 18 8 18
T4 1 0 0
Grade: 2 25 11 11
3 13 11 19
PSA (ng/ml) pre-treatment (range) 18.2 (0.48-159) 20.2 (1.59-61.7) 17.3 (0.68-63.0)
Follow-up (months) 35 (4-84) 30 (4-96) n.a.
Technique:            
4-field 3D-CRT 29 11 n.a.
3-field 3D-CRT 6 9 n.a.
IMRT 3 2 n.a.
Total dose/fraction dose (Gy):
67.5/2.25 32 12 n.a.
70.0/2.5 6 10 n.a.
Treatment with ERB 14 16 n.a.
Potential risk factors:
Previous abdominal surgery 13 9 13
Diabetes 3 1 1
Anticoagulant drugs 11 8 6
Abbreviations: PSA = prostate-specific antigen; 3D-CRT = three-dimensional conformal radiotherapy; IMRT = 
intensity-modulated radiotherapy; ERB = endorectal balloon.
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(correlation coefficients ranging from -0.376 (p = 0.02) to -0.334 (p = 0.05)). Fig. 1 
displays the associations between complaints and the investigated parameters.
Based on the significant differences in dosimetric parameters between the Urgency- 
and No-urgency-group an attempt was made to define low-risk and high-risk groups 
for the development of late anorectal toxicity. In the present study, when applying a 
cut-off value of Anal D
mean
 = 38 Gy, patients with D
mean
 <38 Gy had a 15% risk of 
developing urgency, compared to 62% in patients with D
mean
 >38 Gy. Approximately 
equal differences were observed for Rectal D
mean
 = 44 Gy and several volume and 
surface parameters. For incontinence, cut-off values Anal D
min
 = 5 Gy and Anal V
50
 = 
39% were observed.
The control group scored significantly better on P-resting, V-urge, and V-discomfort 
compared to the irradiated patients, irrespective of the presence of complaints (Table 4). 
Measurements in patients with none of the investigated complaints were not 
significantly different from the control group. However, many differences were seen 
between the Complaints-groups and the control group (Table 2). 
Interestingly, when manometry data between the three groups were compared 
(Complaints-group, No-complaints-group and control group), for most items a gradual 
deterioration was observed, with the best and worst outcomes for the control group 
and Complaints-group, respectively.
and rectal wall than the Urgency-group and a number of volume- and surface-area 
parameters were lower in the No-urgency-group. In addition to the data in Table 3, a 
borderline significant reduction in Anal V
70
 and Rectal A
65
 was observed. In the Incon-
tinence-group, besides a higher Anal D
min
 and Anal V
50
, Anal D
mean
 (40.1 vs. 32.5 Gy, p = 
0.08), Anal V
40
 (42% vs. 28%, p = 0.08) and Anal V
60
 (24% vs. 14%, p = 0.08), and Rectal 
D
min
 (2.1 vs. 5.1 Gy, p = 0.052) were higher as compared to the No-incontinence-group. 
No significant dosimetric differences were observed between the Frequency- and No-
frequency-group. The only significant correlations between function testing and 
dosimetry were Anal D
mean
, V
20
 and V
30
 negatively correlating with V-sense and V-urge 
Table 3   Significant differences in dosimetric parameters (mean ± 1 SD) between 
patients with and without complaints after external beam radiotherapy, 
measured in 36 patients.
  
Symptom
Dosimetric parameter Present Absent p-value
Urgency Anal D
min
 (Gy) 10.1 (9.1) 4.9 (5.3) 0.04
Anal D
mean
 (Gy) 42.1 (12.1) 31.6 (10.6) 0.02
Anal V
30
 (%) 72 (27) 49 (25) 0.02
Anal V
40
 (%) 48 (21) 26 (19) 0.004
Anal V
50
 (%) 36 (17) 18 (15) 0.003
Anal V
60
 (%) 25 (14) 13 (15) 0.04
Rectal D
mean
 (Gy) 45.3 (8.6) 39.6 (6.3) 0.03
Rectal V
30
 (%) 76 (15) 62 (20) 0.04
Rectal V
40
 (%) 54 (15) 39 (10) 0.001
Rectal V
50
 (%) 42 (13) 33 (7) 0.03
Rectal A
40
 (%) 62 (15) 48 (12) 0.007
Rectal A
50
 (%) 52 (14) 39 (9) 0.002
Incontinence Anal D
min
 (Gy) 10.0 (9.1) 5.0 (5.4) 0.04
Anal V
50
 (%) 33 (20) 20 (15) 0.04
Frequency - - - -
Abbreviations: D
min
 = minimum dose; D
mean
 = mean dose; V
x
= relative volume exposed to at least x Gy;
 
A
x
= 
relative surface area exposed to at least x Gy. 
Table 4   Mean (± 1 SD) anorectal manometry and barostat measurements in 
irradiated patients and the control group.
Irradiated Control p-value
P-resting (mm Hg) 46 (17) 59 (17) 0.001
P-squeeze (mm Hg) 153 (58) 175 (61) 0.11
Rectal distension
P (mm Hg)
Sense 14 (5) 13 (4) 0.44
Urge 19 (6) 19 (7) 0.94
Discomfort 32 (9) 32 (8) 0.89
V (mL)
Sense 90 (76) 108 (68) 0.27
Urge 128 (81) 164 (81) 0.05
Discomfort 199 (89) 266 (88) 0.001
Abbreviations: as in Table 2.
80 81
5
CHAPTER 5 ANORECTAL DYSFUNCTION AFTER PROSTATE RADIOTHERAPY
Discussion
This study shows that external beam prostate radiotherapy can lead to specific 
anorectal dysfunction. The type of dysfunction varies between patients with urgency, 
incontinence and frequency, suggesting different anatomical and pathophysiologic 
substrates. Also anorectal dosimetric parameters differ between patients with and 
without the respective complaints. Urgency showed a clear association with P-resting 
and with dosimetric parameters Anal V
30
 and V
40
, as well as Rectal V
40
, A
40
 and A
50
. 
Frequency was strongly associated with V-discomfort. Based on these findings, 
frequency seems to originate from changes in rectal function, suggesting it may be 
caused by an impaired rectal capacity and sensory function. Urgency, and to a lesser 
degree incontinence, seems to have a more complicated pathophysiology, i.e. a 
combination of reduced rectal capacity and anal pressures, as it is associated with 
both anal and rectal wall parameters. 
When patients who were examined before and after radiotherapy were compared, 
significantly reduced anal pressures and tolerated rectal volumes were observed in 
the latter group. These results are consistent with previous studies, where anorectal 
functions in prostate cancer patients were measured before radiotherapy and were 
prospectively followed with repeated function testing [9;10;18]. During a 2-year 
follow-up, Yeoh et al. found progressive deteriorations of anal pressures, rectal 
compliance and rectal volumes associated with sensory perception and the desire to 
defecate. Furthermore, an inverse relationship between fecal incontinence scores and 
rectal compliance and anal squeeze pressure was observed [9;10]. In the present 
study, patients with incontinence tolerated significantly lower pressures to the rectal 
wall than patients without incontinence, and had significantly reduced basal anal 
pressures. Comparable differences applied to patients with and without urgency. 
Interestingly, when patients were classified according to the presence of frequency, 
several differences in sensory functions and rectal capacity were seen in favour of the 
No-frequency-group, whereas anal pressures were not significantly different. Based on 
these results, we hypothesize that frequency is mainly caused by changes in rectal 
wall sensory functions and compliance, leading to an impaired rectal capacity, while 
the pathophysiology of incontinence and urgency involves impairment in both anal 
and rectal functions. The multifactorial pathogenesis of fecal incontinence has been 
acknowledged previously [18;19]. Petersen et al. stated that both the anal sphincter 
muscles and rectal compliance and volume are so-called core factors in the etiology of 
incontinence, while associated factors, like mucosal sensory function, also contribute 
to its development [19]. The role of individual muscles of the continence apparatus on 
specific complaints and possible dose-effect relationships are topics for future 
research (e.g. by separately delineating these structures in treatment planning).
Regression analysis revealed that duration of follow-up had only a significant 
association with P-squeeze (B = -1.08 (95% confidence interval -1.71 to -0.46), beta 
coefficient = -0.414, p = 0.001). For all other investigated parameters (i.e. manometry 
outcomes and presence of complaints) no such effect was observed.
Finally, patients treated with endorectal balloon showed significantly less complaints 
than patients treated without balloon, as well as lower doses to the anal wall and 
rectal wall. Furthermore, P-squeeze was significantly higher in patients treated with 
ERB (Table 5).
Table 5   Significant differences between patients treated without and with 
endorectal balloon.
  
No endorectal 
balloon
Endorectal 
balloon
p- value
Complaints Urgency (%) 57 17 0.001
Incontinence (%) 43 20 0.05
Frequency (%) 60 27 0.009
Function 
testing
P-squeeze (mm 
Hg)
138 (47) 169 (65) 0.04
Dosimetric 
parameters
Anal D
mean
 (Gy) 39.2 (11.6) 29.9 (11.1) 0.02
Anal V
30
 (%) 68 (23) 43 (26) 0.005
Anal V
40
 (%) 44 (20) 20 (17) 0.001
Anal V
50
 (%) 32 (17) 14 (14) 0.001
Rectal D
max
 (Gy) 71.4 (2.0) 74.9 (3.6) 0.001
Rectal V
30
 (%) 73 (16) 58 (21) 0.02
Rectal V
40
 (%) 49 (15) 38 (9) 0.008
Rectal V
50
 (%) 39 (11) 32 (7) 0.03
Rectal A
10
 (%) 81 (13) 89 (8) 0.04
Rectal A
20
 (%) 75 (14) 83 (8) 0.05
Abbreviations: as in Tables 2 and 3.
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Gradual deteriorations in function scores between patients with and without 
complaints, and the control group were observed. As expected, the first group scored 
worse than the last group. Although not all differences reached statistical significance, 
it is interesting to note that the scores of the patients without complaints were in 
between these groups. A possible explanation for this phenomenon might be that 
radiation-induced damage remains subclinical until a certain threshold is reached. 
Furthermore, as the development of late radiation damage is a dynamic process [5;10], 
patients without complaints could theoretically still be in the “developing phase”, and 
reveal complaints (and more deteriorated functional measurements) later on. 
However, as in this study the follow-up time between the Complaints- and No-com-
plaints-group was not significantly different, this is probably not the (only) explanation 
for these observations. Future research with repeated measurements can be useful in 
further investigating possible subclinical damage and its relationship to radiation 
dose.
To our knowledge, this is the first attempt to correlate specific incontinence-related 
anorectal complaints to both functional measurements and dosimetric data for the 
anal canal and the rectum. Previous studies showed no influence of the radiation 
technique (i.e. 2D or 3D) or the radiation dose schedule (i.e. 55 Gy in 20 fractions or 64 
Gy in 32 fractions) on anorectal dysfunction [9;10]. Although in the study comparing 
2D- and 3D-radiotherapy a description of relative D
min
, D
mean
 and D
max
 to the anorectum 
was given, this was only mentioned for patients after 3D-radiotherapy and no 
distinction was made between patients with and without complaints [9]. Also, in 
these studies no dose parameter assessments were performed for anal wall and rectal 
wall separately. 
Retrospective analysis of the treatment plans in the present study shows that 
dosimetric differences in patients with and without urgency, incontinence and 
frequency varied. The Urgency-group had received significant higher doses on both 
the anal wall and the rectal wall, compared to the No-urgency-group (Table 3). Fokdal 
et al. found that Anal D
min
, D
mean
, D
max
 and V
30
-V
60
 were significantly correlated to fecal 
urgency [20], while Al-Abany et al. observed a significant correlation between urgency 
and rectal wall doses in the range of 25-42 Gy [21]. Almost all of these parameters 
proved to be significantly different between the Urgency- and No-urgency-group in 
our study. 
When the Incontinence- and No-incontinence-group were compared, some dosimetric 
parameters were significantly reduced in the latter group, mainly concerning the anal 
wall. In a previous study in 641 patients, however, all dosimetric anal parameters, 
except D
max
 were found to be predictive for incontinence requiring pads [22]. The 
smaller sample size in our study might explain this discrepancy. Surprisingly, despite 
several differences in rectal functions, no differences in dose parameters were seen 
between the Frequency- and No-frequency-group. 
Based on anorectal dose-surface map analysis, Heemsbergen et al. also suggested 
that complaints originate from specific regions [23]. In concordance with the present 
results, they found a dose-effect relationship for soiling and fecal incontinence in the 
anal region and lower rectum, and no dose parameters predicting frequency. 
However, no dose-effect relationships for urgency were found either, whereas in our 
study many differences were seen between the Urgency- and No-urgency-group. 
Differences in toxicity-scoring might contribute to this discrepancy.
In the present study, D
min
, D
max
, and D
mean
 were recalculated to EQD
2
 to correct for 
differences in fractionation schedule. Dose-volume and dose-surface parameters, 
however, were obtained from physical dose-volume histograms (DVHs) and 
dose-surface histograms, respectively. A comparison of physical DVHs and LQ-scaled 
DVHs of two patients showed only small differences (<5%) between the two 
fractionation schedules in the dose regions 40-70 Gy. Based on this comparison, we 
expect the volumes exposed to low EQD
2
-doses to be somewhat lower, and the 
volumes exposed to ≥70 Gy somewhat higher, but the differences between the 
groups with and without complaints will be of the same magnitude.
To extensively describe the effect of endorectal balloons on the abovementioned 
data is beyond the scope of this paper. Although our study showed less complaints 
and lower anorectal doses in the group irradiated with balloon, this is a topic for 
further research. 
The observations from this study can have consequences for clinical practice. First, 
the results suggest that the rectal wall and anal wall are different organs to be 
delineated and spared separately in radiotherapy-planning. Although in this study 
only prostate cancer patients were included, this recommendation could be extended 
to pelvic radiotherapy in general. In women irradiated for cervical or uterine 
carcinoma, 67% reported fecal urgency and anorectal function testing showed 
reduced anal pressures and rectal compliance [24]. Furthermore, rectal cancer patients 
treated with short-course preoperative external beam radiotherapy reported 
significantly more incontinence, soiling and increased bowel movements than 
patients treated with surgery alone [25]. Using anorectal manometry, the first group 
showed significantly reduced anal pressures. Secondly, based on the defined low- 
and high-risk groups for the development of urgency, the following constraints for 
dose planning can be deduced for pelvic RT: Anal D
mean
 <38 Gy, V
30
 <65%, V
40
 <41% and 
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V
50
 <30%, and Rectal D
mean
 <44 Gy, V
30 
<70%, V
40
 <45% and V
50
 <37%. Anal D
min
 <5 Gy 
can be added as constraint, based on differences between the Incontinence- and No-
incontinence-group. 
However, care must be taken in drawing definite conclusions, as this study is 
hypothesis generating and has some limitations. First is the design, as it is an 
observational study with a cross-sectional design in which we explore the relation 
between anorectal function, dosimetric parameters and symptoms. Delineation has 
been performed retrospectively. This design introduces potential biases. Secondly, 
anorectal function testing was performed only once in each patient, thereby ignoring 
the dynamic process of toxicity development. Furthermore there was no fixed 
time-point for all patients at which function testing and symptom scoring was 
performed. A third caveat is the co-existence of multiple complaints per patient, 
which can be a confounding factor in the exact determination of the role of anorectal 
dysfunction and dose on individual complaints or specific clusters of complaints. 
Because the overall number of analyzed patients was relatively small, it was impossible 
to perform further sub-analysis of these groups. Finally, dosimetry could be performed 
in only 36/60 patients, which is a relatively small number and could be subject to 
selection bias. Still, despite these limitations, the present analysis shows interesting 
findings, suggesting specific factors being involved in the development of different 
complaints, which is a basis for future research. 
In conclusion, this study shows reduced anorectal functions after external beam 
prostate radiotherapy, with deterioration of anal pressures and rectal volumes 
associated with sensory perception, the desire to defecate and discomfort. 
Furthermore, when patients with and without complaints after radiotherapy were 
compared, each symptom seems to be associated with specific changes on anorectal 
manometry. While frequency seems mainly caused by deterioration of rectal function, 
urgency and incontinence are associated with both anal and rectal dysfunction. 
Finally, significant dosimetric differences have been observed between patients with 
and without complaints, with a different impact of doses to the anal canal and rectum 
for the various complaints. It seems that the anal wall and rectal wall are separate 
organs to be delineated and spared in pelvic radiotherapy. 
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Introduction
Although dose escalation has proven to lead to improved treatment outcomes in 
external beam radiotherapy (EBRT) for localized prostate cancer [1], higher doses to 
normal tissues lead to increased toxicity rates [2], of which late anorectal toxicity (e.g. 
fecal incontinence, urgency and frequency) is of major concern. 
Several reports have described relationships between dose-volume parameters to 
both the rectum and anal canal and late anorectal toxicity [3;4]. In addition, attempts 
have been made to identify specific anatomic indicators of late rectal toxicity, e.g. by 
correlating late rectal bleeding to rectal dose-surface maps [5;6]. Incontinence-related 
complaints, which appear to bother patients most [7], are thought to be caused by a 
combination of both rectal and anal factors [8]. There are indications that different 
incontinence-related complaints may arise from specific anorectal subsites [5;9]. 
Knowledge of specific regions involved in the development of late toxicity may play a 
key role in the prevention of these side effects, as with modern intensity-modulated 
radiotherapy (IMRT) techniques even small surrounding normal tissues can be 
selectively spared [10].
Rather than just the rectum and anal canal (mostly defined as the distal 3 cm of the 
anorectum), specific pelvic floor muscles are considered to be involved in normal 
fecal continence: the internal anal sphincter, external anal sphincter, puborectalis 
muscle and levator ani muscles [11;12]. The goals of the present study were to 
separately delineate these pelvic floor muscles and to investigate dose-effect 
relationships for fecal incontinence-related complaints after prostate radiotherapy. 
Furthermore, it was assessed whether the anal wall (Awall), used in prostate EBRT 
delineations to represent the anal sphincter complex, is a good representative of the 
total continence apparatus.
Methods and materials
Patients and treatment
Between July and December 2009, during regular follow-up, 48 consecutive patients 
who were at least 90 days after treatment with EBRT for localized prostate cancer 
(T1-4N0M0), were included in this study. For all patients, complete follow-up data and 
CT-based treatment plans were available (Pinnacle3, Philips Medical Systems, 
Fitchburg, WI). Treatment consisted of 3-field or 4-field 3D conformal radiotherapy 
(3D-CRT) and 5-beam IMRT techniques. The prescribed total dose was 67.5 or 70.0 Gy 
in 2.25 or 2.50 Gy fractions, respectively. The clinical target volume (CTV) comprised 
Abstract
Purpose: To delineate individual pelvic floor muscles, considered to be involved in 
anorectal toxicity, and to investigate dose-effect relationships for fecal incontinence-
related complaints after prostate radiotherapy (RT).
Methods and Materials: In 48 patients, treated for localized prostate cancer, the internal 
anal sphincter (IAS), external anal sphincter (EAS), puborectalis muscle (PRM) and 
levator ani muscles (LAM) were retrospectively delineated on planning CT-scans, in 
addition to the anal wall (Awall) and rectal wall (Rwall). Dose parameters were 
obtained and were compared between patients with and without fecal urgency, 
incontinence and frequency. Dose-effect curves were constructed. Finally, the effect 
of an endorectal balloon, which was applied in 28 patients, was investigated.
Results: The total volume of the pelvic floor muscles together was about thrice that of 
the Awall. The PRM was exposed to the highest RT dose, whereas the EAS received 
the lowest dose. Several anal and rectal dose-parameters, as well as doses to all 
separate pelvic floor muscles, were associated with urgency, while incontinence was 
mainly associated with doses to the EAS and PRM. Based on the dose-effect curves, 
the following constraints regarding mean doses can be deduced to reduce the risk of 
urgency: ≤30 Gy (IAS), ≤10 Gy (EAS), ≤50 Gy (PRM) and ≤40 Gy (LAM). No dose-effect 
relationships for frequency were observed. Patients treated with endorectal balloon 
reported significantly less urgency and incontinence, while their treatment plans 
showed significantly lower doses to the Awall, Rwall and all pelvic floor muscles.
Conclusions: Incontinence-related complaints show specific dose-effect relations to 
individual pelvic floor muscles. Dose constraints for each muscle can be identified for 
RT planning. When only the Awall is delineated, substantial components of the 
continence apparatus are excluded.
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All structures were delineated by the same operator (R.J.S.). In three randomly chosen 
patients the muscles were delineated thrice by two operators (R.J.S. and E.v.L.), who 
were blinded for the presence or absence of complaints, to determine the intra- 
operator and inter-operator co-efficients of variation of their volume (defined as the 
ratio of the standard deviation to the mean). Fig. 1 shows an example of the separately 
delineated muscles.
Dose evaluation
In all treatment plans, the minimum, maximum and mean dose (D
min
, D
max
, and D
mean
, 
respectively) to the Awall, Rwall and to the IAS, EAS, PRM, and LAM were calculated. To 
correct for differences in biological effect of the two fractionation schedules, these 
doses were recalculated to a biologically equivalent dose in 2-Gy fractions (EQD
2
) 
using the following formula, based on the linear-quadratic model [17]: 
EQD
2
 = D (d + [α/β])/(2 + [α/β])
where D is the total dose given in fractions of d Gy and α/β is a measure of fractionation 
sensitivity, which was set to 3 Gy for late anorectal toxicity [18]. All D
min
, D
max
, and D
mean
 
are therefore reported in EQD
2
 doses. In addition, volumes (%) exposed to ≥20 Gy 
(V
20
), ≥30 Gy (V
30
), ≥40 Gy (V
40
), ≥50Gy (V
50
), ≥60 Gy (V
60
), and ≥70 Gy (V
70
), to both the 
Awall and Rwall were calculated. The spatial dose distribution to the inner rectal wall 
mucosa was visualized by generating dose-surface maps by means of virtual rectum 
‘unfolding’ [19]. In order to be able to compare these dose distributions between 
patients, the areas (%) exposed to ≥20 Gy (A
20
), ≥30 Gy (A
30
), ≥40 Gy (A
40
), ≥50Gy (A
50
), 
≥60 Gy (A
60
), and ≥70 Gy (A
70
) were calculated in bins of 1 cm2. All dose parameters 
were compared between patients with and without complaints and between patients 
treated with and without ERB.
Statistical analysis
The SPSS 16.0.2 software for Windows (© SPSS Inc., 1989-2007) was used for statistical 
calculations. As Kolmogorov-Smirnoff tests revealed normal distributions of the 
investigated parameters, parametric tests were performed to compare the dose 
parameters. Independent t-tests were used for comparison of the measured 
parameters between patients with and without reported toxicity, and between 
patients treated with and without ERB. One-way analysis of variance was performed 
to compare means between the 3 treatment groups. Pearson’s chi-square was 
calculated to investigate the correlation between the use of ERBs and the presence of 
complaints. The Mann-Whitney U-test was used for comparison of median follow-up 
duration. Differences with a two-tailed p value ≤ 0.05 were considered significant.
 
the prostate, with or without seminal vesicles, depending on the tumor stage. In 28 
patients a daily inserted air-filled (80 or 100 cm3) endorectal balloon (ERB) had been 
applied (QLRAD B.V., Dalfsen, The Netherlands). Not all patients were treated with 
IMRT and/or ERB due to a sequential cohort effect, i.e. some patients were treated 
before introduction of IMRT and/or ERB in our clinical practice. In all patients, late 
anorectal toxicity was scored every 6 months using the radiotherapy-induced lower 
intestinal toxicity (RILIT) instrument [3]. As most patients reported grade 1 toxicity, we 
focused on the presence or absence of fecal incontinence-related complaints (i.e. 
incontinence, urgency and frequency [13]). Complaints were considered present 
when they were reported at the most recent follow-up.
Organ delineation
On the axial CT-slices (thickness 3 mm) of all patients, the Awall and rectal wall (Rwall) 
were retrospectively delineated. The Awall was considered a continuation of the Rwall 
[4]. The outer Awall contour was outlined, extending from the anal verge to the slice 
below the lowest slice with a rectal or ERB lumen. In case of an ERB, an inner Awall 
contour was delineated around the ERB shaft, and the Awall volume was defined as 
the difference between the outer and inner Awall contours. In patients without ERB, 
the Awall volume was defined as the volume within the outer Awall contour, as no 
inner Awall was visible, due to active closure of the anal canal [14]. After the outer 
Rwall contours were indicated on each CT-slice, an inner Rwall was constructed by 
applying a 5 mm wall thickness on slices without ERB, and 3 mm thickness on slices 
with ERB [15]. The Rwall volume was defined as the difference between the outer and 
inner Rwall contours and was delineated from the top of the Awall up to the 
rectosigmoid flexure. 
After delineation of these structures, four pelvic floor muscles, considered to be 
involved in normal fecal continence [11;12], were separately delineated: the internal 
anal sphincter (IAS), external anal sphincter (EAS), puborectalis muscle (PRM) and 
levator ani muscles (LAM), using the following description:
1. The IAS is the distal continuation of the smooth muscle layer of the rectum. 
2. The EAS partially encircles the IAS. It is separated from the IAS by the intersphinc-
teric space, which can be distinguished on the axial CT-slices.
3. The PRM is a U-shaped muscle, which forms a sling around the anorectal junction 
and is connected to the pubic bone. 
4. Cranially, the LAM form a plate-like continuation of the PRM [16]. 
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Dose-effect curves were constructed by plotting the incidence of the respective 
complaints and the dose to a specific subsite, in bins of 5 Gy. A logistic distribution 
model was used for curve fitting, using the formula 
 P(D) =
where P(D) is the risk (%) of developing a certain complaint at a certain dose D, D
50
 is 
the dose leading to a 50% risk, and γ
50
 is the normalized dose-response gradient at the 
50% response level (GraphPad Prism, version 4.00, GraphPad Software, Inc. 1992-2003). 
Goodness of fit (R2) was calculated for each curve.
Results
Patient characteristics
The mean age at evaluation was 71.8 years and did not differ between patients with 
and without complaints. Other predisposing factors for the development of anorectal 
toxicity (use of anticoagulant drugs, previous abdominal surgery, pre-existing anorectal 
complaints, and diabetes (20;21)) were also equally distributed between these groups 
(Table 1). Eighteen patients were treated with 3-field 3D-CRT, 25 with 4-field 3D-CRT 
and 5 with IMRT. The median follow-up time was longer in patients with complaints, 
but this difference did not reach statistical significance: 30 (range 6-55) months vs. 23 
(range 8-48) months (p = 0.06).
Organ delineation and dosimetry
The mean volume (±SD) of the Awall was 16.0 (±4.1) cm3, whereas the mean volumes 
(±SD) of the separate muscles were 13.1 (±3.6), 12.2 (±3.4), 8.30 (±2.2), and 13.2 (±3.6) 
cm3 for IAS, EAS, PRM, and LAM, respectively. This led to a mean volume (±SD) of 46.7 
1
1+( D50 )4.γ50D
Fig. 1   Example of the delineated pelvic floor muscles in coronal (a), sagittal (b) and 
transverse (c-e) view in a patient with endorectal balloon inserted. Red contour: 
internal anal sphincter; green contour: external anal sphincter; blue contour: 
puborectalis muscle; yellow contour: levator ani muscles. Color figure at p 167.
Table 1   Predisposing factors for anorectal complaints in patients without and with 
complaints.
  
Predisposing factor No complaints Complaints p-value
Mean age (SD) 71 (5.9) 72 (4.2) 0.44
Diabetes 0 4 0.07
Preexisting anorectal complaints 0 1 0.33
Previous abdominal surgery 6 3 0.12
Anticoagulant drugs 8 9 0.72
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(±9.2) cm3 for all muscles together. These volumes were not significantly different 
between patients treated with ERB and without ERB. Co-efficients of variation were 
4.2% (IAS), 3.9% (EAS), 4.7% (PRM) and 6.4% (LAM) for intra-operator delineation 
variation. The respective co-efficients of variation for inter-operator variation were 
2.6%, 1.4%, 1.4% and 0.8%. The mean Rwall volume (±SD) was 37.7 (±4.1) cm3 and was 
significantly larger in patients treated with ERB: 41.5 vs. 33.6 cm3 (p = 0.002). No 
significant differences in Awall, Rwall and separate muscle volumes were observed 
between patients with and without complaints.
The mean doses (±SD) to the IAS, EAS, PRM, and LAM were 33.7 (±13.2), 18.7 (±10.8), 
46.0 (±10.1), and 40.5 (±7.3) Gy, respectively, and differed significantly (p < 0.001), 
indicating that, overall, the EAS received the lowest dose and the PRM is exposed to 
the highest dose. The mean dose to all muscles together was 34.0 (±9.5) Gy, whereas 
D
mean
 Awall was 33.6 (±12.6) Gy. Rwall D
mean
 was 40.5 (±7.3) Gy. 
Toxicity and dose parameters
Twenty-two patients reported one or more incontinence-related symptoms with the 
following distribution: frequency (15), urgency (12) and incontinence (10). The 
occurrence of urgency was strongly correlated with both incontinence (p = 0.004) 
and frequency (p = 0.002), whereas incontinence and frequency showed no significant 
correlation (p = 0.16). No significant differences in toxicity rates were seen between 
3-field 3D-CRT, 4-field 3D-CRT, and IMRT. 
In Table 2, doses to the pelvic floor muscles in patients with and without any 
complaint, urgency, incontinence, and frequency are displayed. In Table 3, the dose 
parameters for the Awall and Rwall that showed significant differences between 
these groups are given. Patients with any complaint had an Awall D
mean
 that was on 
average 7.6 Gy higher compared to patients without complaints (Table 3a). Also the 
mean doses to all individual muscles were higher in the former group. In addition to 
the data in Table 3a, an absolute reduction in Rwall A
60
 of 6% was observed in favor of 
the group without complaints (p = 0.06).
When patients were categorized according to the presence or absence of urgency, 
irrespective of other complaints, it appeared that all mean doses were significantly 
higher in the group with urgency, with an 11 Gy difference in Awall D
mean
, 7 Gy in Rwall 
D
mean
 (Table 3b) and 8-13 Gy in D
mean
 of the individual muscles (Table 2). The largest 
differences in mean doses were seen for the IAS, EAS and PRM. Also most of the 
dose-volume and dose-surface parameters on both Awall and Rwall were higher in 
the patients reporting urgency. 
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Patients with and without frequency showed no significant differences in dose 
parameters (Table 2). Rwall A
40
 and A
50
 were 10% and 8% lower in the latter group 
(p = 0.06).
Fig. 2 shows a schematic image of the Awall, Rwall and pelvic floor muscles, as well as 
the observed associations with the incontinence-related complaints. It shows that 
urgency is associated with rectal, anal and all pelvic floor muscle dose parameters, 
while incontinence is only associated with doses to the EAS and PRM. As mentioned 
above, no associations were found for frequency.
Dose-effect relationships
The graphs in Fig. 3 show dose-effect relationships for urgency and incontinence 
with mean doses to the different structures. Estimation of mean doses at which 50% 
of patients report the respective complaint (D
50
) ranged from 30 Gy (EAS) to 55 Gy 
(PRM). As shown, best fits were obtained for urgency and doses to the Awall, IAS, EAS 
and LAM (R2 ranging from 0.77 to 0.89), and for incontinence and dose to the EAS 
(R2 = 0.79). Based on these dose-effect relationships, the following constraints for 
D
mean
 to the pelvic floor muscles can be deduced to keep the risk of complications 
≤5%: ≤30 Gy (IAS), ≤10 Gy (EAS), ≤50 Gy (PRM) and ≤40 Gy (LAM).
When patients with and without incontinence were compared, less pronounced 
differences were observed (Table 2). Although non-significant differences were seen 
in Awall parameters, only D
mean
 and D
max
 of the EAS and D
min
 of PRM were significantly 
higher in patients with incontinence. PRM D
mean
 showed a borderline-significant 
difference (p = 0.06).
Table 3   Mean (SD) dose parameters to the anal wall and rectal wall showing 
significant differences between patients with and without complaints;  
a) any complaints and b) urgency. No significant differences were observed 
between patients with and without incontinence or frequency.
a) NO COMPLAINTS COMPLAINTS p-value
Awall Dmean (Gy) 30.1 (11.4) 37.7 (11.4) 0.04
V30 (%) 44 (27) 61 (28) 0.04
V40 (%) 24 (19) 39 (24) 0.02
V50 (%) 17 (14) 30 (19) 0.01
V60 (%) 11 (14) 21 (15) 0.03
Rwall V40 (%) 38 (10) 46 (16) 0.04
A40 (%) 44 (13) 53 (17) 0.04
A50 (%) 36 (10) 45 (15) 0.02
b) NO URGENCY URGENCY p-value
Awall Dmean (Gy) 31.7 (13.6) 42.8 (11.9) 0.002
V20 (%) 65 (23) 82 (23) 0.03
V30 (%) 45 (26) 73 (26) 0.002
V40 (%) 25 (19) 50 (21) <0.001
V50 (%) 18 (15) 38 (17) <0.001
V60 (%) 12 (14) 26 (15) 0.004
Rwall Dmean (Gy) 38.9 (6.2) 45.5 (8.2) 0.005
V30 (%) 58 (21) 77 (14) 0.001
V40 (%) 37 (10) 54 (14) <0.001
V50 (%) 31 (7) 43 (12) 0.008
V60 (%) 25 (6) 33 (11) 0.02
A30 (%) 62 (18) 77 (13) 0.02
A40 (%) 43 (13) 63 (17) <0.001
A50 (%) 36 (10) 54 (14) <0.001
A60 (%) 28 (7) 38 (12) 0.001
Abbreviations: Awall = anal wall; Rwall = rectal wall; D
min
 = minimum dose; D
mean
 = mean dose; D
max
 = 
maximum dose; V
x
 = relative volume exposed to ≥ x Gy; A
x
 = relative surface area exposed to ≥ x Gy.
Fig. 2   Schematic image of the rectum, anal canal and individual pelvic floor muscles 
(I: internal anal sphincter; E: external anal sphincter; P: puborectalis muscle;  
L: levator ani muscles). Lines represent associations between complaints and 
subsites. Color figure at p 168.
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Effect of ERBs
Significantly fewer complaints were observed in patients treated with ERB compared 
to those treated without ERB: 29% vs. 70% (p = 0.005). Regarding specific symptoms, 
urgency and incontinence occurred less frequently in the group treated with ERB: 7% 
vs. 50% (p = 0.001) and 7% vs. 40% (p = 0.006), respectively. Frequency was reported 
by 40% of the patients treated without ERB and in 25% of patients irradiated with ERB 
(p = 0.27). It should be noted, however, that due to a sequential cohort effect, median 
follow-up in patients treated with ERB was significantly shorter than in patients 
treated without ERB (17 vs. 36 months, p < 0.001).
Fig. 3   Dose-effect curves for urgency (left column) and incontinence (right column) 
with doses to different structures.
Abbreviations: D
mean
: mean dose; Awall: anal wall; IAS: internal anal sphincter; EAS: external anal sphincter; 
PRM: puborectalis muscle; LAM: levator ani muscles.
Table 4   Mean (SD) dose parameters to the anal wall, rectal wall and pelvic floor 
muscles showing significant differences between patients treated with and 
without endorectal balloon. 
No ERB ERB p-value
Awall Dmean (Gy) 39.9 (11.6) 30.6 (14.4) 0.02
V20 (%) 77 (20) 63 (24) 0.03
V30 (%) 69 (23) 40 (26) <0.001
V40 (%) 45 (20) 21 (17) <0.001
V50 (%) 33 (17) 15 (14) <0.001
V60 (%) 22 (14) 11 (14) 0.008
Rwall Dmax (Gy) 71.4 (2.0) 75.2 (3.2) <0.001
V30 (%) 74 (15) 54 (21) 0.001
V40 (%) 50 (14) 36 (9 0.001
V50 (%) 39 (11) 30 (7) 0.001
V60 (%) 31 (9) 24 (6) 0.007
A40 (%) 57 (15) 42 (13) 0.001
A50 (%) 47 (15) 35 (10) 0.005
A60 (%) 34 (11) 28 (8) 0.04
IAS Dmean (Gy) 40.4 (11.6) 28.9 (12.3) 0.002
Dmax (Gy) 68.9 (5.5) 62.2 (15.0) 0.04
EAS Dmean (Gy) 24.5 (11.0) 14.5 (8.8) 0.001
Dmax (Gy) 62.8 (13.2) 48.4 (21.6) 0.006
PRM Dmin (Gy) 30.7 (9.8) 23.1 (7.6) 0.004
Dmean (Gy) 53.0 (7.1) 41.0 (9.0) <0.001
LAM Dmin (Gy) 32.0 (7.3) 23.0 (6.0) <0.001
Dmean (Gy) 46.8 (5.6) 36.1 (4.6) <0.001
 
Abbreviations: Awall = anal wall; Rwall = rectal wall; D
min
 = minimum dose; D
mean
 = mean dose; D
max 
= 
maximum dose; V
x
 = relative volume exposed to ≥ x Gy; A
x
 = relative surface area exposed to ≥ x Gy; IAS = 
internal anal sphincter; EAS = external anal sphincter; PRM = puborectalis muscle; LAM = levator ani muscles.
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When the treatment plans of patients treated with and without ERB were compared, 
doses to the Awall, Rwall, and all pelvic floor muscles were significantly lower when 
an ERB was applied (Table 4). Only Rwall D
max
 was significantly increased in the ERB 
group (75.2 vs. 71.4 Gy, p < 0.001).
Discussion
This study shows that pelvic floor muscles can be delineated separately on planning 
CT scans, and are not equally exposed to radiation doses in prostate EBRT. When the 
Awall is delineated, approximately two-thirds of this total continence apparatus is 
excluded. Although all muscles seem to be involved in the development of late 
anorectal toxicity, different incontinence-related complaints seem to be associated 
with different structures. Furthermore, specific dose-effect relationships were shown 
for different incontinence-related complaints.
To our knowledge, this is the first attempt to separately delineate and evaluate pelvic 
floor muscles that may play a role in anorectal toxicity after prostate EBRT. In previous 
reports, the anal canal, considered to be a continuation of the rectal wall, has been 
used as a surrogate for the continence apparatus and evaluated as such [4;5]. By 
separately delineating the individual muscles considered to be involved in fecal 
continence, we observed an almost threefold increase in volume as compared to the 
Awall. Regarding dosimetry and anatomy, the Awall seems to be more or less equal to 
the IAS. This means that by delineating the Awall substantial components of the 
continence apparatus are excluded. 
We observed that the puborectalis muscle receives the highest radiation dose in 
prostate EBRT, followed by the levator ani muscles, internal anal sphincter and external 
anal sphincter. The anatomical relation of these muscles to the target volume (i.e. a 
large portion of the PRM is adjacent to the prostate) might explain these findings. It 
has been suggested that the PRM is most directly responsible for fecal continence 
[11]. Its function is maintaining the anorectal angle, thereby preventing the passage of 
solid stool. Fernández-Fraga et al. mentioned failure of the LAM as major contributor 
to fecal incontinence. However, they regarded the PRM to be a component of the 
LAM [12]. The fact that the PRM receives the highest radiation dose in prostate EBRT 
might thus be hazardous for fecal continence. In the future, this might be a 
consideration in defining, especially lateral, margins around the CTV, in order to spare 
the PRM as much as possible. The fact that prostate motion is least in the lateral 
direction [22], may support the consideration to use small lateral margins. In the 
present study, a borderline significant difference in PRM D
mean
 and a significant 
difference in PRM D
min
 were observed between patients with and without 
incontinence. Also, a significant difference in doses to the EAS was observed in favor 
of the latter group. Although the IAS is thought to be responsible for anal continence 
in rest, as it contributes 70-85% of the resting pressure of the anal sphincter complex 
[23], the dose to the IAS was not significantly higher in patients with incontinence, 
compared to patients without incontinence. These observations might indicate that 
in the development of radiation-induced incontinence, in particular the EAS and PRM 
play a role. As Awall D
mean
 was not significantly different between patients with and 
without incontinence, the Awall might not be a good surrogate for the continence 
apparatus when the influence of radiation dose on incontinence is investigated.
When patients with and without urgency were compared, D
mean
 to both the Awall, 
Rwall and all individual pelvic muscles were significantly lower in the latter group, as 
well as several dose-volume and dose-surface parameters. This suggests that urgency 
is caused by a combination of not only anal, but also rectal factors, and that all pelvic 
muscles play a role in its development. Besides a borderline significant difference in 
Rwall A
40
 and A
50
 between patients with and without frequency, no dose-effect 
relationships for frequency were found. This might explain why no significant 
difference in the occurrence of frequency between patients treated with and without 
ERB was observed, despite a beneficial effect on anorectal doses. Possibly, additional 
factors contribute to the development of frequency. 
Applying constraints for pelvic floor muscles might reduce incontinence-related 
complaints. Based on the results from the present study, although hypothesis-gener-
ating, we suggest ≤30 Gy, ≤10 Gy, ≤50 Gy and ≤40 for D
mean
 to IAS, EAS, PRM and LAM, 
respectively, with an associated risk of urgency or incontinence ≤5%. It has been 
shown previously that sparing of rather small structures (e.g. vessels involved in penile 
erection) is feasible with prostate IMRT [10].
Yeoh et al. observed an increased bowel frequency, urgency and fecal incontinence at 
2-year follow-up after prostate EBRT [13]. Furthermore, repeated anorectal manometry 
testing showed progressive reductions of anal pressures, rectal compliance and rectal 
volumes associated with sensory perception and the desire to defecate. Weakening of 
both the IAS and EAS was observed, while ultrasonography showed an increased EAS 
thickness, without changes in IAS thickness. According to the authors, this weakness 
was most likely a result of pudendal nerve damage, as striated muscle (EAS) is thought 
to be radioresistant. This does, however, not explain the increased EAS thickness. It 
was suggested that this increased thickness is due to hypertrophy of motor units 
spared from radiation damage. Although no difference was observed between two 
radiation schedules, dose-effect relationships regarding specific anorectal subsites 
were not investigated.
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The suggestion that specific anorectal complaints originate from different anatomic 
regions was published previously [9]. Heemsbergen et al. came to similar conclusions, 
based on anorectal dose-map analysis [5]. In their study, a dose-effect relationship for 
incontinence was observed in the anal and lower rectal region. No such explanatory 
effects were observed for urgency and frequency. In the present study, it was 
observed that several dose-parameters were associated with urgency and only some 
to be associated with incontinence. A possible explanation for this discrepancy might 
be a difference in toxicity scoring. As anorectal toxicity comprises different symptoms, 
precise categorization is essential to be able to compare results between studies. 
Patients reporting a sudden urge to have a bowel movement may be scored as 
urgency. In some cases, however, especially when one is far from a toilet, this urge 
might cause loss of stools and could therefore be scored as incontinence too.
The reduced Awall and Rwall doses due to ERBs is in concordance with previous 
studies [14;15;19;24;25]. Only Rwall D
max
 was significantly higher in patients treated 
with ERB, probably because the anterior rectal wall is pushed towards the CTV. 
Previously, however, it has been shown that, despite this, a reduction in Rwall damage 
and toxicity was observed with ERB application [24]. The present study shows that, 
when pelvic floor muscles are delineated separately, the sparing effect of an ERB 
applies to all muscles. Given the abovementioned dose-effect relationships, this 
might explain that in patients treated with ERB less incontinence and urgency were 
reported than in patients treated without ERB. However, it should be noted that this is 
not a prospective trial, but an observational study with cross-sectional design, 
potentially leading to bias. Furthermore, the number of patients reporting complaints 
was relatively low (e.g. 10 reported incontinence). Other limitations include differences 
in length of follow-up between different groups (e.g. with and without ERB and also 
between patients with and without complaints), and bias due to the sequential 
cohort effect of ERB application. Given the dynamic process of toxicity development 
over time [13], shorter follow-up might underestimate the eventual toxicity incidence. 
Finally, given the relative small number of patients, multivariate testing to investigate 
the dose parameters independently was not possible. Hence, conclusions derived 
from this study should be considered hypothesis-generating, and might be a basis for 
future research. 
As this is the first attempt to delineate the pelvic floor muscles separately, no 
comparison with previous studies can be made regarding these delineations. 
Although CT-imaging is not a regularly used diagnostic tool in the evaluation of fecal 
incontinence [16], it proved to be possible to recognize the separate muscles on the 
planning CT-scans. However, fusion of the CT-images with magnetic resonance 
images might improve the accuracy of the delineation. Furthermore, one might 
question the day-to-day reproducibility of the rather small delineated individual 
muscles, i.e. whether the dosimetric parameters obtained from the planning CT-scan 
are representative for the whole treatment due to movement and other setup 
uncertainties. However, in our opinion, the same accounts for Awall and Rwall doses 
from previous studies. Daily cone-beam CT-imaging with adaptive planning might be 
useful to investigate this issue, as well as the influence of ERBs on anatomic consistency.
In conclusion, pelvic floor muscles, considered to be involved in normal fecal 
continence are not exposed equally to radiation doses in prostate EBRT: the EAS is 
exposed to the lowest dose, while the PRM receives the highest dose. By delineating 
the Awall, most of the continence apparatus is excluded from evaluation. Incontinence, 
urgency and frequency show associations with different subsites, suggesting different 
pathogenesis. Incontinence seems associated with doses to the PRM and EAS, while 
in the development of urgency both anal and rectal factors are involved. Based on 
dose-effect curves for urgency and incontinence, constraints for treatment planning 
could be established. No dose-effect relationships for frequency were observed. 
Finally, patients treated with ERB showed several reduced dose parameters to both 
the Awall and Rwall, as well as to all individual pelvic floor muscles, and reported 
significantly less urgency and incontinence. This suggests that ERBs might reduce 
anorectal toxicity. Prospective trials, however, are needed to confirm this hypothesis.
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Introduction
During the course of radiotherapy (RT) the prostate position varies [1], both during 
the actual treatment and in-between fractions, commonly characterized by 
intrafraction and interfraction variation, respectively [2]. Planning target volume (PTV) 
margins are applied to ensure proper dose coverage of the clinical target volume 
(CTV). Applying these margins inevitably leads to irradiation of normal tissues, 
potentially causing radiation-induced toxicity. However, when using tight margins, 
the prostate motion may compromise dosimetric coverage of the CTV. In particular 
for hypofractionated or stereotactic body RT, consisting of only a few fractions, target 
motion at a single fraction may have a large impact [3].
Endorectal balloons (ERBs) have been applied in prostate RT to reduce anorectal 
toxicity, mainly because of their rectal wall sparing effect by pushing parts of the 
rectal wall out of the high-dose regions [4-7], but also for its assumed prostate 
immobilizing effect [7-9], thereby enabling smaller CTV-to-PTV margins. There is, 
however, no consensus on the effect of ERBs on interfraction prostate motion, and 
additional position verification and correction protocols have been advised [10;11]. 
Two studies reported reduced intrafraction motion in patients with ERB, compared to 
patients without ERB, one using repeated CT-imaging [8], another using cine-MRI [12]. 
Recently, real-time tracking data on the effect of an ERB on prostate motion during 
treatment have been described [13]. However, no direct comparison was made to 
patients treated without ERB.
The main purpose of the present study is to investigate whether an air-filled ERB has 
a prostate immobilizing effect in RT, by comparing intrafraction prostate gland 
motion between prostate cancer patients treated with ERB and without ERB. The 
second goal is to assess the influence of an ERB on interfraction prostate variation. A 
four-dimensional electromagnetic tracking system was used for continuous, real-time 
tracking of intrafraction prostate motion [14]. 
Methods and materials
Patients and treatment
Thirty patients were treated for localized prostate cancer at the M.D. Anderson Cancer 
Center Orlando, FL, USA, using a 5- to 7-field IMRT technique, delivered with a Novalis 
system (BrainLAB AG, Heimstetten, Germany). A total dose of 80 Gy in 2-Gy fractions to the 
prostate was given to all patients, 5 times a week. An isotropic CTV-to-PTV margin of 6 mm 
was applied, except in the posterior direction, where a margin of 4 mm was used. 
Abstract
Purpose: To investigate the effect of endorectal balloons (ERBs) on intrafraction and 
interfraction prostate motion during radiotherapy. 
Methods and Materials: 30 patients were treated with intensity-modulated radiotherapy, 
to a total dose of 80 Gy in 40 fractions. In 15 patients a daily-inserted air-filled ERB was 
applied. Prostate motion was tracked, in real-time, using an electromagnetic tracking 
system. Interfraction displacements, measured before each treatment, were quantified 
by calculating the systematic and random deviations of the center of mass of the 
implanted transponders. Intrafraction motion was analyzed in timeframes of 150 s, 
and displacements >1 mm, >3 mm, >5 mm and >7 mm were determined in the ante-
rior-posterior (AP), left-right (LR), and superior-inferior (SI) direction, and for the 
3D-vector. Manual table corrections, made during treatment sessions, were retro-
spectively undone. 
Results: 576 and 567 tracks have been analyzed in the No-ERB-group and ERB-group, 
respectively. Interfraction variation was not significantly different between both 
groups. After 600 s, 95% and 98% of the treatments were completed in the respective 
groups. Significantly fewer table corrections were performed during treatment 
fractions with ERB: 88 vs. 207 (p = 0.02). Intrafraction motion was significantly reduced 
with ERB. During the first 150 s, only negligible deviations were observed, but after 
150 s, intrafraction deviations increased with time. This resulted in cumulative 
percentages of 3D-vector deviations >1 mm, >3 mm, >5 mm and >7 mm that were 
57.7%, 7.0%, 0.7% and 0.3% in the ERB-group vs. 70.2%, 18.1%, 4.6% and 1.4% in the 
No-ERB-group after 600 s. The largest reductions in the ERB-group were observed in 
the AP direction. These data suggest that a 5 mm CTV-to-PTV margin is sufficient to 
correct for intrafraction prostate movements when using an ERB.
Conclusions: ERB significantly reduces intrafraction prostate motion, but not 
interfraction variation, and may in particular be beneficial for treatment sessions 
longer than 150 s.
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These corrections were documented to enable retrospective calculation of the 
uncorrected prostate position during treatment (i.e. without table shifts).
Data analysis
MATLAB, version R2007b (The Mathworks, Natick, MA, USA) was used for data analysis. 
Interfraction variation of the transponder displacement after initial patient positioning, 
relative to the position at simulation, was determined for the AP, LR and SI direction. It 
was quantified by calculating the mean of means (MoM) of all patients, the systematic 
dispersion ∑ and the random variation σ [16] of the centre of mass of the three 
transponders for both treatment groups in all directions. Similar calculations were 
carried out for the 3D-vectors and the rotations around the AP, LR and SI axes. For the 
analysis of intrafraction displacements, each track (i.e. continuously tracked data 
during one treatment fraction) was divided into time frames of 150 s, for which the 
deviations >1 mm, >3 mm, >5 mm, >7 mm, and >10 mm were assessed for each 
direction, as well as the 3D-vector. The cumulative percentages of tracked data over 
the elapsed time frames, exceeding these thresholds, were determined. To 
discriminate between the impact of the ERB on slow and rapid intrafraction motion, 
each track was divided into 3 separate signals, representing (1) “trends”, persisting 
more than 1 min, (2) somewhat faster “transients” that were present several seconds, 
and (3) “spikes” that lasted less than 1 s and were attributed to instrumental noise. For 
that purpose, a running average filter was used over 1000 and 20 data points to detect 
and subsequently subtract the slow trends and the faster transients respectively, 
while the remainder of the original track was attributed to the signal noise. Finally, the 
number of manual table corrections was recorded in all patients.
Statistical analysis
A left-sided independent-samples t-test, using a significance level of p ≤ 0.05 was 
used for (a) the comparison of the interfraction random variation σ between both 
patient groups, and (b) the comparison of the mean intrafraction percentages of 
tracked data exceeding specific thresholds. The differences between the variances 
around the mean percentage, as well as the systematic interfraction dispersion Σ of 
both groups, were tested using the F-test, also with a significance level of p ≤ 0.05.
Results
Prostate motion data of 1143 treatment sessions were available for analysis: 576 in the 
No-ERB-group and 567 in the ERB-group, corresponding to an average of 38.4 and 
37.8 tracks per patient in the respective groups. The remaining 57 tracks were not 
useful for analysis due to a short duration of tracking or data acquisition interruptions. 
Calypso four-dimensional localization system
In all patients, three electromagnetic transponders, each with a unique resonant 
frequency (Beacon transponders, Calypso Medical Technologies, Seattle, WA, USA) 
were transrectally implanted into the prostate under ultrasound guidance, at least 4 
days before the planning CT-scan was performed. In addition to the transponders, the 
Calypso system consists of an array, containing source and receiver coils, an infrared 
camera for localization of the array within the treatment room, and data acquisition 
and analysis computers. The source coils, placed in a known position above the 
patient, excite the transponders. After excitation, the transponders emit an electro-
magnetic signal, which is detected by the receiver coils, at a frequency of 10 Hz. The 
position of the transponders, relative to the isocenter, is detected by the system and 
can be used for both patient positioning and to continuously monitor the 
transponders’ position during treatment. An extensive description of the system and 
its properties has been published previously [14;15].
Endorectal balloon
Prostate motion data from 30 patients were analyzed under an IRB-approved study. In 
15 consecutive patients an ERB was used daily, the other patients were treated without 
ERB, referred to as the ERB-group and the No-ERB-group, respectively. The ERB 
consists of a 20-cm-long flexible shaft of polyvinylchloride with a silicon balloon 
(QLRAD B.V., Dalfsen, The Netherlands). A deflated ERB has a diameter of 13 mm and 
after inflation with 100 cc of air, the diameter and length of the balloon are 60 mm 
and 65 mm, respectively. Radiotherapists inserted the deflated balloon before 
CT-simulation and before each treatment fraction, facilitated by lubricant, with the 
patients lying on their left side. To maintain a good ERB position in relation to the 
prostate, it was fixed with an individually adjustable stopper after inflation, preventing 
ERB movement in the superior-inferior direction. 
Protocol
All patients were scanned and treated in a supine position according to local protocol, 
which included the application of a knee cushion for patient comfort, a rubber band 
around their feet for immobilization, and no instructions regarding bladder and 
rectum filling. Before each treatment fraction, the transponders were localized, and 
after the patients were aligned properly using the coordinates of the transponders at 
simulation as a reference, continuous tracking of the transponders’ position commenced. 
Whenever a displacement in a certain direction exceeded 3 mm for a prolonged time 
(i.e. did not resolve by the end of a single beam delivery), a manual table correction 
was made by the radiotherapists in-between two treatment beams. The delivery of a 
single beam was never interrupted, regardless of any observed prostate displacement. 
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Fig. 1 shows the graphs representing the cumulative percentage of 3D-vector 
displacements >1 mm, >3 mm and >5 mm for the ERB-group and No-ERB-group. 
During the first 150 s, only small displacements were observed in both groups, with 
3D-vector displacements >1 mm in 14.7% and 10.0% in the No-ERB-group and 
ERB-group, respectively (p = 0.001). There was, however, a linear increase with time, 
which increased after 150 s, especially for displacements >3 mm. For example, after 
150 s, for displacements >3 mm a constant rate equal to 2.3%.min-1 and 0.8%.min-1 was 
observed for the No-ERB-group and ERB-group, respectively. After 600 s, most of the 
fractions had finished, resulting in flattening of the curves and leading to a cumulative 
percentage of 18.1% and 7.0% displacements >3 mm in the No-ERB-group and 
ERB-group, respectively.
Ninety-eight percent and 95% of the treatment sessions were completed within 600 s 
for the ERB-group and No-ERB-group, respectively. Therefore, data analysis was 
limited to 600 s.
In the ERB-group, 88 manual table corrections were made, compared to 207 in the 
No-ERB-group (p = 0.02). The maximum number of corrections per patient was 22 and 
42, respectively. In each group, one patient needed no corrections.
Interfraction variation
Interfraction variations in the ERB-group and No-ERB-group are displayed in Table 1. 
The largest MoM in the ERB-group was -2.6 mm in the AP direction, and in the 
No-ERB-group this was -2.2 mm in the LR direction. No significant differences between 
both groups in Σ (p = 0.06-0.92) and σ (p = 0.10-0.32) were observed. Maximum Σ was 
observed in the AP direction in both groups (5.6 and 6.7 mm), while maximum σ 
occurred in LR direction (5.4 and 6.3 mm). Maximum rotational displacement was 
observed around the LR-axis, both with and without ERB, and was also not significantly 
different between the groups.
Intrafraction variation
An overview of the cumulative percentage of tracked data with displacements >1 
mm, >3 mm, >5 mm, and >7 mm for both the ERB-group and No-ERB-group is given 
in Table 2. By far, most displacements were smaller than 5 mm. Displacements >10 
mm were negligible in frequency and were therefore not included in the analysis. 
Table 1  Interfraction variation in the ERB-group (top) and No-ERB-group (bottom).  
ERB LR (mm) SI (mm) AP (mm) Rot LR ( ° ) Rot SI  ( ° ) Rot AP ( ° )
MoM -0.8 1.5 -2.6 3.0 -0.8 0.9
S 3.9 3.2 6.7 16.0 5.8 4.6
s 6.3 3.0 3.9 4.3 2.6 1.7
No-ERB LR (mm) SI (mm) AP (mm) Rot LR ( ° ) Rot SI  ( ° ) Rot AP ( ° )
MoM -2.2 0.6 -0.4 3.8 -0.1 -1.2
S 3.8 5.3 5.6 10.2 7.0 2.9
s 5.4 2.7 3.8 3.9 1.5 1.3
Abbreviations: ERB = endorectal balloon; MoM = mean of means; S = systematic displacement; s = random 
displacement; Rot = rotation; LR = left-right; SI = superior-inferior; AP = anterior-posterior.
Fig. 1   Cumulative percentage of 3D-vector deviations >1 mm, >3 mm and >5 mm. 
Solid line: patients without ERB; dashed line: patients with ERB.
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Fig. 2 shows the graphs for the observed displacements in each direction for the 
ERB-group and No-ERB-group. Overall, no large differences in results between the 
different directions were observed, except for displacements <3 mm that occurred 
more frequently in the SI direction in both groups. Displacements >3 mm were rare, 
in particular for the ERB-group. Similar as observed for the 3D-vector displacements, 
displacements in the three directions were always smaller in the ERB-group than in 
the No-ERB-group, although significant differences were limited to AP displacements 
>1 mm (Table 2). The largest differences between the ERB-group and No-ERB-group 
were observed in the AP and LR directions for displacements >1 mm, with reductions 
from 9.3% to 3.3% in the LR direction and from 9.4% to 3.8% in the AP direction after 
600 s. In particular in the AP direction, the ERB reduces large displacements. In 
addition, the variances of the cumulative percentage of displacements in the AP 
direction were significantly smaller in the ERB-group (p < 0.02). For the LR direction, 
this was only the case for the thresholds >1 mm and >3 mm, and for the SI direction 
only for the threshold >3 mm. 
As shown in Fig. 1, the cumulative percentages of 3D displacements were always 
smaller in the ERB-group than in the No-ERB-group and were significantly different for 
3D displacements <7 mm (Table 2). Eventually, after 600 s, absolute differences in 
favor of the ERB-group of 12.5% (p = 0.008), 11.1% (p = 0.008), 3.9% (p = 0.02), and 1.1% 
(p = 0.06) were observed for 3D-vector displacements >1 mm, >3 mm, >5 mm, and >7 
mm, respectively. The variances of the cumulative percentage of 3D displacements >3 
mm, >5 mm, and >7 mm were significantly smaller for the group of patients treated 
with ERB.
Table 2   Cumulative percentages of deviations exceeding 1, 3, 5, and 7 mm in 
patients without and with ERB. Bold entries indicate significant differences 
(t-test), * significantly different variances (F-test).  
> 1 mm > 3 mm > 5 mm > 7 mm
No ERB ERB No ERB ERB No ERB ERB No ERB ERB
LR 150 s 1.4%* 0.3%* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
300 s 4.0%* 1.2%* 0.1%* 0.0%* 0.0% 0.0% 0.0% 0.0%
450 s 6.8%* 2.7%* 0.3%* 0.0%* 0.0% 0.0% 0.0% 0.0%
600 s 9.3%* 3.3%* 0.4%* 0.0%* 0.0% 0.0% 0.0% 0.0%
AP 150 s 2.0%* 0.7%* 0.4%* 0.0%* 0.1%* 0.0%* 0.0%* 0.0%*
300 s 4.8%* 1.9%* 1.0%* 0.1%* 0.4%* 0.0%* 0.1%* 0.0%*
450 s 7.6%* 3.3%* 1.9%* 0.2%* 0.9%* 0.0%* 0.2%* 0.0%*
600 s 9.4%* 3.8%* 2.6%* 0.3%* 1.2%* 0.0%* 0.4%* 0.0%*
SI 150 s 3.2% 2.5% 0.3%* 0.0%* 0.0%* 0.0%* 0.0% 0.0%
300 s 7.2% 6.7% 1.0%* 0.3%* 0.1%* 0.0%* 0.0%* 0.0%*
450 s 11.1% 10.9% 1.8% 0.8% 0.3% 0.1% 0.0%* 0.0%*
600 s 13.3% 12.3% 2.5%* 1.2%* 0.4% 0.2% 0.1% 0.1%
3D-vector 150 s 14.7% 10.0% 1.4%* 0.2%* 0.3%* 0.1%* 0.1%* 0.0%*
300 s 34.8% 29.0% 5.4%* 1.3%* 1.1%* 0.2%* 0.4%* 0.1%*
450 s 56.2% 50.4% 12.1%* 4.6%* 2.6%* 0.4%* 0.8%* 0.2%*
600 s 70.2% 57.7% 18.1%* 7.0%* 4.6%* 0.7%* 1.4%* 0.3%*
Abbreviations: ERB = endorectal balloon; LR = left-right direction; AP = anterior-posterior direction; SI = 
superior-inferior direction.
Fig. 2   Cumulative percentage of deviations >1 mm, >3 mm and >5 mm in three 
directions. Solid line: patients without ERB; dashed line: patients with ERB.
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In Fig. 4 and 5, the contribution of both trends and transients to the deviations in 
three directions is shown. Trends constitute approximately 80% of all observed 
displacements and transients approximately 20%. LR displacements, however, are 
almost totally caused by trends. Application of an ERB diminishes both the trends and 
transients. Significant reductions in trends were observed for AP displacements >1 
mm, in transients for AP displacements >1 mm and >3 mm. 
Different types of motion
An example of a track of one treatment fraction is shown in Fig. 3a. The decomposition 
of this track in transients, trends and spikes attributable to instrumental noise is 
displayed in Fig. 3b, 3c and 3d, respectively. Large variations were observed in the 
occurrence of these contributions, both between different tracks of the same patient, 
and between patients, and in the No-ERB-group as well as the ERB-group.
Fig. 3   Example of a track of one treatment fraction (a) with decomposition into 
transients (b), trends (c) and instrumental noise (d).
Fig. 4   Cumulative percentage of trends >1 mm, >3 mm and >5 mm in three 
directions. Solid line: patients without ERB; dashed line: patients with ERB.
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and with the same protocol, we found percentages equal to 20.4% and 5.6% for these 
thresholds, respectively (Table 2). These differences can be explained by the large 
inter-patient and interfraction variation of the observed displacements with respect 
to the small number of patients included in both studies (17 and 15 patients, 
respectively). Even larger intrafraction deviations were observed by Kotte et al. [17]. A 
direct comparison of their results with the results from our study is difficult, because 
the timescale in their study was not quantified. However, after analyzing the data 
from our study in a similar way (data not shown), it was observed that in particular 
deviations >2 mm occurred considerably less frequent in the group treated without 
ERB than described by Kotte et al. Because the effect of the ERB is larger for larger 
displacements, it would therefore possibly be more pronounced in the latter 
population than in the present study.
Studies using cine-MRI to assess intrafraction motion without application of an ERB 
revealed that rectal filling was a predictor of prostate movements [18;19]. It was stated 
that a filled rectum is associated with mobile gas pockets, leading to rectal movements 
and hence prostate displacements. It seems unlikely that moving stool and mobile 
gas pockets also induce intrafraction motion when an ERB is applied, which is 
presumably the most important mechanism by which the ERB reduces intrafraction 
prostate movement. Other mechanisms may include fixation of the prostate by 
pushing it towards the pubic bone during treatment. All patients in this study were 
treated in a supine position, as it has been shown that this reduces prostate 
movements due to ventilation as compared to a prone position [20]. A recent study 
using the Calypso system showed a threefold decrease in prostate movements >3 
mm and >5 mm [21].
In two other studies intrafraction motion was compared between patients with and 
without ERB. In the first study, D’Amico et al. concluded that an ERB reduced 
intrafraction motion, as repeated CT-imaging with 1 min time intervals showed a 
decrease in maximum prostate AP displacement from 4 mm to ≤1 mm [8]. Although 
intermittent imaging using this interval is not as sensitive as continuous real-time 
tracking [22], it confirmed the prostate immobilizing effect, as observed in the present 
study. Recently, the ERB-induced reduction in intrafraction prostate displacements 
has been confirmed in a second study, using cine-MRI [12]. Application of a 100 ml 
water-filled ERB was shown to reduce intrafraction prostate motion in both prone and 
supine patient position, as compared to 100 ml of water infused directly into the 
rectum in proton therapy. In that study, the scanning time was 240 s, in which a 3D 
prostate displacement of 3 mm was observed in approximately 5% of time, both with 
and without ERB. Smaller displacements were observed more frequently in patients 
without ERB. In the present study, patients without ERB had 3D displacements >3 mm 
Discussion 
The results from the present study show that intrafraction displacements are 
negligible during the first 150 s of an average treatment fraction, but the percentage 
of prostate displacements increases with time. Application of an ERB reduces these 
displacements, in particular in the AP direction. In spite of the large variance of the 
occurrence of displacements within both groups, the reduction is significant for 3D 
displacements. However, for individual directions the reduction is only significant for 
displacements <3 mm in the AP direction. Interfraction setup deviations were not 
significantly different between patients treated with and without ERB. 
Langen et al. found that, averaged over all patients, the prostate was displaced >3 mm 
and >5 mm in 13.6% and 3.3% of the total treatment time, respectively [14]. In the 
present study, for a similar group of patients treated without ERB at the same institute 
Fig. 5   Cumulative percentage of transients >1 mm, >3 mm and >5 mm in three 
directions. Solid line: patients without ERB; dashed line: patients with ERB.
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in 5.4% of time after 300 s, while this was significantly lower in patients treated with 
ERB: 1.3%. It should be noted, however, that these studies cannot be directly 
compared, because water-filled ERBs were used in the cine-MRI study, and water 
infused in the rectum in the control group. Both et al. recently reported on intrafraction 
prostate displacements, also measured with electromagnetic tracking, for a different 
type of ERB [13]. Small displacements were observed, and it was concluded that ERBs 
stabilize the prostate. Similar to the present study, correlations were observed 
between displacements and elapsed treatment time. In contrast to the present study, 
however, the data was not directly compared to patients treated without ERB. When 
comparing the displacements with ERB from both studies, those in the present study 
are somewhat smaller than in the study by Both et al, which might be caused by the 
use of a different ERB. 
With regard to interfraction deviations, Wachter et al. observed maximum prostate AP 
displacements >5 mm in 2/10 patients treated with ERB, compared to 8/10 patients 
treated without ERB, using repeated CT-examinations, leading to the conclusion that 
an ERB reduces prostate movements during treatment [7]. Also other investigators 
observed only limited prostate motion with ERB application, using biweekly CT scans, 
with a maximum mean displacement (1 SD) of 0.98 (1.78) mm [9;23]. However, in both 
studies prostate displacements were measured based on CT scan comparison, and 
patient setup data were not mentioned. Results from the present study could confirm 
neither these small displacements, nor an ERB-induced reduction of interfraction 
displacements, which confirms the results from a previous study from our group 
using a slightly different ERB [11]. Another study by El-Bassiouni et al. confirmed that 
interfraction deviations are not reduced by ERB application [24]. An important 
contribution to interfraction variation of prostate position is the patient’s body 
position after initial treatment setup and contraction or relaxation of musculature, 
which cannot be altered by application of an ERB. Furthermore, on planning CT scans, 
sporadically, stool proximal to the ERB and prostate is observed. This indicates that 
stool -when present- may get trapped at insertion of the ERB, and may give rise to 
interfraction variation of the prostate position, but, as stated before, does not induce 
intrafraction motion when an ERB is applied.
Application of tight CTV-to-PTV margins may be possible when prostate motion is 
tracked continuously, as has been suggested previously [25]. However, tight margins 
require a strict re-alignment or tracking protocol, potentially leading to an increased 
workload for radiotherapists. In this study, a repositioning threshold of 3 mm was 
used, leading to 88 and 207 corrections in the ERB-group and No-ERB-group, 
respectively. This means that usage of an ERB leads to less treatment interruptions, 
hence a decreased workload for radiotherapists. These corrections were retrospec-
tively undone to analyze the actual displacements, showing that after 600 s (when 
most of the treatments had finished) in the No-ERB-group 18.1% of tracked data in 3D 
exceeded 3 mm, compared to 7.0% in the ERB-group (Table 2). This means that 
application of an isotropic CTV-to-PTV margin of 3 mm in patients without ERB 
theoretically leads to underdosage of the CTV in almost 20% of treatment time, when 
no intrafraction corrections are done. In case of a 5 mm uniform margin, this 
percentage decreases to 4.6%, compared to 0.7% with ERB, indicating that when 
using an ERB and 5 mm margins, even without intrafraction corrections, the CTV 
exceeds the PTV in <1% of time, suggesting this is a sufficient margin when on-line 
corrections are used to minimize interfraction variation. It should be noted, however, 
that in the present study, additional factors that might influence CTV-to-PTV margins, like 
seminal vesicle motion and prostate deformation, were not included in the analyses.
Real-time image guidance has been recommended for hypofractionated stereotactic 
body RT of the prostate to compensate for intrafraction motion >5 mm, to prevent an 
unacceptable reduction of CTV coverage [3]. Langen et al. also observed severe 
underdosage for some individual fractions in helical tomotherapy without ERB, 
although these had a small effect on the cumulative dose [26]. It should be 
emphasized, however, that these observations were specific for helical tomotherapy. 
As shown in the present study, with ERB application 3D deviations >5 mm are reduced 
to <1%, even after 600 s, indicating a negligible effect on the total dose. 
As shown in Fig. 3, intrafraction prostate motion can be decomposed into three 
components: a slow trend, somewhat faster transients and spikes. The trend is 
thought to be a result from relaxation of the pelvic floor musculature or slowly moving 
stool, while the transient movements are probably caused by peristaltic motion or the 
passage of gas [14]. The spikes can most likely be attributed to instrumental noise. LR 
deviations are mainly caused by trends, suggesting that peristaltic motion has no 
influence on the lateral prostate displacements. AP and SI deviations, on the other hand, 
are composed of both trends and transients, the former constituting approximately 
80% of the deviations. Both types of motion are decreased by ERB application. It has 
been suggested that waiting some time after ERB insertion might reduce intrafraction 
motion, due to patient relaxation after insertion [27]. The present study shows, 
however, that the cumulative percentage of time with prostate displacements 
increased linearly with time, both without and with ERB. Figures 4 and 5 show that in 
the plot of the trends, a kink appears after 150 s, which is not the fact for transients. 
Although it was not possible to determine whether this kink is a significant trend 
break considering the possibly not optimal division in trends and transients and the 
rather crude time interval used in the analysis, one could speculate that this kink is 
related to pelvic floor musculature relaxation.
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In conclusion, an air-filled ERB significantly reduces intrafraction prostate motion, 
especially after 150 s, making it a potentially beneficial instrument to use during 
longer treatments, like stereotactic hypofractionated RT. Interfraction variation, 
however, was not influenced by ERB application.
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General Discussion
This thesis aims to identify anatomic structures involved in the development of fecal 
incontinence-related complaints after prostate radiotherapy (RT) and to investigate 
dose-effect relationships. Furthermore, the potential beneficial effect of endorectal 
balloons on anorectal wall doses and the development of toxicity are described. 
Anorectal toxicity
Anorectal toxicity after prostate RT comprises different symptoms [1], and patients 
seem to be bothered most by incontinence-related complaints, such as fecal loss and 
urgency [2]. The first step in investigating its origin is a proper assessment of these 
complaints. There are many different instruments to assess radiation-induced 
anorectal toxicity, although it has been acknowledged that the use of general toxicity 
scales, such as the combined Radiation Therapy Oncology Group/European 
Organisation for Research and Treatment of Cancer toxicity scale, should not be used, 
as it may lead to the loss of information [3]. As mentioned in Chapter 5, at our 
department the Radiation-Induced Lower Intestinal Toxicity (RILIT) scoring system is 
used to record anorectal complaints during regular follow-up. This instrument 
investigates eight different complaints (anal blood loss, mucus loss, abdominal 
cramps, diarrhea, urgency, incontinence, frequency and anal pain), scored on a four or 
five point scale [1]. Although it specifically pays attention to incontinence-related 
complaints, it may still underestimate the actual toxicity rates, as physician-reported 
rates tend to underestimate both the frequency and severity of toxicity [4]. This 
suggests that the use of patient questionnaires should be encouraged. Therefore, 
nowadays patients at our department are asked to fill out the Expanded Prostate 
cancer Index Composite (EPIC) [5] at follow-up. However, when questionnaires are not 
applied, in our opinion, patients should always be actively asked for specific symptoms 
(e.g. loss of stools), rather than whether they do or do not have intestinal complaints, 
as these may then be underreported (e.g. due to embarrassment).
Given the differences in recording complaints, toxicity rates vary largely in the 
literature, and reported late anorectal toxicity rates after intensity-modulated 
radiotherapy vary from 5% to 65% [6;7]. The use of different scoring instruments 
makes direct comparison of toxicity data between studies very difficult [8], particularly 
of specific complaints, as in many studies general toxicity scales are used. We therefore 
advocate the use of specific scoring systems, enabling comparison of individual 
complaints between trials. Still, even when specific complaints are recorded, these 
may be scored differently by different observers, as is discussed in Chapter 6.
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The development of histological and functional changes after prostate RT is a dynamic 
process [11;15], indicating that these may be progressive over time. However, also 
spontaneous improvement of rectal wall damage has been described [16]. Anorectal 
manometry and barostat testing, as described in Chapter 5, were only performed 
once in each patient, and were used to show differences between patients with and 
without complaints. To get a good overview of the dynamics of anorectal damage, 
however, repeated function testing is needed. 
Endorectal balloons
The results from Chapter 3 show that endorectal balloons (ERBs) significantly reduce 
doses to the anal wall, in addition to the known rectal wall sparing effect, described 
in Chapter 2. Furthermore, in post-prostatectomy RT also a beneficial effect of ERBs on 
anorectal doses was shown, in particular with regard to the anal wall (Chapter 4). 
Although these results were derived from planning studies, the observed decrease in 
anal wall and rectal wall doses may lead to lower toxicity rates, given the observed 
dose-effect relationships for both the anal wall and rectal wall [3;17]. Peeters et al. 
observed a hazard ratio for fecal incontinence of 1.039 for 1 Gy increase in anal wall 
mean dose [3]. As 12 Gy and 7.5 Gy reductions in anal wall mean doses were observed 
when ERBs were applied in 3D conformal RT (3D-CRT) and intensity-modulated RT 
(IMRT), respectively, application of an ERB might thus reduce the risk of fecal 
incontinence by a factor (1.03912 =) 1.58 and (1.0397.5 =) 1.33 for the respective 
techniques. When these anal wall mean doses are used in the dose-effect model for 
urgency, as described in Chapter 6, for 3D-CRT, the risk of urgency would decrease 
from 29% (41 Gy) to 6% (29 Gy) with application of an ERB. For IMRT, the incidence 
would decrease from 5% to 1%. It should be noted, however, that this is a model-based 
assumption, based on a relatively small group of patients, in contrast to the 
abovementioned study by Peeters et al., which included 641 patients. 
The observed dosimetric advantages of ERBs were confirmed by data presented in 
Chapters 5 and 6. Patients who had been treated with ERB, had received significantly 
lower doses to the anorectum. Although these studies were not designed to 
investigate this difference, patients treated with ERB reported significantly less 
complaints than patients treated without ERB. The sum of the abovementioned 
results on ERB application, i.e. reduced anorectal wall doses and the observed 
dose-effect relationships for anorectal complaints, strongly suggests that the use of 
ERBs leads to reduced anorectal toxicity rates in prostate RT. The low toxicity rates, 
reported by patients treated with ERB, support this. A final conclusion on the effect of 
ERBs on toxicity, however, can only be drawn from a prospective trial, comparing 
patients treated with and without ERB. So far, only one study with such a design has 
been described in the literature, showing reduced late rectal mucosal changes on 
Pathophysiology
Results from Chapters 5 and 6 suggest that specific incontinence-related complaints 
arise from different anatomic subsites, confirming the statement that these complaints 
truly differ, and should be scored differently. It has been suggested previously, based 
on anorectal dose-surface map analysis, that anorectal complaints have specific sites 
of origin in the anorectal region, with dose-effect relationships for soiling and fecal 
incontinence in the anal region and lower rectum [9]. This is in concordance with our 
findings discussed in Chapter 5 and 6, as is the absence of dose-effect relationships 
for frequency. For urgency, however, no dose-effect relationship was observed in the 
previous study, while our results suggest an association with both anal and rectal 
dose-parameters. Potentially, differences in scoring, as described above, attribute to 
this discrepancy.
The multifactorial pathogenesis of incontinence has been confirmed by others [10;11], 
suggesting that a combination of anal and rectal factors are involved in the 
development of incontinence. Our anorectal manometry and barostat results showed 
a reduced anal resting pressure and lower tolerated rectal pressure in patients with 
incontinence and/or urgency, suggesting that these complaints are caused by a 
combination of reduced rectal capacity and impaired anal sphincter function. Others 
have reported comparable deteriorations of anorectal function after RT [11;12]. Further 
exploration of these complaints, which is described in Chapter 6, showed dose-effect 
relationships for urgency and incontinence with regard to individual pelvic floor 
muscles, suggesting that radiation-induced incontinence is associated with 
dysfunction of the external anal sphincter and puborectalis muscle, while in the 
development of urgency all investigated muscles seem to play a role. These 
observations lead to hypotheses about the anatomic origin of these complaints, but 
do not answer questions about the underlying pathophysiology. In previous histo-
pathologic studies in patients with radiation-induced anorectal complaints smooth 
muscle hypertrophy and damage to the myenteric plexus has been observed [13], 
suggesting that these changes may play a role in its development.
The absence of dose-effect relationships for frequency with regard to the anorectum, 
despite significant reductions in rectal functions, as mentioned in Chapter 5, is 
somewhat surprising. Potentially, the observed rectal dysfunction is associated with 
other, non-investigated dose parameters, like the shape of the spatial dose distribution 
to the rectal mucosa. Recently, it has been shown that the lateral extent of the dose 
distribution is correlated with rectal bleeding, whereas longitudinal extent was 
associated with loose stools [14]. Possibly, the rectal wall is less compliant when the 
whole circumference received a high radiation dose, as it may lead to a more rigid 
rectum due to fibrosis. 
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It is important to note that in many studies, including those described in this thesis, 
dose evaluation with regard to the organs at risk is performed on the planning CT 
scan, which is actually a snapshot that might not be representative for the whole 
treatment. It has been shown that rectal wall doses exceed the set constraints in 
almost 30% of actual treatments, when daily CT images were compared to the 
planned dose on the planning CT, suggesting that adaptive RT with repeated 
delineation may be of benefit [24]. The same may apply to dose parameters obtained 
from the studies presented in this thesis. Daily CT imaging, e.g. using cone-beam CT, 
may be useful to further investigate this issue.
Future perspectives
At this moment, a prospective cohort study is being conducted at our department, in 
which 60 localized prostate cancer patients are followed 2 years after RT. At baseline, 
anorectal function testing is performed, which is repeated after 6, 12 and 24 months. 
Furthermore, patients fill out EPIC questionnaires at baseline and regular follow-up. 
Finally, after 24 months, an endoscopy is performed. This trial should give a better 
insight in the dynamics of anorectal dysfunction after prostate RT and its relation to 
dosimetric parameters and subjective complaints. As most of these patients are also 
enrolled in a randomized multicentre phase III trial on hypofractionation, comparing 
2 Gy per fraction to 3.4 Gy per fraction, the effect of dose per fraction on anorectal 
function can also be explored. 
Furthermore, as mentioned above, clinical studies on the application of ERBs are 
needed, preferably randomized trials. Based on the results from previous studies and 
from the studies mentioned in this thesis, in our institution ERBs are used in all 
prostate cancer patients. A multicentre study together with departments where ERBs 
are not routinely used may be an option to investigate its effect on late anorectal 
toxicity.
repeated endoscopy, and reduced late rectal toxicity [15]. It is clear that more comparative 
studies are needed to confirm this.
In addition to the anorectal wall sparing effect, in Chapter 7 it is shown that ERBs 
significantly reduce intrafraction prostate motion. This effect was especially observed 
when the treatment lasts longer than 2.5 min, indicating that the use of an ERB may 
have a beneficial effect in long daily treatment sessions, like stereotactic body 
irradiation. Interfraction prostate variation, however, was not influenced by the ERB, 
which is consistent with a previous study from our group [18] and  indicates that 
additional set-up and correction protocols are needed to minimize this. With ERB 
application and an on-line position verification system, an isotropic margin of 5 mm 
around the prostate may be sufficient in prostate IMRT, as the prostate then exceeds 
this margin in < 1% of treatment time. Clearly, when real-time electromagnetic 
tracking is used, such as the Calypso system described in Chapter 7, even smaller 
margins can be applied, as manual table corrections can be done during the actual 
treatment.
Delineation of organs at risk
In previous studies, when the rectum was delineated, this often included the anal 
canal [19;20]. Several investigators, however, have suggested that the anal region 
should be considered separately in RT planning to reduce fecal incontinence [3;21-23]. 
The different dose-effect relationships regarding anal wall and rectal wall doses for 
anorectal complaints, described in this thesis, support this statement to consider the 
anal canal and rectum to be separate organs. Because there is no consensus in the 
literature about the delineation method of the anal canal, we compared two methods 
in Chapter 3, both with and without ERB. It was shown that in both situations the anal 
wall can be delineated consistently. However, when separately contouring the pelvic 
floor muscles, considered to be involved in fecal continence, the continence apparatus 
proved to be thrice the volume of the suggested anal wall contour, as is described in 
Chapter 6. Given the observed dose-effect relationships for these specific muscles, it 
may be appropriate to delineate the total continence apparatus to be able to spare 
this in IMRT. 
Based on the dose-effect curves in Chapter 6 the following constraints (mean dose) 
can be deduced for application in RT planning in order to minimize the risk of late 
fecal urgency and/or incontinence: anal wall < 30 Gy, rectal wall < 45 Gy, internal anal 
sphincter < 30 Gy, external anal sphincter < 10 Gy, puborectalis muscle < 50 Gy, levator 
ani muscles < 40 Gy. 
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Summary
In this thesis, several aspects of fecal incontinence-related complaints after prostate 
radiotherapy (RT) are discussed, in order to investigate its pathophysiology. Also, the 
role of endorectal balloons (ERBs) in the reduction of these bothering complaints is 
described. 
In Chapter 2, the results of a literature review on the application of ERBs in prostate 
RT are presented. Overall, ERBs are tolerated well, although care must be taken in 
patients with pre-existing anorectal disease, who seem to have an increased risk of 
developing ERB-related toxicity. Several planning studies have shown a beneficial 
effect of ERBs on anorectal wall doses, which may lead to reduced toxicity rates. 
However, only one prospective study has been performed to compare late toxicity 
between patients treated with and without ERB, showing less rectal bleeding in the 
former group. More comparative trials are needed to investigate this issue. Finally, 
although some investigators have reported reduced interfraction and intrafraction 
prostate variation with ERB application, this has not been confirmed by others. 
Therefore, as potential pitfalls have been described in the use of ERBs, it is 
recommended to use additional set-up and correction protocols.
Chapter 3 shows that, in a planning study, an ERB reduces anal wall doses in both 
3-field and 4-field three-dimensional conformal RT (3D-CRT) and intensity-modulated 
RT (IMRT), planned to a total dose of 78 Gy. Because in the literature different methods 
of anal wall contouring are described, the effect of an ERB was tested using two 
different methods. It is shown that the anal wall can be delineated consistently on 
both the CT scans with ERB and those without ERB, leading to identical volumes. With 
ERB application, the mean dose to the anal wall is reduced by 12 Gy and 7.5 Gy in 
3D-CRT and IMRT, respectively, irrespective of the method of anal wall delineation. 
Given the dose-effect relationships of fecal incontinence to the anal wall, these 
observations may lead to reduced anal toxicity. 
In Chapter 4, the results of another planning study show that, in addition to a 
beneficial effect in definitive RT, an ERB reduces anorectal wall doses in post-operative 
RT as well. The largest advantage is observed for anal wall dose parameters, with a 
reduction of 6 Gy in mean dose. Also, several anal wall dose-volume parameters are 
reduced by the ERB. Regarding the rectal wall, dose-volume and dose-surface 
parameters in the intermediate dose range are significantly reduced. Since these 
parameters are predictive for late anorectal toxicity, application of an ERB may thus 
reduce this. However, like in the investigation presented in Chapter 3, clinical studies 
are needed to confirm this hypothesis.
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significantly lower anal and rectal wall doses, as well as lower doses to all delineated 
muscles. 
Finally, Chapter 7 discusses the effect of an ERB on interfraction and intrafraction 
prostate deviations, by using continuous electromagnetic tracking. It is shown that 
application of an ERB has no effect on the magnitude of interfraction deviations. 
However, intrafraction motion is significantly decreased when an ERB is used, 
especially when the treatment lasts longer than 2.5 min. The largest reductions are 
observed in the anterior-posterior direction. Also, the number of corrections needed 
to re-align a patient during treatment is significantly lower in patients treated with ERB. 
These results suggest that when an on-line correction strategy is used to minimize 
the interfraction variation, an isotropic CTV-to-PTV margin of 5 mm may suffice to 
correct for intrafraction motion when an ERB is used, as in < 1% of time the CTV will 
not be covered by the predefined PTV. Based on these observations, ERBs may be 
beneficial in long daily treatment sessions (e.g. hypofractionated stereotactic RT).
In conclusion, specific fecal incontinence-related complaints after prostate RT seem 
to have a different pathophysiology, based on function testing and dosimetry, and 
the anorectum should not be considered one continuous organ in RT planning and 
dose evaluation. Instead, it should at least be separated in a rectal wall and anal wall. 
Endorectal balloons reduce doses to the anal wall, rectal wall and individual pelvic 
floor muscles in planning studies and retrospective analyses. Also, they reduce 
intrafraction prostate motion. These findings suggest that ERBs may reduce late 
anorectal toxicity. Comparative clinical trials, however, are needed to draw definite 
conclusions on this topic. 
As discussed in Chapter 5, differences in anal wall and rectal wall dosimetry, as well 
as in anorectal manometry and barostat testing imply that fecal incontinence, urgency 
and frequency after prostate RT arise from different anatomic substrates. Sixty 
patients, treated with RT for localized prostate cancer, were categorized according to 
the presence or absence of the abovementioned symptoms, and it is shown that 
patients with urgency or incontinence have an impaired anal squeeze pressure, as 
well as a lower tolerated pressure to the rectal wall. In addition, urgency seems 
associated with many anal and rectal wall dose parameters, while incontinence is only 
associated with some anal parameters. Patients with frequency, on the other hand, 
show a reduction on almost all rectal wall parameters, measured with barostat testing, 
without an association with any of the dosimetric parameters. This leads to the 
hypothesis that in the pathophysiology of urgency, and to a lesser degree incontinence, 
an impairment of both anal pressures and rectal capacity plays a role, while frequency 
may be caused by an impaired rectal capacity and sensory function. When treated 
patients, irrespective of complaints, are compared to a control group of untreated 
men, significantly lower anal resting pressures and tolerated rectal volumes are 
observed in the former group. Based on the observed associations between complaints 
and dose parameters, dose constraints for RT planning are suggested (e.g. anal wall 
mean dose < 38 Gy). Finally, although not a primary objective of the study, patients 
treated with ERB in this study showed significantly lower anal and rectal wall doses, 
and reported less complaints than patients treated without ERB. 
A further exploration of potential anatomic structures, involved in the development 
of fecal incontinence-related complaints after prostate RT is presented in Chapter 6. 
In 48 patients treated with prostate RT, four individual pelvic floor muscles, considered 
to be involved in normal fecal continence, were delineated on the planning CT scans: 
the internal anal sphincter, external anal sphincter, puborectalis muscle and levator 
ani muscles. The mean, maximum and minimum doses to these muscles were 
retrieved from the treatment planning system. All patients were seen during regular 
follow-up and, like in Chapter 5, the absence or presence of urgency, incontinence 
and frequency was recorded. It is shown that the volume of the total continence 
apparatus exceeds the volume of the ‘conventionally delineated’ anal wall 
approximately by a factor three. Furthermore, urgency seems associated with doses 
to all four delineated muscles, while incontinence seems mainly associated with doses 
to the external anal sphincter and puborectalis muscle. As could be expected, based 
on the results from Chapter 5, no associations between frequency and any of the 
investigated dose parameters were observed. Based on the observed associations, 
dose-effect curves for the different structures were constructed and dose constraints 
for RT planning are formulated in this chapter. It is shown that less urgency and 
incontinence were reported in patients treated with ERB, and that this group received 
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Summary in Dutch (Nederlandse Samenvatting)
Prostaatcarcinoom is in Nederland de meest gediagnosticeerde vorm van kanker bij 
mannen boven de 45 jaar, met een incidentie van meer dan 9.500 nieuwe patiënten 
per jaar. Eén van de curatieve behandelopties bij patiënten met een gelokaliseerd 
prostaatcarcinoom is uitwendige radiotherapie. Echter, doordat door set-up variaties 
gedurende de behandeling, zoals interfractie en intrafractie variatie van de prostaat, 
marges rondom de prostaat worden toegepast om onderdosering van de tumor te 
voorkomen, worden ook omliggende organen (deels) meebestraald, wat kan leiden 
tot het optreden van bijwerkingen. In het geval van prostaatradiotherapie moet 
hierbij worden gedacht aan anorectale klachten, mictieproblemen en erectiestoor-
nissen. Wanneer deze klachten permanent zijn, blijkt met name anorectale toxiciteit 
een impact op de kwaliteit van leven te hebben, waarbij het van belang is te 
onderkennen dat dit uit verschillende klachten kan bestaan. Hiervan lijken vooral 
klachten met betrekking tot faecale incontinentie patiënten zorgen te baren.
Verschillende studies hebben uitgewezen, dat er een dosis-respons relatie bestaat bij 
radiotherapie voor prostaatcarcinoom, waardoor de tendens bestaat tot dosisescalatie. 
Echter, aangezien ook voor anorectale klachten dosis-effect relaties bekend zijn, is het 
van belang de radiatiedoses op het anorectum zo laag mogelijk te houden. In de 
afgelopen jaren hebben de ontwikkeling van 3D conformatie radiotherapie en later 
intensity-modulated radiotherapy (IMRT) het mogelijk gemaakt preciezer te bestralen, 
waardoor aan het doelgebied een hogere dosis kan worden gegeven, terwijl de 
omliggende structuren worden gespaard. Verder maakt de toepassing van image- 
guided radiotherapy, zoals het gebruik van portal imaging met behulp van goud - 
markers en cone-beam CT, prostaat positieverificatie en -correctie mogelijk, waardoor 
kleinere marges kunnen worden toegepast. Echter, zelfs na IMRT worden incidenties 
van late anorectale toxiciteit gemeld, variërend van 5% tot 65%.
Om het risico op anorectale toxiciteit verder te verlagen kan tijdens de bestralingsbe-
handeling gebruik gemaakt worden van dagelijks ingebrachte endorectale ballonnen, 
enerzijds omdat is gebleken dat deze de dosis op het rectum reduceren, anderzijds 
vanwege een verondersteld prostaat-immobiliserend effect. Het effect van deze 
ballonnen op klachten met betrekking tot faecale incontinentie is echter niet bekend.
Teneinde anorectale klachten te kunnen voorkomen, is kennis van het ontstaansme-
chanisme noodzakelijk. Wanneer bekend is welke anatomische structuren betrokken 
zijn bij de ontwikkeling van deze klachten, kan met behulp van moderne bestralings-
technieken getracht worden deze te sparen. Een manier om hier meer inzicht in te 
krijgen is het identificeren van objectieve veranderingen bij patiënten met dergelijke 
klachten en deze te correleren met bestralingsdoses. Zo zijn bij patiënten met rectaal 
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Naast een primaire bestralingsbehandeling, kunnen ook patiënten met een lokaal 
tumorrecidief na prostatectomie in opzet curatief worden bestraald. Hoofdstuk 4 
laat het effect zien van een endorectale ballon op doses op het rectum en het anale 
kanaal bij patiënten na prostatectomie. Het blijkt dat ook in deze situatie een reductie 
in anorectale doses optreedt, met name ten aanzien van het anale kanaal. Ook 
rectumdoses in het intermediaire dosisbereik worden hierdoor verlaagd. Aangezien 
deze parameters predictief zijn gebleken voor anorectale toxiciteit, zouden 
endorectale ballonnen het risico hierop dus kunnen verlagen. Echter, evenals geldt 
voor de resultaten uit Hoofdstuk 3, dient deze hypothese in een klinische studie te 
worden bevestigd. 
Hoofdstuk 5 beschrijft de resultaten van een onderzoek, waarbij gebruik is gemaakt 
van anorectale manometrie en barostat onderzoek om anale drukken en rectale 
compliantie en sensibiliteit te kunnen meten. Bestraalde patiënten blijken een 
significant lagere rustdruk in het anale kanaal en verlaagde tolerantie van 
rectumvolumes te hebben dan een controlegroep van niet-behandelde patiënten. 
Voorts werden patiënten met faecale incontinentie (verlies van ontlasting), urgency 
(verhoogde aandrang) en frequency (toegenomen frequentie) na prostaatradiothera-
pie vergeleken met patiënten zonder deze klachten na bestraling. Het blijkt dat 
patiënten met incontinentie en urgency een significant lagere anale knijpkracht 
hebben, en een lagere rectumdruk tolereren, dan patiënten zonder deze klachten. 
Wanneer dosisparameters tussen deze groepen worden vergeleken, blijkt verder dat 
verschillende anale en rectale parameters geassocieerd zijn met urgency, terwijl 
enkele anale parameters predictief lijken voor incontinentie. Frequency, daarentegen, is 
niet geassocieerd met de onderzochte dosisparameters, maar patiënten met frequency 
scoorden wel significant lager op bijna alle functionele rectumparameters. Deze 
observaties leiden tot de hypothese, dat urgency, en in mindere mate incontinentie, 
worden veroorzaakt door een combinatie van anale en rectale dysfunctie, terwijl 
frequency vooral een probleem lijkt van een gestoorde rectumcompliantie en 
-sensibiliteit. Op basis van de geobserveerde dosis-effect relaties wordt een voorstel 
gedaan voor verschillende dosislimieten, die gebruikt kunnen worden bij de radio-
therapieplanning. Tenslotte blijken patiënten, die bestraald zijn met ballon lagere 
doses op het anorectum te hebben gehad en tevens lijken deze patiënten minder 
klachten te rapporteren dan patiënten die zonder ballon zijn behandeld. 
In navolging van Hoofdstuk 5, wordt in Hoofdstuk 6 dieper ingegaan op mogelijke 
anatomische structuren, die geassocieerd zijn met het ontstaan van faecale 
incontinentie. Hiertoe werden vier bekkenbodemspieren, die beschouwd worden 
betrokken te zijn bij normale faecale continentie, separaat ingetekend: de interne 
anale sfincter, externe anale sfincter, musculus puborectalis en musculus levator ani. 
bloedverlies veranderingen aan het rectumslijmvlies beschreven, alsmede verschillende 
dosis-volume en dosis-oppervlakte parameters, die predictief zijn voor het ontstaan 
hiervan. In het geval van hinderlijke klachten die samenhangen met faecale 
incontinentie is echter weinig bekend, behoudens dat patiënten na prostaatradiothe-
rapie een verminderde anale sfincterfunctie en capaciteit van het rectum hebben 
vergeleken met daarvoor. Om kennis te verwerven over de relatie met bestralingsdo-
sis, worden de te onderzoeken structuren ingetekend op planning CT-scans, waarna 
de verschillende dosisparameters worden berekend door een treatment planning 
systeem. In veel voorgaande studies is daartoe het anorectum als één orgaan 
ingetekend, terwijl naast dosis-effect relaties toxiciteit met betrekking tot het 
anorectum, deze ook zijn beschreven voor het anale kanaal alleen.
In dit proefschrift wordt een aantal studies besproken, waarin dieper ingegaan wordt 
op het mogelijke ontstaansmechanisme van anorectale klachten, met name met 
betrekking tot faecale incontinentie, en of deze klachten kunnen worden voorkomen 
door het gebruik van endorectale ballonnen. 
In Hoofdstuk 2 wordt een overzicht gegeven van de internationale literatuur over 
het gebruik van endorectale ballonnen bij prostaatradiotherapie. Het blijkt dat 
patiënten deze ballonnen goed verdragen, hoewel patiënten met preëxistente 
anorectale klachten, zoals hemorrhoïden, een verhoogd risico lopen op ballon-geïn-
duceerde toxiciteit. Verder blijkt uit verschillende planningsstudies dat toepassing 
van een endorectale ballon anorectale doses reduceert. Dit zou kunnen leiden tot 
minder toxiciteit, hoewel slechts één klinische studie dit voordeel heeft onderzocht 
en bevestigd. Meer vergelijkende studies zijn daarom noodzakelijk om dit effect 
definitief te kunnen bevestigen. Tot slot blijkt dat er geen consensus bestaat over het 
effect van endorectale ballonnen op interfractie en intrafractie variatie, waardoor 
wordt geadviseerd deze te combineren met set-up en correctieprotocollen. 
Hoofdstuk 3 behandelt vervolgens een planningsstudie, waaruit blijkt dat endorectale 
ballonnen de dosis op het anale kanaal verlagen bij zowel 3D conformatie radio -
therapie als IMRT, met een afname in de gemiddelde dosis van 12 Gy, respectievelijk 
7,5 Gy. Gezien de bekende dosis-effect relatie van faecale incontinentie met betrekking 
tot het anale kanaal, zou dit kunnen leiden tot minder anale toxiciteit. Verder wordt in 
dit hoofdstuk een manier beschreven om het anale kanaal separaat van het rectum in 
te tekenen, aangezien dit in eerdere studies vaak als één orgaan is beschouwd. Het 
blijkt dat intekening van het anale kanaal op een consistente manier kan plaatsvinden 
op scans met en zonder endorectale ballon. 
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Aan het eind van dit proefschrift (hoewel het voor sommige lezers de eerste, en 
mogelijk enige, regels zullen zijn die gelezen worden) rest mij nog een woord van 
dank uit te spreken aan eenieder die het mogelijk heeft gemaakt dit hier vandaag in 
het openbaar te kunnen verdedigen. In eerste instantie betreft dit alle patiënten die 
hun medewerking hebben verleend aan de in dit proefschrift beschreven onder- 
zoeken, en iedereen die in meer of mindere mate een bijdrage heeft geleverd aan de 
totstandkoming ervan. Met het risico iemand te vergeten, waarvoor alvast mijn 
excuses, wil ik een aantal personen in het bijzonder dank toezeggen.
Prof. dr. J.H.A.M. Kaanders, beste Hans, in het begin van mijn assistententijd inventari-
seerde je bij mij de interesse voor het doen van wetenschappelijk onderzoek. Samen 
bespraken we toen mijn voorkeur voor de klinische aspecten hiervan, in tegenstelling 
tot het laboratoriumonderzoek. Gedurende mijn opleiding begon een en ander 
steeds meer vorm te krijgen en het uiteindelijke resultaat is dit proefschrift. Meestal 
van een afstandje, maar altijd betrokken en volledig op de hoogte van de voortgang 
van het onderzoek, loodste je mij naar de eindstreep. Dank voor je prettige 
begeleiding en goede adviezen. 
Dr. E.N.J.Th. van Lin, beste Emile, als beginnend assistent Radiotherapie kwam ik door 
jou in aanraking met het prostaatonderzoek. Wat begon als een idee over het 
intekenen van het anale kanaal, is inmiddels uitgegroeid tot een multidisciplinair on-
derzoeksproject. Door vele brainstorm-sessies werd het gebouw steeds een 
verdieping hoger. Trips naar Orlando, San Diego en Wiesbaden leidden steeds weer 
tot nieuwe ideëen. Dank voor je grote enthousiasme en fijne samenwerking. Ik kijk 
ernaar uit onze plannen in de toekomst verder vorm te geven.
Klinisch fysici, in willekeurige volgorde: ir. A.L. Hoffmann, beste Aswin, dank voor je 
goede adviezen en je rol als sparring partner. Dankzij jouw kennis en kunde hebben 
we een aantal fysische vraagstukken naar tevredenheid kunnen oplossen. Ik hoop dat 
je in MAASTRO je ambities kunt verwezenlijken en dat we ondanks de afstand toch 
onze samenwerking nog eens kunnen voortzetten. Dr. M. Kunze-Busch, beste Martina, 
dank voor al je inspanningen bij de nauwkeurige herberekeningen en beoordeling 
van Hoofdstukken 4 en 5, alsmede voor je tomeloze optimisme en de altijd 
klaarstaande chocolaatjes, die al menig hypoglykemie hebben voorkomen. Dr. R.J.W. 
Louwe, beste Rob, dank voor de prettige samenwerking bij het totstandkomen van 
Hoofdstuk 7. Mede door jouw inspanningen en kennis van Matlab heeft ons Calypso-
onderzoek in korte tijd geleid tot een mooie publicatie. Dank ook voor de reisverhalen 
en ik hoop dat je je plek hebt gevonden bij de Kiwi’s. Dr. K.M. Langen and dr. A.P. Shah, 
Patiënten werden vergeleken op basis van de aan- of afwezigheid van dezelfde 
klachten als genoemd in Hoofdstuk 5, en het blijkt dat, terwijl urgency geassocieerd 
lijkt met alle ingetekende bekkenbodemspieren, dit voor incontinentie enkel geldt 
voor de externe anale sfincter en musculus puborectalis. Frequency was wederom 
niet geassocieerd met de onderzochte dosisparameters. Op basis van de gevonden 
associaties, zijn in Hoofdstuk 6 verschillende dosis-effectcurves voor de individuele 
structuren geconstrueerd, leidend tot dosislimieten, die kunnen worden toegepast in 
radiotherapieplanning. Wederom bleken patiënten, bestraald met ballon, lagere 
doses op het anale kanaal, het rectum en de bekkenbodemspieren te hebben 
gekregen, alsmede minder incontinentie en urgency te rapporteren. 
Hoofdstuk 7 tenslotte, laat het effect van endorectale ballonnen zien op interfractie 
en intrafractie prostaatverplaatsingen. Hiertoe is een studie gedaan in samenwerking 
met het M.D. Anderson Cancer Center in Orlando (V.S.), waarbij 30 patiënten vóór 
behandeling electromagnetische transponders in de prostaat geplaatst kregen, 
waarmee de prostaatpositie continu kan worden geregistreerd. De helft van deze 
patiënten werd vervolgens behandeld met endorectale ballon, de andere helft 
zonder. Het blijkt dat de ballon geen effect heeft op de interfractie variatie. Intrafractie 
bewegingen daarentegen, worden significant gereduceerd met gebruik van de 
ballon, vooral na 150 seconden. Tevens zijn bij toepassing van de ballon minder posi-
tioneringscorrecties nodig tijdens de bestraling. Op basis van deze resultaten kan, bij 
gebruik van een on-line correctieprotocol om de interfractie variatie te minimaliseren 
én een endorectale ballon, een marge van 5 mm rondom de prostaat volstaan om 
onderdoseringen te voorkomen. Met name bij de toepassing van lange dagelijkse 
behandelingen, zoals gehypofractioneerde stereotactische radiotherapie, kan een 
ballon van voordeel zijn.
Concluderend lijken verschillende klachten, gerelateerd aan faecale incontinentie, 
een verschillend ontstaansmechanisme te hebben, gebaseerd op de functionele 
metingen en dosimetrie, zoals beschreven in dit proefschrift. Het anorectum moet 
dan ook niet worden beschouwd als één orgaan, maar in ieder geval worden opgedeeld 
in een anaal kanaal en rectum. Verder reduceren endorectale ballonnen doses op het 
rectum, het anale kanaal en bekkenbodemspieren, alsmede de intrafractiebeweging 
van de prostaat. Deze observaties suggereren dat endorectale ballonnen het risico op 
anorectale toxiciteit verlagen, hoewel vergelijkende klinische studies noodzakelijk zijn 
om dit definitief te bevestigen.
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rokkostuum willen flankeren. Een en ander doet oude tijden herleven. Laten we er 
een mooie dag van maken.
Tot slot. Lieve Jiske, het is bijna onvoorstelbaar hoezeer ik in jou mijn soulmate heb 
gevonden. Wat ik ook doe, als ik het met jou doe gaat het beter. Reizen, sporten, 
lekker uit eten of gewoon samen op de bank een film kijken, ik geniet van ieder 
moment samen. Ik heb zin in een fantastische toekomst met jou, en straks met zijn 
drietjes! 
dear Katja and Amish, thank you for the pleasant cooperation on our project regarding 
Calypso measurements in patients treated with or without endorectal balloon at the 
M.D. Anderson Cancer Center Orlando. 
Alle medewerkers van de afdeling Radiotherapie UMCN, artsen, verpleegkundigen, 
FT-groep, laboranten, ondersteunend personeel, en iedereen die niet in deze 
categorieen is te vangen, dank voor de prettige samenwerking de afgelopen 7 jaar. 
Een speciaal woord van dank aan Peter van Kollenburg en Gill McColl. Beste Peter, dank 
voor alle tijd die je hebt gestoken in het vele planningswerk voor Hoofdstukken 4 en 
5. Beste Gill, dank voor het vervaardigen van de dose-surface maps en je uitleg aan mij 
over hoe ik deze zelf kon construeren. AIOS Radiotherapie UMCN, zowel degenen die 
hun opleiding reeds hebben afgerond als zij die nog in opleiding zijn, dank voor een 
prettige en gezellige opleidingstijd. Jullie begrip en interesse voor het doen van 
onderzoek tijdens de opleiding werkt motiverend en verdient een compliment. 
Medewerkers van de functieafdeling MDL, in het bijzonder dr. W.P.M. Hopman, beste Wim, 
onze ideëen over het verrichten van functieonderzoeken na prostaatbestraling werden 
door jou direct positief ontvangen. Ik wil je bedanken voor al je tijd, niet alleen met 
betrekking tot het verrichten van de vele functietesten, maar ook voor je zeer 
nauwgezette beoordeling en correcties van Hoofdstukken 5 en 6. Ik hoop de samen - 
werking tussen onze afdelingen nog lang op deze manier voort te kunnen zetten.
Leden van manuscriptcommissie. Prof. dr. J.A. Witjes, prof. dr. J.P.H. Drenth en prof. dr. M. 
van Vulpen, hartelijk dank voor de nauwkeurige beoordeling van het manuscript voor 
dit proefschrift en de goedkeuring ervan.
Familie en vrienden, zonder specifiek namen te willen noemen, hartelijk dank voor niet 
alleen de interesse voor mijn bezigheden tijdens het promotietraject, maar misschien 
nog wel belangrijker, voor de afleiding daaromheen. Gezellige etentjes, samen een 
biertje drinken in St. Anneke, weekenden weg, daar kan geen promotie tegenop.
Paranimfen. Drs. B.F.L. van Nuenen, beste Bart, op de drempel van je eigen promotie kun 
je de ceremonie alvast eens van dichtbij meemaken en zien hoe het moet (of niet). 
Of het nu gaat om het lopen van de Vierdaagse, behoefte aan iemand om een 
biertje mee te drinken of een dag als vandaag, het is goed te weten dat er een goede 
vriend is om op terug te vallen, bedankt daarvoor! Dr. J. Honings, beste Jimmie, twee 
jaar na je eigen promotie zijn de rollen omgedraaid. Nu mag ik zweten en kun jij het 
water inschenken. Vandaag wordt ongetwijfeld weer een mooie herinnering om bij 
te schrijven naast vele andere, zoals Rembo&Rembo, St. Gallen en de Pret met de 
Fret Show. Dank voor dat alles! Mannen, ik vind het mooi dat jullie mij vandaag in 
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Robert Jan Smeenk was born in Tubbergen on the 23rd of February 1980. After 
graduating from the Lorentz College in Arnhem in June 1998, he started medical 
school at the Catholic University Nijmegen (today Radboud University Nijmegen). On 
May 16th 2002, he received the Student award from the Catholic University Nijmegen, 
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Color Figures
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Fig. 2   Transverse (top) and sagittal (bottom) dose distribution of IMRT plans  
without (left) and with ERB (right) in place (prescribed dose 78 Gy). Contours: 
rectal wall (green), anal wall (purple) and PTV (blue).
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Fig. 2   Transversal (top), sagittal (middle) and frontal (bottom) view of delineated 
Rwall (green) and Awall (purple) for CT-scans without ERB (left column) and 
with ERB in place (right column).
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Fig. 3   Differences in dose distribution on the anal wall (purple contour) between  
6 different plans within 1 patient (3-field technique without ERB (a), 3-field 
technique with ERB (b), 4-field technique without ERB (c), 4-field technique 
with ERB (d), IMRT without ERB (e), and IMRT with ERB (f), respectively.  
Blue area: planning target volume; green contour: rectal wall).
Fig. 2   Sagittal (a), transverse (b-d) and coronal (e-g) views of delineated CTV on 
CT-scans without endorectal balloon (left column) and with endorectal 
balloon (right column). Red contour: CTV; blue contour: PTV; green contour: 
rectal wall; purple contour: anal wall.
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Fig. 2   Continued.
Fig. 3   Example of a relative rectal wall dose-surface map in a patient without 
endorectal balloon (left) and with endorectal balloon (right).
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Fig. 4   Sagittal (a) and transverse (b-c) views of dose distributions in one patient 
without endorectal balloon (left) and with endorectal balloon (right).  
Contours as in Fig. 2.
Fig. 1   Example of the delineated pelvic floor muscles in coronal (a), sagittal (b) and 
transverse (c-e) view in a patient with endorectal balloon inserted.  
Red contour: internal anal sphincter; green contour: external anal sphincter; 
blue contour: puborectalis muscle; yellow contour: levator ani muscles.
Fig. 2   Schematic image of the rectum, anal canal and individual pelvic floor muscles 
(I: internal anal sphincter; E: external anal sphincter; P: puborectalis muscle;  
L: levator ani muscles). Lines represent associations between complaints and 
subsites.
